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ABSTRACT 
 
The potential application for stem cell therapy is vast. Despite a limited 
understanding of their mechanisms of action, clinical trials assessing stem cells 
in human stroke are underway. Colony stimulating factors (CSF) such as 
granulocyte colony stimulating factor (G-CSF), which have been used to 
mobilise haematopoietic stem cells (HSC), also show promise in treating stroke. 
 
Preclinical experiments evaluating the effect of G-CSF in stroke were meta-
analysed; G-CSF significantly reduced lesion size in transient but not 
permanent models of ischaemic stroke. Further studies assessing dose-
response, administration time, length of ischaemia and long-term functional 
recovery are needed. 
 
Tracking iron-labelled cells with MRI may help to establish migratory patterns 
following transplantation. Our systematic review of iron-labelled stem cells in 
experimental stroke suggests that compounds already licensed for humans 
(ferumoxide and protamine) may potentially be used in clinical trials. 
  
In a phase IIb single-centre randomised controlled trial (n=60), the safety of G-
CSF in recent stroke was assessed (STEMS-2). G-CSF appears safe when 
administered subacutely and may reduce stroke lesion volume.  Phase III trials 
are required to test efficacy. 
 
An updated Cochrane review on CSFs in stroke shows that G-CSF was 
associated with a non-significant reduction in early impairment but had no effect 
on functional outcome in 6 small studies. In two trials, erythropoietin therapy 
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was significantly associated with death by the end of the trial. It is too early to 
know whether G-CSF could improve functional outcome in stroke. 
 
In 8 recruits randomised into STEMS-2, mobilised CD34+ HSCs were 
paramagnetically labelled, re-infused and tracked with serial T2* MRI. Post-
stroke HSC labelling appears safe and feasible. There is suggestive evidence in 
one patient that labelled HSCs migrate to the ischaemic lesion.  
 
Our in vitro evaluation of CD34+ HSCs has revealed that uptake of 
superparamagnetic iron oxide (SPIO) is enhanced but not dependent upon a 
transfection agent. Iron labelling of CD34+ cells in this manner did not affect cell 
viability or inhibit growth. This methodology could be applied to clinical trials. 
 
We have established the expression of G-CSF protein, its receptor (G-CSFR) 
and CD34 antigen in post-mortem brain tissue from participants recruited to 
STEMS-2. Areas of angiogenesis and expression of G-CSFR in acute and 
chronic infarction suggest potential targets for therapy. 
 
There are many preclinical studies reporting the effects of stem cells in treating 
stroke (with a noticeable lack of neutral or negative articles). Despite the wealth 
of literature there remain many unanswered questions and patients should not 
undergo stem cell therapy unless it is as part of a well designed clinical trial. 
  16 
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CHAPTER 1 
INTRODUCTION 
 
Publications contributing to this chapter: 
 
England T, Martin P, Bath PM. Stem cells for enhancing recovery after stroke: a 
review. International Journal of Stroke. 2009;4:101-110 
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Background 
Definition 
The most widely accepted definition of a stroke is Ôa clinical syndrome 
characterised by rapidly developing clinical symptoms and/or signs of focal (and 
at times global) loss of cerebral function with symptoms lasting for more than 24 
hours or leading to death, with no apparent cause other than that of vascular 
originÕ.1 This encompasses stroke secondary to its three pathological subtypes: 
cerebral infarction, primary intracerebral haemorrhage and subarachnoid 
haemorrhage.  
 
Symptom duration of greater than 24 hours is an arbitrary cut-off point primarily 
developed for epidemiological purposes to distinguish a stroke from a transient 
ischaemic attack (TIA). The definition of a TIA is therefore a sudden focal 
neurological deficit of the brain or eye, presumed to be of vascular origin and 
lasts less than 24 hours. Whilst this definition is valid and useful, it is based on 
the assumption that TIAs are associated with complete resolution of cerebral 
ischaemia with no permanent brain injury. Advances in acute stroke imaging 
have shown this to be false and a new Ôtissue-basedÕ definition has been 
proposed: Ôa TIA is a brief episode of neurological dysfunction caused by focal 
brain or retinal ischaemia, with clinical symptoms typically lasting less than one 
hour, and without evidence of acute infarctionÕ.2 
 
Epidemiology 
Stroke is the third leading cause of death worldwide 3 and is devastating to both 
patients and carers. Its incidence (the number of new cases per unit of person-
time) and prevalence (the total number of cases at a given time) vary according 
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to the population studied; in the United Kingdom there are 110,000 first strokes 
and 30,000 recurrent strokes each year.4 Incidence rises with age with less than 
one quarter of cases aged less than 65.5, 6 Apart from the very elderly, males 
have a higher prevalence than females.6 Incidence of stroke also varies 
according to ethnic background; for example, there is a higher incidence of 
stroke in black compared to white populations,7 blacks are more susceptible to 
stroke caused by small vessel disease,8 and far eastern countries have higher 
rates of primary intracerebral haemorrhage.9 Overall stroke affects 
approximately 1% of the population; this is going to increase as the population 
ages but whether incidence will change remains unclear.  
 
Mortality 
Stroke mortality is dependent upon aetiological subtype (table 1).10 In the 
Oxford Community Stroke Project (OCSP), 675 patients were followed up for 
6.5 years after their first ever stroke;11 19% were dead within 30 days and those 
who survived 30 days had an annual risk of death 2.3 times higher than the 
general population. After 30 days, non-stroke cardiovascular disease becomes 
an increasingly important cause of death. Very broadly, 1 year after a first ever 
stroke, one third of patients have died, one third are independent and one third 
are dependent on others for everyday activities.10 The risk of recurrent stroke 
among survivors is about 2-4% in the first month, and 10-16% within the first 
year, thereafter this falls to 4-5% per year.12 
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Table 1. Case fatality, recurrence and functional status from the Oxford Clinical 
Stroke Project.  
 Subtype  
 TACI 
(n=92) 
PACI 
(n=185) 
POCI 
(n=129) 
LACI 
(n=137) 
All Patients 
(n=543) 
30 Days      
Dead 39 4 7 2 10 
Dependent 56 39 31 36 39 
Independent 4 56 62 62 50 
6 months      
Dead 56 10 14 7 18 
Dependent 39 34 18 26 29 
Independent 4 55 68 66 52 
1 year      
Dead 60 16 19 11 23 
Dependent 36 29 19 28 28 
Independent 4 55 62 60 49 
Recurrence 6 17 20 9 14 
Independent = modified Rankin scale (mRS) 0-2; Dependent = mRS 3-5; TACI, total 
anterior circulation infarct; PACI, partial anterior circulation infarct; LACI, lacunar 
infarct; POCI; posterior circulation infarct. Data given as %. 
 
Aetiological classification 
Stroke and TIA are merely symptoms and signs of a number of possible 
underlying disease processes. In Caucasians, 80-85% of strokes are due to 
cerebral infarction, 10-15% to primary intracerebral haemorrhage (PICH) and 
5% to subarachnoid haemorrhage (SAH).13 Black and South East Asians have 
a higher incidence of PICH.14 The division in classification is important it has 
implications on treatment, management and prognosis. Ischaemic stroke and 
PICH are considered in turn but SAH is clinically distinct from these and will not 
be considered further in this thesis.  
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Ischaemic stroke 
Though there are clinical indicators that might differentiate between ischaemic 
stroke and PICH (e.g. presence of headache and decreased conscious level in 
PICH), the only reliable method is with brain imaging such as a computerised 
tomography (CT) scan. The aetiology of ischaemic stroke is best considered 
using the following subtypes, the TOAST (Trial of org 10172 in acute stroke 
treatment) classification,15 which identifies the most probable pathophysiological 
mechanism on the basis of clinical findings and the results of investigations. 
 
Large artery atherosclerosis 
Atherosclerosis is a chronic inflammatory disorder that results in hardening and 
thickening of arterial walls. Though it inevitably accompanies aging, it is not a 
degenerative process. The initial insult, called a Ôfatty streakÕ, is a purely 
inflammatory lesion and has been observed in infants.16 Over many years 
circulating monocyte-derived macrophages adhere to and invade the arterial 
wall.17 An inflammatory response and deposition of cholesterol and other lipids 
create arterial plaques. Over time, these plaques narrow the arterial lumen (and 
at times dilate it) and subsequently rupture, causing platelet activation, 
aggregation and resultant thrombus (and embolus) formation.18 It remains 
unclear as to what causes a stable plaque to rupture but it may be due to 
mechanical stress (e.g. hypertension) and the large lipid core redistributing 
shear stress over weakened areas in a thin fibrous cap.19 
 
Atherosclerosis mainly affects large and medium sized arteries at places of 
arterial branching (e.g. carotid bifurcation) and it accounts for approximately 
50% of ischaemic strokes in white people.20 Atherosclerotic TIA or ischaemic 
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stroke occurs when there is insufficient blood flow to part of the brain as a result 
of (i) in-situ thrombotic arterial occlusion, (ii) low flow distal to an occluded or 
severely narrowed artery or (iii) embolism from an atherosclerotic plaque or 
thrombus. Many factors (such as the nature of the stroke, the presence of bruits 
on examination) can implicate large artery atheroma as a cause, but in reality it 
is often difficult to prove since there are multiple potential sites where atheroma 
can develop and imaging is often performed after the vessel has been given the 
chance to spontaneously re-canalise. Nonetheless, it is known that increasing 
age, male sex, hypertension, lipid abnormalities, diabetes and cigarette 
smoking increase the risk of atheroma formation, making it reasonable to 
assume atherothromboembolism as a potential cause in many cases.  
 
Small vessel disease 
Strokes caused by occlusion of the smaller arteries in the brain (less than 
approximately 500µm in diameter) account for between 11% and 20% of 
ischaemic strokes.20, 21 These infarcts are usually less than 15mm in size (a 
lacunar infarct) and it is felt that microatheroma is the commonest underlying 
mechanism. Lipohyalinosis accounts for many of the smaller lacunes, especially 
those that are asymptomatic.22 Patients with a lacunar stroke have a similar risk 
factor profile to those with large vessel disease with diabetes, hypertension, 
hyperlipidaemia and current smoking most prominent.23, 24 The high risk 
associated with hypertension but absent risk with heart disease supports the 
hypothesis of a unique pathophysiological mechanism for lacunar stroke.24 
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Cardio-embolism 
Embolism of cardiac origin accounts for about 20% of ischaemic strokes.25 
These are generally severe and prone to early recurrence. The most common 
source of embolism from the heart is non-rheumatic atrial fibrillation (AF) with a 
prevalence of 12%.26 Other major sources include mitral incompetence (6%), 
myocardial infarction within 6 weeks (5%), mitral stenosis (1%) and paradoxical 
embolism (1%).26 Rarer causes include endocarditis and intracardiac tumours. 
The average absolute risk of ischaemic stroke in unanticoagulated non-valvular 
AF is 5% per annum (6 times greater than those in sinus rhythm) and 12% per 
annum in unanticoagulated AF in patients with previous stroke or TIA.27 Cardio-
embolic strokes are more prone to haemorrhagic transformation, reported in up 
to 71% of cases.28 
 
Primary intracerebral haemorrhage 
Primary intracerebral haemorrhage (PICH) causes 10-15% of strokes in white 
people 29, 30 and the risk of PICH appears higher in black Caribbean and black 
African groups compared with whites.31 Patients with PICH have a high early 
case fatality but survivors have a similar outcome to patients with cerebral 
infarction.29 Most cases of PICH are related to hypertension and intracranial 
small vessel disease.32 These haemorrhages are usually deep in the brain in 
the areas supplied by small penetrating arteries. Pathophysiologically, 
hypertension causes early proliferation of arteriolar smooth muscle followed by 
smooth muscle death and collagen deposition; collagen is non-elastic and is 
liable to break under pressure and hence lead to haemorhage.33 In older 
individuals, amyloid angiopathy is more common and is typically associated 
with multiple (typically lobar) haemorrhages and cognitive decline. Underlying is 
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a progressive fibrillosis of arterioles and deposition of beta-amyloid, increasing 
the fragility of these vessels.33 If the patient is younger, underlying vascular 
abnormalities such as an arteriovenous malformation should be suspected and 
investigated appropriately. Intracerebral haemorrhage may also be secondary 
to conditions such as intracranial tumour (primary or secondary), intracranial 
venous thrombosis, inherited bleeding diatheses, iatrogenic causes (e.g. 
thrombolysis, anticoagulation) and drug use (e.g. cocaine 34, 35 or 
amphetamines 35). 
 
Other causes 
Conditions such arterial dissection, vasculitis and thrombophilia causing stroke 
are rare but should be suspected in the young and those presenting with 
unusual features. 
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The ischaemic penumbra 
Occlusion of a major cerebral artery leads to a severe reduction in cerebral 
blood flow (CBF). Cell death then occurs in a spatial and temporal continuum; 
CBF reduction is greatest at the core of the ischaemic area where there is 
metabolic failure and cell death within minutes. Surrounding this area is tissue 
at risk of death but the reduction in CBF is less severe due to collateral blood 
supply. The area of salvageable tissue is known as the penumbra (figure 1).36 
Brain tissue within the penumbra is dysfunctional (occurs when CBF falls below 
0.16-0.17mls/g/min) but it has the potential to recover hence many therapeutic 
and experimental interventions attempt to re-establish CBF sufficiently to 
prevent cell death in the penumbra. 
 
Figure 1. Schematic of the ischaemic penumbra 
An area of ischaemic but potentially viable tissue surrounds an infarct core. 
Over time, the core grows at the cost of the penumbra. The blue area 
represents the brain; yellow, the punumbra; red, the infarct core. 
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Mechanisms of cell death 
The figure below summarises the pathophysiological mechanisms in focal 
ischaemic brain. The mechanisms are then discussed further. 
 
Figure 2. Overview of the mechanisms of cell damage and cell death after 
ischaemic injury 37 
 
 
 
Excitotoxicity  
After focal ischaemia, the loss of oxygen and glucose leads to depolarisation in 
neurons and glia, activation of voltage gated calcium channels and subsequent 
release of toxic amino acids, including glutamate, into the extracellular matrix. 
Reuptake of glutamate via the N-methyl-D-aspartate (NMDA) receptor leads to 
cellular calcium influx, triggering mitochondrial depolarisation and eventual cell 
death.38 In addition, the influx of sodium (followed by water) regulated largely by 
the !-amino-3hydroxyl-5-methyl-4-isoazole propionic acid (AMPA) receptor, 
causes cytotoxic intracellular oedema. Antagonism of both of these receptors 
leads to neuroprotective effects 39, 40 and are therefore possible targets for 
therapeutic intervention. 
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Oxidative stress 
Further direct tissue damage following reperfusion is caused by the generation 
of reactive oxygen species (ROS) such as superoxide, hydrogen peroxide and 
nitric oxide, via mitochondrial apoptotic mechanisms.41 Endogenous ROS 
scavengers (e.g. superoxide dismutase, glutathione), which mitigate the effects 
of ROS,42 are insufficient in reducing the damage caused by significant focal 
ischaemia.  
 
Peri-infarct depolarisation  
Cells within the ischaemic penumbra experience an exchange of potassium and 
neurotransmitters across the cell membrane leading to repolarisation after the 
initial depolarisation. This can occur repetitively, at the expense of further 
energy consumption, originating at the ischaemic core and passing to the 
periphery in a wave-like fashion. The infarct grows larger as the number of 
depolarisations increase.43 These events may propagate ischaemic injury and it 
is suggested that some neuroprotective molecules (e.g. NMDA-antagonists) 
reduce infarct volume by inhibiting this process. 
 
Inflammation 
An inflammatory reaction can last for days to weeks after an ischaemic insult 
and can contribute to exacerbation of focal neurological deficits. Several cell 
populations, including endothelial cells, neurons, astrocytes and microglia are 
able to secrete proinflammatory cytokines including tumour necrosis factor-! 
(TNF-!), interleukins (ILs) IL-1§ and IL-6 and interferon.44 Research strategies 
aim at reducing the potential detrimental effects of inflammation within a 
potentially wide therapeutic window. It, however, needs to be balanced with 
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potential protective effects of inflammation, for example, neuroprotection 
mediated through ischaemic tolerance (brain cells preconditioned to induce a 
state of resistance to a subsequent ÔchallengeÕ that would otherwise be lethal).45 
 
Proinflammatory cytokines induce adhesion molecule expression, such as 
vascular adhesion molecule (VCAM), intercellular adhesion molecule-1 (ICAM-
1), intergrins and selectins on endothelial cells, leucocytes and platelets.44 
Signalling through adhesion molecules leads to leucocyte infiltration into the 
brain parenchyma (via Ôleucocyte-rollingÕ) after an ischaemic insult and usually 
occurs within 4-6 hours, starting with an infiltration of neutrophils. This process 
may exacerbate stroke injury since depleting stroke rats of circulating 
neutrophils will lead to a reduction in infarct volume and improve functional 
outcome.46 The significance of lymphocyte recruitment into the brain remains 
unclear. 
 
Multiple other molecules are implicated in regulating inflammation post-stroke, 
including inducible nitric oxide synthase (iNOS), which catalyses the production 
of nitric oxide (a free radical);47 iNOS and its neuronal form (nNOS) are 
damaging under ischaemic conditions, whereas a third isoform, endothelial 
nitric oxide synthase (eNOS) may play a protective role in improving cerebral 
blood flow. Other important molecules implicated in post-ischaemic 
inflammation include cyclooxygenase-2 (a rate limiting enzyme in the 
production of prostaglandins) and toll-like receptors (TLRs).48, 49 
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Clinical Diagnosis 
The diagnosis of a stroke is initially based on a detailed history (taken from the 
patient or witness) and medical examination, and confirmed with diagnostic 
radiological imaging. A typical history is one of a sudden loss of neurological 
function determined by the site of the brain that has been damaged by 
ischaemia or haemorrhage. Symptoms are usually maximal at onset but 
occasionally they worsen gradually or in a stepwise fashion. Alternative 
diagnoses (such as intracerebral malignancy) should be considered if ictus is 
not sudden. Table 2 summarises typical clinical features following a stroke or 
TIA.  
 
Table 2. Typical clinical features of stroke and TIA 
 
Symptom Descriptive term 
Motor Symptoms 
Weakness of one side of the body 
Difficulty swallowing 
Imbalance 
Inability to perform certain actions not due to 
weakness 
 
Hemiparesis 
Dysphagia 
Ataxia 
Dyspraxia 
Sensory Symptoms 
Altered feeling on one side of the body 
Neglect of one side 
Loss of vision in one eye 
 
Loss of vision in a visual field 
Double vision 
A spinning sensation 
 
Hemisensory disturbance 
Tactile or visual inattention 
Monocular blindness or amaurosis fugax 
Hemianopia or quadrantanopia 
Diplopia 
Vertigo 
Speech or language disturbance 
Difficulty understanding or expressing spoken 
language 
Difficulty writing 
Difficulty calculating 
Slurred speech 
 
Receptive or expressive dysphasia 
 
Dysgraphia 
Dyscalculia 
Dysarthria 
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Symptoms in isolation (dysphagia, ataxia, vertigo, dysarthria) or non-focal 
neurological symptoms (generalised weakness, dizziness, loss of 
consciousness, confusion, incontinence) suggest an alternative cause other 
than stroke. Moreover, if there are unusual clinical features such as a young 
age or unexplained fever then underlying diagnoses must be sought. 
 
Clinical Classification 
Stroke syndromes based on clinical features, established by the Oxfordshire 
Community Stroke Project (OCSP),50 allow the clinician to estimate information 
on the anatomical and vascular location of the stroke, its aetiology and 
prognosis. All strokes do not fit perfectly into these subtypes but they are 
categorised as follows: 
 
1) Total Anterior Circulation Syndrome (TACS) 
A TACS is a combination of all three of: 
i. Hemiparesis involving at least two of face, arm and leg, with or without 
hemisensory loss. 
ii. Homonymous hemianopia 
iii. Cortical (or Ôhigher cerebralÕ) dysfunction, usually a dysphasia if involving 
the dominant hemisphere or inattention / neglect if involving the non-
dominant hemisphere. 
These are usually large infarcts involving the middle cerebral or anterior 
cerebral artery or due to large lobar haematoma. The patient is often drowsy 
and confused as a consequence. Prognosis is poor with 60% dead and 35% 
dependent at 1 year post stroke.50 
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2) Partial Anterior Circulation Syndrome (PACS) 
A PACS consists of 
a. A combination of two of the three features of a TACS or 
b. Isolated high cerebral dysfunction or 
c. Sensory motor deficit isolated to one of the face, arm or leg. 
PACS are usually secondary to occlusion of one of the branches of the middle 
cerebral or anterior cerebral arteries or due to lobar haemorrhage. Risk of 
recurrence is high but prognosis significantly better than TACS;50 15% dead 
and 30% dependent at 1 year. 
 
3) Lacunar Syndrome (LACS) 
There are 4 main lacunar syndromes: 
a. Pure motor hemiparesis (up to 50% of lacunar cases) causes unilateral 
weakness of two of three of face, arm or leg. The lesion occurs where 
the motor pathways are tightly packed such as in the internal capsule or 
pons. 
b. Pure hemisensory loss is less common and consists of unilateral sensory 
symptoms with or without signs. The lesion is usually in the thalamus. 
c. Hemisensorimotor loss (35% of lacunar cases) is a combination of 
unilateral motor and sensory loss with no other features. The lesion may 
be in the thalamus, internal capsule, corona radiata or pons. 
d. Ataxic hemiparesis (10% of lacuna cases) is a combination weakness 
and ataxia in the arm and/or leg. The responsible lesion is usually in the 
pons, internal capsule or cerebral peduncle. This category also includes 
clumsy hand dysarthria syndrome. Prognosis is fair with 10% dead and 
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30% dependent at 1 year.50 A LACS syndrome is usually due to a 
lacunar infarct in 80-90% of cases.51 
 
4) Posterior Circulation Syndrome (POCS) 
Strokes involving the posterior circulation include those affecting the brainstem, 
cerebellum, thalamus or occipital lobe and can cause multiple signs and 
syndromes (e.g. isolated hemianopia and cranial nerve palsies, lateral 
medullary syndrome, Ôlocked-inÕ syndrome). 60% are independent at 1 year.50 
 
Diagnostic Imaging 
A CT or MRI (magnetic resonance imaging) brain scan should be performed as 
soon as possible and immediately (within 1 hour) in suspected stroke if any of 
the following apply:52 
- indications for thrombolysis or early anticoagulation 
- a depressed level of consciousness (Glasgow coma score <13) 
- on anticoagulation treatment or a known bleeding tendency 
- unexplained progressive or fluctuating symptoms 
- severe headache at onset 
- papilloedema, fever or neck stiffness. 
 
Both CT and MRI are equally effective at detecting acute PICH 53 but a CT scan 
is usually the initial investigation of choice because it is more widely available, 
less expensive and safer to use in acutely ill stroke patients. Subtle signs of 
early ischaemia on CT include loss of grey-white differentiation (especially of 
the insular ribbon or lentiform nucleus), succal effacement and the hyperdense 
artery sign, which are all associated with a poor outcome.54, 55  
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Figure 3. The appearance of acute haemorrhage and ischaemic stroke on CT 
imaging. 
 
 
 
 
Nonetheless, particular MRI sequences have specific uses, for example, in 
determining whether a stroke is acute or chronic (diffusion weighted MRI) or by 
adding information to help establish the underlying mechanism (MR 
angiography). If imaging is delayed for more than 1-2 weeks after stroke onset it 
becomes increasingly difficult to distinguish infarct from haemorrhage. As the 
blood is gradually reabsorbed, CT appearances change from a white 
hyperdense area to a black hypodense area. To make the distinction, an MRI 
(gradient echo / T2*) can detect haemosiderin deposition secondary to 
haemorrhage months or even years after the event. Overall, relative to the final 
clinical diagnosis of acute stroke, MRI has a sensitivity of 83% and CT 26%.53 
 
The role of brain imaging in patients who have suffered a TIA is less clear. A 
wide variety of brain pathologies can present with transient focal neurological 
deficits and brain imaging is important to rule these out. Guidelines from the 
National Institute of Health and Clinical Excellence (NICE) state that people who 
Hyperdense area 
representing blood 
Hypodense area 
representing infarction 
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have had a suspected TIA in whom the vascular territory or pathology is 
uncertain should undergo urgent brain imaging.52 This should be done more 
urgently if they are at high risk, for example, those with an ABCD2 score (based 
on age, blood pressure, clinical features, duration of symptoms and presence of 
diabetes) of 4 or above,56 or with crescendo TIA, and preferably with diffusion-
weighted MRI. Up to 10% of people with TIA will have a recurrent stroke within 
48 hours.57 
 
Other investigations 
All stroke and TIA patients should have ÔbaselineÕ tests performed including full 
blood count, erythrocyte sedimentation rate, biochemistry, glucose, lipid profile, 
and electrocardiogram. Further specific tests are aimed at establishing an 
underlying cause and future treatment options. These depend upon the 
patientÕs symptoms, age and pre- and post-stroke condition and may include an 
echocardiogram, duplex carotid ultrasound, immunological assays or 
thrombophilia testing. 
 
Acute Management 
Pre-hospital management 
Stroke is a medical emergency and should be treated with the same urgency as 
acute myocardial infarction. Acute stroke care begins in the community and 
ambulance system with recognition of a Ôbrain attackÕ; educating paramedics 
can increase their diagnostic accuracy from 60 to 80% and lead to an increase 
in the rates of thrombolysis.58 A useful tool to enhance recognition within the 
community and for paramedics is the FAST test (Face Arm Speech Test) which 
shows good agreement with physician assessment.59, 60 
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General Measures 
Once the diagnosis of stroke is suspected or established there are a number of 
general measures that should be addressed for both ischaemic and 
haemorrhagic subtypes.   
 
Maintenance of the airway to help avoid aspiration and adequate oxygenation 
are fundamental measures in initial management. Supplementary oxygen does 
not appear to be beneficial in mild and moderate strokes 61 but further trial 
evidence is awaited to determine whether there is benefit in severe strokes.62 
The presence of a fever is likely to be due to infection but can be secondary to 
the stroke itself. Nevertheless, a raised temperature is associated with 
increased morbidity and mortality 63 and should be treated with anti-pyretics for 
the patientÕs comfort and perhaps to improve outcome.64 Other general 
measures aim to prevent complications of stroke such as avoiding pressure 
sores with consideration for positioning and continence, and early intervention 
with hydration and nutrition in those with an unsafe swallow.65 The routine use 
of compression stockings to prevent deep vein thrombosis (DVT) has been 
abandoned since the recent completion of the CLOTS (Clots in Legs Or 
sTockings after Stroke) trial, revealing no significant reduction in DVT and an 
associated increase in skin tears and necrosis.66 Assessment of serum glucose 
is also important as hypoglycaemia can mimic stroke but whether routine 
treatment of hyperglycaemia is beneficial remains unclear. NICE guidelines 
suggest maintaining blood glucose between 4 and 11 mmol/L.52 
 
Hypertension is present in approximately 80% of acute stroke patients and is 
independently associated with a poor outcome.67 Its management is 
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controversial with recommendations based on opinion rather than evidence. 
Lowering blood pressure may be of benefit by reducing brain oedema and 
haemorrhagic transformation but this needs to be balanced against the potential 
reduction of perfusion to the ischaemic penumbra (an area of salvageable 
tissue surrounding an infarcted core). More recent guidelines recognise the lack 
of evidence and suggest treating blood pressure when post-stroke conditions 
are stable.68, 69 Others recommend blood pressure control only if there is a 
hypertensive emergency (for example, aortic dissection) 52 or if the systolic 
blood pressure exceeds 200mmHg in haemorrhagic stroke 52. There appears to 
be no benefit in lowering BP gradually with candesartan within 30 hours of 
ictus,70 and a lower blood pressure produced by continuing pre-stroke anti-
hypertensive drugs does not appear to be harmful.71 Hypotension, on the other 
hand, is less common after acute stroke and other potential factors such as 
hypovolaemia, co-existent heart failure and underlying sepsis must be 
recognised and treated. 
 
Acute ischaemic stroke 
Despite numerous clinical trials, there are only two effective drug interventions 
for acute ischaemic stroke: aspirin and thrombolysis. 
 
Antiplatelet therapy 
Aspirin has been assessed in two mega-trials. The Chinese Acute Stroke Trial 
(CAST) used 160mg of aspirin versus placebo given within 48 hours of stroke 
onset in 21,106 patients,72 and the International Stroke Trial (IST) examined 
aspirin (300mg), heparin, both or neither within 48 hours in 19,435 patients.73 
Treatment increased the odds of making a complete recovery (odds ratio, OR 
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1.06; 95% confidence interval, CI 1.01-1.11) and at the end of follow-up 13 
more patients were alive and independent for every 1000 patients treated. This 
was offset by a small increase in symptomatic intracranial haemorrhage (SICH) 
occurring in 2 for every 1000 patients treated. 
 
Two other commonly used antiplatelet agents, dipyridamole (a 
phosphodiesterase inhibitor) and clopidogrel (an ADP antagonist), have not 
been assessed for use in acute ischaemic stroke but trials are underway (e.g. 
TARDIS).  A phase III trial assessing abciximab, a glycoprotein IIb IIIa inhibitor, 
was stopped early because of increased rates of SICH.74 
 
Thrombolysis 
If a stroke is due to blockage of an artery by a blood clot then prompt treatment 
with thrombolysis can restore the blood flow before significant brain damage 
has occurred. In the first, pivotal, thrombolysis trial, treatment with intravenous 
rtPA within three hours of the onset of ischemic stroke improved global clinical 
outcome at 3 months (OR 1.7, 95% CI 1.2-2.6) despite an increased incidence 
of SICH (6.4% of patients given rtPA but only 0.6% of patients given placebo).75 
Figure 4 below illustrates the outcome at three months from this trial - scores of 
<1 on the National Institutes of Health Stroke Scale (NIHSS), 95 or 100 on the 
Barthel index, <1 on the modified Rankin scale, and 1 on the Glasgow outcome 
scale were considered to indicate a favorable outcome). The ECASS (European 
Cooperative Stroke Study) thrombolysis trials, however, did not show benefit if 
treatment was given within 6 hours.76, 77 Pooled analysis of rtPA trials have 
suggested that treatment is effective up to 4.5 hours post ictus; this has been 
confirmed with the recent ECASS 3 trial.78 Furthermore, the sooner that rtPA is 
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given to stroke patients, the greater the benefit, especially if started within 90 
min.79 Overall, in 18 thrombolysis trials (with significant heterogeneity and not 
including ECASS 3) including 5727 patients, there is a net reduction in the 
proportion of patients dead or dependent in activities of daily living at a cost of 
an increase in deaths within the first seven to ten days, SICH, and deaths at 
follow-up at three to six months.80 Ongoing trials (IST-3) are assessing the 
effectiveness of rtPA beyond 4.5 hours. Other thrombolytic agents,81, 82 intra-
arterial thrombolysis 83 and mechanical clot retrieval devices under are 
evaluation.84 Streptokinase is associated with an unacceptable risk of 
haemorrhage and death.85 
 
Figure 4. Outcome at 3 months according to treatment from the National 
Institute of Neurological Disorders and Stroke (NINDS) rtPA trial.75 
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Anticoagulation 
Currently, the evidence does not suggest any role for early anticoagulation in 
acute ischaemic stroke. In a meta-analysis of 22 trials, anticoagulant therapy 
was associated with about 9 fewer recurrent ischaemic strokes per 1000 
patients treated but it was also associated with a similar sized 9 per 1000 
increase in symptomatic intracranial haemorrhages.86 
 
Neuroprotection 
Neuroprotectants are drugs that protect the brain from injury. Early trials that 
have shown initial promise, for example with the free radical scavenger NXY-
059,87 have failed to demonstrate any benefit in follow up studies.88 This is 
discussed in more detail later. 
 
Decompressive Surgery 
In a selected group of patients with malignant middle cerebral artery infarction, 
trials have shown that hemicraniectomy, when compared to control, can 
improve outcome and survival.89 In those not suitable for surgery, medical 
therapy with mannitol 90 or glycerol 91 can be used to reduce intracranial 
pressures. 
 
Rehabilitation and Regeneration strategies 
Motor, sensory and cognitive dysfunctions are common consequences of stroke 
and cause considerable disability and social distress. Restoration of movement 
and function form the focus of rehabilitation based on physical therapy. 
Recovery of motor and cognitive function occurs to a variable degree through a 
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number of pathways:92-96 unmasking Ð recruitment of existing but latent 
connections; sprouting Ð development of new neural connections (including 
synaptogenesis); long term potentiation Ð enhancement of memory and 
learning; resolution of diaschisis (remote functional depression); and 
neurogenesis Ð replacing lost neurones. The addition of drugs that might help 
improve this process of neural plasticity has provided some interesting results.  
 
The use of oral amphetamines could potentially modulate synaptic function, and 
studies in rats with stroke have suggested possible benefit.97 However, the 
results from a meta-analysis of 11 small clinical trials (n=329) of amphetamines 
and stroke showed no benefit on functional outcome (despite a trend toward 
improved motor scores), a non-significant trend toward death and an increase 
in adverse events in patients treated with amphetamines.98 The dopaminergic 
system could also be stimulated with levodopa, a precursor of dopamine used 
routinely in the treatment of ParkinsonÕs disease. The DARS trial (Dopamine 
Augmented Rehabilitation in Stroke) is ongoing and aiming to recruit 572 
patients to receive co-careldopa or placebo in conjunction with routine 
rehabilitation.99 Other drugs licensed for use in humans for other conditions also 
show promise. In the FLAME study (fluoxetine for motor recovery after acute 
ischaemic stroke), 118 patients were randomly assigned to 20mg of fluoxetine 
(an anti-depressant) or placebo for 3 months 5 to 10 days after stroke onset.100 
The primary outcome, improvement in the Fugl-Meyer motor scale, was 
significantly better in the treatment group. These findings now need to be 
confirmed in larger studies.  
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The brain can also be stimulated via physical means, and in its simplest form, 
comes as physiotherapy and repeated practice. Animal models of recovery of 
function after stroke reveal that repetitive practice or exercise can evoke 
endogenous neurogenesis and the expression of signalling molecules such as 
brain derived neurotrophic factor (BDNF), which then promotes neuronal repair, 
enhancing learning and memory.101 Repetitive task training in stroke survivors 
can result in modest improvements in limb function, and task orientated 
exercise can help restore gait, balance and strength in a paretic limb.102 Other 
approaches to physical manipulation include constraint induced movement 
therapy (forced use of the affected arm by restraining the unaffected arm), for 
which there may be value in the short term but further larger trials are needed to 
show evidence of persisting benefit.103 The brain may also be manipulated by 
non-invasive brain stimulation such as transcranial magnetic stimulation (TMS); 
these techniques can act to either stimulate or inhibit somatosensory 
processing and could be used in adjunct with rehabilitation.104 Interestingly, a 
recent meta-analysis of 18 randomised controlled trials (RCT) (n=392) 
assessing repetitive TMS in stroke  found a significant effect on improving motor 
function,105 calling for further trials in larger populations. 
 
Ideally, all stroke patients should be cared for on a specialist stroke unit 
containing of both acute and rehabilitation wards; compared to general medical 
wards, care in a stroke unit decreases the likelihood of death, dependency and 
the need for institutionalised care.106 It is also more cost-effective. Furthermore, 
there is increasing interest (often from a financial perspective) in Ôearly 
supported dischargeÕ for patients with mild to moderate handicap,107 which 
reduces hospital length of stay as well as reducing long-term dependency. The 
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stroke unit facilitates recovery by using organised multidisciplinary care, 
involving doctors, nurses, physiotherapists, occupational therapists, speech and 
language therapists, dieticians, social workers and pharmacists. The length of 
stay should be tailored to individual needs, using goal-based therapy, allowing 
progress to be measured. Complications such as deep vein thrombosis and 
pulmonary embolus, infections, recurrent stroke, seizures, pressure ulcers and 
post-stroke depression can often inhibit targeted goals. The overall aim is to 
minimise handicap and return the patient to an optimal functional state. 
 
Haemorrhagic stroke  
No specific medical treatment has been shown to improve outcome in 
haemorrhagic stroke and treatment is largely supportive care. The use of 
recombinant activated factor VIIa (a haemostatic agent) showed early promise 
in a phase II trial demonstrating reduced mortality and improvement in 
functional outcomes at 90 days.108 These findings were not reproduced in the 
larger phase III trial.109 Surgical evacuation is unproven but early surgery for 
large cerebellar or superficial bleeds should be considered.110 
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Animal models of stroke 
A pre-clinical stroke model should ideally mimic the pathophysiological 
mechanisms that occur in human stroke, which is inherently difficult considering 
its heterogeneous presentationÐ the anatomical location, aetiology, severity and 
co-morbidities are all factors that will confound interpretation and produce 
variability in outcome. There is therefore no single stroke model that will fairly 
represent all forms of human stroke. Various models are considered. 
 
Focal models of ischaemic 
Focal models of ischaemia involve occluding a specific vessel, usually the 
middle cerebral artery, and can be either permanent or transient (reversible). 
Permanent models allow examination of ischaemic core and surrounding area 
of less damaged tissue (penumbra), whereas transient models build in the 
consequences of reperfusion on ischaemic brain (in the clinical setting, 
recanalization occurs to a variable degree hence both transient and permanent 
models hold value).  Transient ischaemia will produce varying degrees of 
infarction, depending on the length of occlusion, and there are more likely to be 
higher survival rates than permanent models of ischaemia. Surgical techniques 
that induce vessel occlusion include cauterisation, clips, threads, use of an 
intraluminal filament 111 and endothelin-1 administration.112 Surgery can be 
extensive and therefore reduce the ability to perform advanced behavioural 
testing. Some anaesthetic agents can also confound matters by producing their 
own neuroprotective effects (e.g. ketamine 113). 
 
Intraluminal middle cerebral artery occlusion involves inserting a monofilament 
suture into the internal carotid artery to block blood flow to the middle cerebral 
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artery inducing either permanent or transient occlusion. It produces a 
reproducible infarct size with a substantial penumbra, making it appropriate for 
studies of neuroprotection. Potential complications include subarachnoid 
haemorrhage secondary to suture induced arterial rupture and spontaneous 
hyperthermia when occlusion is longer than 2 hours.114 
 
Thrombo-embolic models utilise homologous blood clot fragments injected 
directly into the carotid artery.115 This produces infarcts predominantly in the 
area of the middle cerebral artery. The main disadvantage is that the location of 
the infarct can be inconsistent due to micro-embolisation and re-canalisation. 
Reproducibility of the model is influenced by the size and length of the clot and 
improved by using a fibrin-rich thrombus.116 
 
A photochemical model of stroke is attractive since it is relatively non-
invasive.117 A photosensitive dye (rose bengal) is injected intravenously and the 
brain (no craniectomy required) is exposed to light of a specific wavelength. A 
photochemical reaction between the light and the dye generates thrombosis 
within the vessel. The size of the stroke is dependent on the beam diameter. A 
rapid ischaemic insult develops with significant vasogenic oedema and no 
penumbral region as seen in other models of ischaemia. This lack of 
representation to human stroke is probably why the model is less often used. 
 
Global models of ischaemia 
This involves occluding all major blood vessels to the brain producing a large 
area of infarction. It is generally used to analyse cerebral ischemia after cardiac 
arrest rather than stroke. 
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Haemorrhagic stroke model 
Intracerebral haemorrhage can be induced via direct injection of a bacterial 
collagenase (a metalloproteinase that degrades interstitial and basement 
membrane collagen).118 The size of the haematoma is dependent on the dose 
injected. A pronounced inflammatory response occurs with neutrophils evident 
at 12 hours and lipid-filled macrophages infiltrating after 7 days. Consolidation 
of the necrotic mass results in a cyst by three weeks. 
Animal size 
The use of small (rodents) over large animals (dogs, cats, monkeys) offers a 
number of advantages. Small animals (especially mice) are genetically 
homogenous and can be more easily manipulated to investigate mechanisms of 
disease, such as producing genetic knock-out models or over expression of 
certain proteins. The small brain size in mice and rats may be considered an 
advantage for quicker fixation and analytical procedures. However, anatomical 
and functional aspects may be better represented by larger gyrencephalic 
brains. Small animals are less costly and easier to maintain but sophisticated 
physiological monitoring is more challenging compared to larger animals. 
 
Species 
The majority of studies assessing ischaemic brain have used rat models, 
probably reflecting their cheaper cost but also due to their greater similarity to 
the human cerebral circulation compared to other species.119 Several species 
should be studied if possible when addressing the effects of a drug due to 
potential differences. For example dizocilpine (MK-801, a glutamate antagonist) 
is neuroprotective in rabbits,120 rats 40 and gerbils,121 but not in primates.122 
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Behavioural testing in animal models of stroke 
Assessment of neurological status in animals is difficult. Simple measures of 
motor function in rodents are available, including neurological stroke scales that 
correlate with the size of the infarcted area.123 Generally, however, there is a 
poor correlation between behavioural testing and reductions in infarct size.114 
Tests assessing sensorimotor function include rotarod, grid walking, limb 
placement, beam walking and the adhesive label test.124 Some of these 
behavioural tests appear more likely to yield a positive treatment effect than 
others (such as rotarod, adhesive tape removal and neurological scales 125), but 
it must also be acknowledged that improvement during the tests may simply be 
due to compensatory learning (e.g. gradual improvement on a rotarod because 
the animal learns to rely on other limbs for balance).126 Cognitive tests are also 
available, for example, the Morris water maze test assessing memory and 
learning. The table below provides examples of commonly used behavioural 
outcome tests. 
 
Table 3. Behavioural tests used in experimental models of stroke 
(adapted from 125) 
Test Assessment 
Neurological stroke scale Motor and sensory functions, balance, reflexes 
Adhesive tape removal Forelimb sensory asymmetry 
Rotarod Coordination, balance, motor function 
Limb placement Response to tactile and proprioceptive stimulation 
Cylinder Spontaneous use of forelimbs 
Treadmill Gait, motor function 
Beam-walking Hind-limb function 
Morris water maze Cognitive function 
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Combining the results of behavioural testing with histological assessment and 
infarct volume measurements are important in determining the effectiveness of 
a drug in the pre-clinical setting.  
 
Therapeutic interventions and pre-clinical studies of neuroprotection 
Sodium and potassium channel blockers 
Sodium channel inhibition is neuroprotective in experimental stroke, but in a 
dose escalation phase II trial of sipatrigine (619C89) administered within 12 
hours of stroke, an excess of adverse events was observed, including vomiting, 
neuropsychiatric effects and hyponatraemia.127 BMS-204352, a potassium 
channel modulator that decreases neuronal excitability and neurotransmitter 
release, reached a phase III trial and failed to demonstrate efficacy in stroke 
patients.128 
 
Calcium stabilising drugs 
During ischaemia, influx of intracellular calcium via glutamate receptors and 
voltage-dependent calcium channels eventually leads to cell death and multiple 
clinical trials (mostly assessing nimodipine) have assessed the use of calcium 
channel blockers in treating stroke, both as a neuroprotectant and anti-
hypertensive strategy. A meta-analysis of 29 randomised controlled trials 
investigating a calcium channel antagonist administered within 12 hours of 
ischaemic stroke found no overall effect on functional outcome.129 A 
subsequent systematic review on nimodipine in animal model experiments of 
focal cerebral ischemia concluded that there was no convincing evidence to 
substantiate the decision to perform clinical trials of nimodipine in large 
numbers of patients.130 
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Anti-excitotoxic agents 
Several agents that inhibit glutamate/NMDA receptors have been tested in 
experimental models and humans. Dizocilpine (MK-801), a non-competitive 
NMDA antagonist is neuroprotective in some animal models 131, 132 but 
investigations were halted due to safety concerns including finding evidence of 
neuronal vacuolation in rats 133 and psychotic side effects in human clinical 
trials. Other competitive and non-competitive NMDA antagonists have been 
found to be neuroprotective in animals but have failed to demonstrate efficacy 
in humans; selfotel administered within 6 hours of stroke onset was assessed in 
a phase III clinical trial and was stopped early (n=576) due to a trend in 
increased mortality.134 Similarly, a trial using aptiganel (n=628), another NMDA 
antagonist, was terminated for the same reasons. AMPA antagonists, such as 
YM-872 have also been studied in humans following initial promise in preclinical 
studies without yielding any positive results.135 Magnesium also inhibits the 
NMDA receptor and is neuroprotective through other mechanisms including 
inhibiting neurotransmitter release, blocking voltage-gated calcium channels 
and promoting vasodilation. Trials assessing its hyperacute administration are 
ongoing.136 
 
Antioxidants 
Free radical scavengers have also shown promise in experimental stroke and 
again have failed to demonstrate efficacy in human trials. The most recent 
example is that of NXY-059. In an RCT of 1722 patients, NXY-059 given within 
6 hours of stroke onset was well tolerated and improved outcome as measured 
by the modified Rankin scale at 90 days.87 Unfortunately, the follow up trial in 
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3195 patients demonstrated no evidence of efficacy in any of the primary or 
secondary end points. 
 
Anti-apoptotic agents 
Caspases are a family of proteins essential in the regulation of cell apoptosis. 
Inhibition of these enzymes in experimental stroke may be beneficial. 
Granulocyte-colony stimulating factor, a glycoprotein hormone involved in the 
regulation of granulopoeisis (and discussed in more detail later) is a candidate 
neuroprotective agent thought to reduce apoptosis and possess anti-
inflammatory properties.137, 138 
 
Anti-inflammatory drugs 
Inflammatory cells can exacerbate stroke injury through production of cytotoxins 
and by forming aggregates that re-occlude vessels. Inhibiting interaction 
between inflammatory cells and adhesion molecules is another potential 
therapeutic approach. Anti-p-selectin antibodies can decrease infarct volume by 
up to 70% in mice (when administered before stroke induction) 139 and anti-
ICAM-1 antibodies will reduce lesion volume in transient but not permanent rat 
models of ischaemia.140 The clinical trial assessing enlimomab (a murine ICAM-
1 monoclonocal antibody) in 625 patients was negative, causing an increase in 
mortality and a significantly poorer outcome in the treatment group.141 A follow-
up preclinical experiment investigating the cause of this negative trial suggested 
that enlimomab causes host antibodies to exacerbate the inflammatory 
reaction.142 The ASTIN (Acute Stroke Therapy by Inhibition of Neutrophils) trial 
investigated UK-279,276 (a selective CD11b/CD18 antagonist, a neutrophil 
inhibitory factor) in 966 patients with ischaemic stroke and was also 
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administered within 6 hours on onset.143 The trial was stopped early on grounds 
of futility, though the drug was well tolerated. Other anti-inflammatory 
approaches have shown success in animal models of stroke including mitogen 
activated protein kinase (MAPK) inhibitors, 144 which alter cytokine production, 
but to date there have been no successful trials of anti-inflammatory drugs in 
stroke. 
 
Corticosteroids and immunotherapy 
Vasogenic oedema associated with intra-cerebral tumours responds well to 
steroids.145 There is no current evidence that corticosteroids are beneficial in 
reducing stroke associated cytotoxic oedema. A meta-analysis of eight trials 
and 466 people showed no difference in outcome but pooling the data was 
difficult due to large inconsistencies between trials.146 Tacrolimus is a potent 
immunosuppressant used in transplant medicine for many years and has shown 
promise in experimental stroke; a systematic review of 1759 animals reported a 
31% improvement in outcome compared to placebo but concerns were raised 
with regards to study quality and publication bias.147 Another potential 
immunotherapy in stroke is the use of intravenous immunoglobulin (IVIG), which 
is used widely in clinical practice, particularly in neuro-autoimmune diseases. 
Administration of IVIG to experimental stroke mice reduces infarct volume, 
possibly by reducing production of cell adhesion molecules thereby decreasing 
the inflammatory infiltrate.148 
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Why have clinical trials failed despite favourable pre-clinical data? 
 
Therapeutic window 
It seems reasonable to assume that drugs designed to work on a specific 
mechanism should be administered when that mechanism is active. For 
example, glutamate release occurs seconds after the ischaemic event and 
NMDA-antagonists are effective in animal models up to 90 minutes after 
ischaemia.149 Despite this, most of the trials evaluating NMDA-antagonists 
allowed inclusion of patients up to 6 hours post stroke. This could be 
considered a reasonable time window, however, since the cascade of events in 
the penumbra is often delayed compared to the infarct core due to collateral 
blood flow. The figure below represents the cascade of damaging events in 
focal ischaemia over time.37 Nonetheless rt-PA (thrombolysis) is the only 
compound licenced for use in acute ischaemic stroke when given within 4.5 
hours and it is effective in animal models over a similar time frame.150 This 
suggests trials of novel compounds should mimic the time window used in the 
pre-clinical experiments. The duration of treatment should also reflect the 
mechanism to which the drug is targeting. Previous neuroprotectant trials have 
varied from using a single bolus to 12 weeks of oral therapy;151 neuroprotective 
drugs should probably cover the first 72 hours of excitotoxicity. In addition to 
drug pharmacology, administration will also depend on tolerability, practical 
issues of administration and interaction with other therapies. 
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Figure 5. Cascade of events in focal ischaemia depicting the impact of each 
event over time 37 
 
 
Dose of drug 
A drug dose that is effective in animal models may not be effective in humans, 
and it may not be sufficient to scale up a dose of a drug in mg/kg from rodent 
models to larger animals and humans. In addition, drug delivery to the brain at 
risk is affected by the blood brain barrier, cerebral blood flow and drug 
pharmacokinetics which may vary between species. 
 
Monotherapy 
Targeting just one component of the ischaemic cascade may not be enough. 
Using 2 or more compounds, however, is likely to increase the risk of adverse 
events. The ideal neuroprotective drug might be a single compound that targets 
greater than one component of the pathophysiological process. 
 
Animal models 
As discussed, there are multiple animal models of stroke, and there is no clear 
ÔbestÕ model to use. It is important to study the same strain of rodent throughout 
the experimental stage due to variations in infarct size and it is suggested that 
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determining efficacy in a permanent model of ischaemia will maximise the 
chances of clinical success.152 Ideally, the models should incorporate other co-
morbidities such as including older animals and animals with diabetes and 
hypertension, to more closely mimic the clinical setting. Furthermore, the most 
appropriate animal model should be selected; for example, using reperfusion 
models if a drug is to be used in patients with thrombolysis would strengthen 
the validity of the experiment. 
 
Stroke Therapy Academic Industry Roundtable (STAIR) 
Despite multiple drugs demonstrating efficacy in experimental stroke, none 
have been translated into clinical use. To help identify and address barriers to 
translation of animal studies to human clinical trials, the Stroke Therapy 
Academic Industry Roundtable (STAIR) produced a series of recommendations 
in 1999, outlined in the table below.152 
 
Table 4. Initial STAIR pre-clinical recommendations 
1. Establish an adequate dose response curve 
2. Define the time-window in a well characterised model 
3. Use blinded, physiologically controlled reproducible studies 
4. Assess histological and functional outcomes acutely and long-term 
5. Initially use rodent studies, then consider gyrencephalic species 
6. Assess permanent occlusion models, then transient in most cases 
 
Since these initial recommendations, data explored from 1026 neuroprotective 
strategies (and 8516 experiments) in a systematic review 153 were analysed 
using a simple checklist derived from STAIR I and provided an overview of the 
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quality of the data. 550 drugs were reported to be effective in pre-clinical animal 
models but only 5 fulfilled the criteria. There was a relationship between 
increasing study ÔqualityÕ score and declining efficacy (i.e. poor quality studies 
over-estimated efficacy). However, absence of the above recommendations in a 
pre-clinical experiment does not necessarily mean that it was carried out to a 
poor standard; these experiments have to explore mechanisms of action and it 
would be inappropriate to involve each of the components to in order for it to 
represent a good quality study. The impact of various ÔqualityÕ items on efficacy 
has further been assessed;154 the presence or absence of randomisation to a 
treatment group, blinding of drug allocation and blinding of outcome 
assessments were the most powerful determinants of outcome. Additional 
recommendations from STAIR in 2009 are described in the table below.155 
 
Table 5. Summary of the updated STAIR recommendations  
1. Use sample size calculations 
2. State inclusion and exclusion criteria 
3.  Randomisation Ð explain the methods of allocation into experimental 
groups 
4.  Allocation concealment Ð explain methods of investigator blinding 
5.  Report animals excluded from analysis 
6. Blinding of outcome assessment 
7. Report conflicts of interest and study funding 
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Stem cells for enhancing recovery after stroke 
One potentially important area of development in the treatment of stroke is the 
use of stem cells to enhance recovery. The definition of a Ôstem cellÕ continues 
to evolve. The current definition requires a cell to demonstrate two properties: 
the capacity for self-renewal and the ability to differentiate into multiple cell 
types (potency).156 A Ôprogenitor cellÕ also has these characteristics but with a 
more restricted potential, i.e. it can only differentiate into a limited number of cell 
types and has a reduced capacity for self-renewal.156 Stem cell transplant trials 
are already underway in conditions such as diabetes, cancer, 
neurodegenerative disease (e.g. ParkinsonÕs disease) and heart disease.157-160  
 
The mechanism by which stem cells may improve recovery is still poorly 
understood. There are two theories: neuroprotection - preventing damaged 
neurons undergoing cell death in the acute phase of cerebral ischaemia; and 
neurorepair - the repair of broken neuronal networks in the chronic phase of 
cerebral ischaemia. It seems probable that stem cells promote recovery with 
elements of both neuroprotection and neurorepair. 
 
Reduced apoptosis and inflammation 
An intervention that reduces stroke lesion size, usually by decreasing cell death 
within the ischaemic penumbra, indicates neuroprotective activity. This has 
been seen with intravenous administration of haematopoietic stem cells and via 
intracerebral grafting of human neural stem cells in ischaemic stroke models.161, 
162 However, a reduction in lesion volume is not always observed with 
transplantation of stem cells (from a variety of sources 163-166), this perhaps 
relating to the method and time of administration post stroke. 
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Neuroprotection may also be achieved by reducing inflammatory responses. It 
is likely that stem cells play a pivotal role in the regulation of the inflammatory 
cascade through the production of cytokines and growth factors and it might be 
expected that a cell transplant would induce or exacerbate inflammation. An 
exaggerated inflammatory response in the peri-infarct area has been observed 
in a murine model of stroke treated with G-CSF.167 Conversely, the use of 
human cord blood cells in a rat model of stroke had the opposite effect by 
decreasing the inflammatory infiltrate as indicated by a reduction in the 
expression of pro-inflammatory cytokines.168  
 
Recruitment of endogenous neural progenitor cells (NPC) 
Since progenitor cells exist within the brain, and neurones, glia and vascular 
cells can be renewed, it might be thought that significant neurogenesis would 
take place after stroke. Although there are a number of rodent models 
investigating endogenous neurogenesis in cerebrovascular disease,169-171 few 
studies have been reported in humans. In one, histological examination was 
performed in an 84 year old patient who suffered a stroke 1 week prior to 
death.172 Using a neural stem cell label, large numbers of neural stem cells, 
vascular endothelial growth factor-immunopositive cells, and new blood vessels 
around the region of infarction were identified suggesting the presence of 
ischaemia induced NPC recruitment and neovascularisation. Other studies 
have also shown the presence of ischaemia-induced endogenous 
neurogenesis.173 
 
Growth factors such as brain derived neurotrophic factor (BDNF) and nerve 
growth factor (NGF) are involved in the regulation of brain stem cell division and 
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differentiation. Augmenting these naturally occurring neurogenic factors through 
exogenous administration offers a potential treatment for stroke. A recent 
Japanese study investigated neurotrophic factors released in rat brain tissue 
following intravenous transplantation of human mesenchymal stem cells 
(MSCs) one day after middle cerebral artery occlusion (MCAo);174 compared to 
controls (iv phosphate buffered saline), treated rats produced increased 
exogenous (human origin) insulin-like growth factor (IGF-1) and endogenous 
(rat origin) vascular endothelial growth factor (VEGF), epidermal growth factor 
(EGF) and basic fibroblast growth factor (bFGF). However, only one molecule 
has been tested to date in humans; in a phase II/III trial (286 patients) of bFGF, 
treatment was ineffective, even showing a trend to hazard, and caused 
leucocytosis and hypotension.175 The use of treatments targeting a single 
growth factor pathway in pathophysiological states may be limited, as has been 
seen with numerous neuroprotectants with unimodal mechanisms of action.176 
Stem cells offer a potential multimodal mechanism of action, including 
recruitment of endogenous progenitor cells via secretion of growth factors.  
 
Neurogenesis 
Whether stem cells can improve recovery by replication and differentiation 
(Ôdirect neurogenesisÕ), and thereby replace damaged brain cells and 
reconstruct neural circuitry, remains unclear, with limited and conflicting 
evidence. In rats with induced MCAo, transplanted neurospheres survived 4 
weeks post transplant with the majority of migrating cells expressing a neuronal 
phenotype (including doublecortin, !-tubulin and glial fibrillary acid protein 
[GFAP] markers).163 Neurospheres (non-adherent spherical clusters of neural 
stem cells) derived from adult stroke rats can also differentiate into glia (as well 
as neurons), and can migrate towards the ischaemic lesion.177 A human neural 
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stem cell line (CTX0E03, ReNeuron Group plc 178), derived from human somatic 
stem cells following genetic modification with an immortalising gene, can 
differentiate into neurons and astrocytes, and induce significant improvements 
in both sensorimotor and gross motor function in the rat MCAo model of stroke 
6 to 12 weeks post grafting;179 this cell line has now reached safety trials in 
human stroke.180 In mice incapable of developing cells of myeloid and lymphoid 
lineages, transplanted adult bone marrow cells (BMCs) migrated into the brain 
and differentiated into cells that expressed neuron specific antigens (NeuN, a 
nuclear protein that is found exclusively in neurons).181 In contrast, no evidence 
of neural-like cells was found in another study of mice transplanted with 
BMCs.182 Other groups have also failed to detect differentiation of 
haematopoietic stem cells into neural tissue.183 In the positive studies showing 
cell differentiation into a neural phenotype, only small numbers of cells survived, 
suggesting that integration into host circuitry is not the only or main mechanism 
of action to enhance functional recovery. However, the finding that response 
may depend on the number of cells administered (Ôdose responseÕ) is 
compatible with beneficial effects being mediated by cell replacement.184  
 
Angiogenesis 
Neurogenesis alone will not lead to recovery since neurones need nutritional 
support and new blood vessels will need to develop. Hence, a rich vascular 
environment mediated by CD34+ cells might enhance subsequent neuronal 
regeneration. Angiogenesis has been found experimentally, as shown when 
bone marrow-derived CD34+ cells were administered intravenously to mice 48 
hours after stroke induction;161 accelerated neovascularisation occurred in 
comparison with mice injected with CD34- cells. Furthermore, administration of 
an antiangiogenic agent prevented the beneficial effect of CD34+ precursors.161 
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While angiogenesis could be the result of differentiation of haematopoietic stem 
cells into blood vessel wall cells, an indirect effect is also likely since human 
CD34+ cells have been shown to secrete numerous angiogenic factors, 
including vascular endothelial growth factor (VEGF) and insulin-like growth 
factor (IGF-1).185  
 
Plasticity 
Neuroplasticity refers to organisational changes in the brain so that individual 
neurones or networks adapt their function. This theory forms the basis for goal-
directed, therapeutic rehabilitation. In stroke, stem cells may augment this 
process through enhancing various mechanisms of recovery, including 
sprouting and unmasking, but the evidence remains limited. Sprouting has been 
seen in experimental stroke following intravenous administration of human bone 
marrow stromal cells to rats; a 50% reduction in lesion volume was seen in 
comparison to saline-treated controls.186 In contrast, treatment with human 
umbilical cord blood cells did not improve sensorimotor or cognitive outcome in 
stroke rats in one of the few reported negative studies.166  
 
Sources of stem cells for stroke therapy 
A number of cell sources for stem cell transplantation are available and these 
can be categorised in several dimensions: exogenous or endogenous; 
embryonic, foetal or adult derivation; neural or non-neural origin; and 
pluripotential (which can divide indefinitely) or multipotential (which usually 
regenerate their Ôown tissueÕ but have the ability to transdifferentiate into other 
tissue cell types). However, to date, there is no set of markers that precisely 
identifies a neural stem cell and distinguishes it from other more limited 
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progenitors, precursors or differentiated cells. The isolation of true neural stem 
cells and the regions in which they exist remains under investigation. For 
example, cells cultured from areas outside the striatal subventricular zone in the 
post-natal brain demonstrate a more limited capacity for self renewal than well 
characterised ventricular subependymal neural stem cells.187 The formal 
identification of cells as stem cells still requires functional demonstration of 
multipotency, self-renewal and longevity. Potential stem cell sources are 
considered below. 
 
Neural progenitor cells (NPCs) 
Although a commonly held belief that Ôthe brain does not regenerateÕ, it is now 
accepted that spontaneous post-natal (adult) neurogenesis can occur.188 In 
both human and animal adult brain there are multiple sites of ongoing neuronal 
and glial formation. During development human neural stem cells reside in the 
periventricular regions and cerebral cortex and have been shown to persist into 
adulthood in a number of sites including the dentate gyrus of the hippocampus, 
substantia nigra and olfactory bulb.188-192 Animal models demonstrate that 
ischaemic stroke is associated with differentiation of cells into neurons 
phenotypically similar to those lost in the ischaemic lesion,173 a finding 
suggesting that the adult brain has capacity for self repair. As observed in 
rodents, subventricular and hippocampal cells from adult human brain can be 
expanded in vitro, can differentiate into all three neural cell lineages (neuronal, 
astrocytic and oligodendroglial) 193 and were shown to improve functional 
recovery when administered intravenously into a rat model of stroke.194 
Conflicting results were been seen when human foetal derived neural stem cells 
were transplanted into stroke rats;195 though the cells were shown to migrate 
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throughout the damaged striatum, cells within the transplant core were 
undifferentiated and of immature neural lineage. Virtually none of the grafted 
cells differentiated into astrocytes or oligodendrocytes.  
 
Embryonic and foetal stem cells  
Embryonic stem cells are capable of producing large quantities of neural 
progenitors and, in principle, are pluripotent with unlimited expandability; murine 
embryonic stem cells have been observed to differentiate into neurons and glial 
cells when grafted into stroke rats 196, 197 and survive for up to 12 weeks. One 
potential drawback is that they tend to develop a heterogeneous mix of neural 
precursors and differentiated neurons or glia as well as residual stem cells and 
a small percentage of non-neural cells;198 the challenge here is to direct 
differentiation into producing a homogenous cell population. Another 
disadvantage is their potential for malignant transformation. For example, when 
undifferentiated murine embryonic stem cells were xenotransplanted into a rat 
model of stroke, neuronal differentiation was observed; when the same cells 
were transplanted into the homologous mouse brain, the cells did not migrate 
and they produced a highly malignant teratocarcinoma.199  
 
Sufferers of ParkinsonÕs disease appear to have benefited from human foetal 
stem cell transplantation,200 but these cells are in limited supply and their use is 
fraught with ethical issues in obtaining human tissue for the purpose of 
obtaining stem cells. Patients with ParkinsonÕs disease and HuntingtonÕs 
disease also have undergone stem cell transplantation with foetal porcine 
neurons 201, 202 and this donor source is considered as relatively safe. However, 
the insertion of foreign cells brings the risk of rejection and the need for chronic 
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immunosuppression. Furthermore, xenotransplantation may lead to 
transmission of porcine viruses, such as the porcine endogenous retrovirus, 
although one study did not find any evidence of this problem.203 
 
Immortalised cell lines 
Cells derived by either genetic transformation or cultured embryonic and adult 
tissue offer a ready and unlimited source of cells and thereby remove the 
ethical concerns of obtaining aborted foetal tissue. For example, LBS-Neurons 
(Layton Bioscience, Inc) were produced from a NT2/D1 human precursor cell 
line and were induced to differentiate into neurons by the addition of retinoic 
acid. This cell line was originally derived from a human testicular tumour more 
than 20 years ago.204 The final product gives a neuronal cell population virtually 
indistinguishable from terminally differentiated post-mitotic neurons.205 
Malignant transformation following therapeutic transplantation of such cells is a 
key concern for this approach. 
 
Induced pluripotent stem cells 
Somatic cells (such as fibroblasts) can be programmed, with the addition of 
transcription factors, to pluripotent stem (iPS) cells.206 These cells exhibit the 
morphology and growth properties of embryonic stem (ES) cells, and like ES 
cells, they have the potential to form tumours when transplanted into the 
ischaemic brain;207 in this particular study, transplanted iPS cells formed much 
larger tumours in post-ischaemic brain than in sham operated animals. 
Nonetheless, transplanted iPS cells have been shown to induce functional 
recovery in the stroke-damaged mouse in a more recent study, without 
evidence of tumour formation.208 Improvement was probably due to enhancing 
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endogenous plasticity (with evidence of increased vascular endothelial growth 
factor levels) rather than through direct neuronal replacement. Functional 
neurons can also be generated through reprogramming somatic cells without 
Ôde-differentiatingÕ to pluri-potent stem cells.209 These induced neuronal (iN) 
cells may, therefore, eliminate the risk of tumour formation posed by iPS cells. 
Both cell types offer a potential patient-specific approach to autologous cell 
transplantation. 
 
Stem cells derived from the blood and bone marrow 
Bone marrow stromal cells, umbilical cord blood and peripheral blood stem cells 
(PBSCs) are alternative sources of stem cell and their use carries minimal 
ethical unease when transplanted in an autologous manner. Bone marrow and 
umbilical cord blood are composed of multiple cell types containing 
haematopoietic and endothelial precursors (CD34+ cells) and non-
haematopoietic cells (mesenchymal stromal or CD34- cells). Approximately 10-
20% of bone marrow derived stem cells (BMSCs) are multipotent, with the 
remainder representing more differentiated committed cells.210  
 
The CD34 molecule is a cell surface glycoprotein expressed on haematopoietic 
stem cells (HSCs) and used to facilitate their identification, though CD34-ve 
HSCs may exist.211 An ischaemic stroke leads to mobilisation of CD34+ cells 
(as also seen in myocardial infarction 212), which occurs in bursts over the first 
10 days post stroke;213, 214 those with higher levels of CD34+ cell mobilisation 
have a better neurological outcome.213 Furthermore, levels of stromal derived 
factor (SDF-1") and stem cell factor (implicated in stem cell signalling) are 
correlated with increases in endothelial progenitor cells post ischaemic 
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stroke.215 The origin and fate of these cells are not known. Interestingly, 
circulating CD34+ counts are inversely related to subsequent recurrent cerebral 
infarction 216 and cardiovascular events.217 Considering these changes, it is 
reasonable to hypothesise that promoting the mobilisation of CD34+ cells may 
be of therapeutic benefit. In one recent study, mononuclear cells were isolated 
and cultured ex vivo from the peripheral blood of 30 acute stroke patients.218 
These ÔoutgrowthÕ cells were a heterogeneous population of cells with 
endothelial and neuronal morphologies; the neuronal outgrowth cells, 
transplanted 4 days post ischaemia into rat brains, survived (for over 6 months), 
differentiated into neuronal phenotypes and helped improve functional recovery. 
 
It is contentious as to whether BMSCs can transdifferentiate into neural cells; 
they can adopt neural characteristics 181, 219, 220 but the cells are atypical 
(spherical in nature with few processes 221) and it is argued that transplanted 
cells spontaneously fuse with recipient cells and subsequently adopt their 
phenotype.222 Additionally, murine haematopoietic stem cells demonstrate an 
age-dependent diminution of self-renewal, increased apoptosis and functional 
exhaustion under conditions of stress.223 Nevertheless, BMSCs improved 
outcome in experimental models of stroke,164, 224 and cognitive function was 
seen to be preserved with intravenous transplantation of mesenchymal stem 
cells into rat models of MCAo.225  
 
The stem cell marker CD133, a transmembrane cell surface antigen, is 
specifically expressed on 30-75% of CD34+ cells and has potential benefit for 
stem cell transplantation since they are less differentiated. Behavioural and 
neurological improvement has been demonstrated with intravenous infusion of 
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CD133+ cells in stroke rats;226 however, in this particular study,226 behavioural 
improvement was only apparent using intravenous transplantation within 1 hour 
of the stroke (compared to delivery at 3 days post stroke) and reduction of 
cerebral infarct size was only seen when the cells were transplanted 
intracerebrally. 
 
Bone marrow derived stem cell trials have progressed further in cardiac 
patients. Preliminary safety studies have evaluated stem cell use in both acute 
and chronic ischaemic heart disease but data are limited.227 In a recent 
Cochrane Review of 33 randomised controlled trials (1765 participants),228 
stem/progenitor cell treatment of acute myocardial infarction improved left 
ventricular function, which was maintained in the long-term, but there was no 
effect on morbidity and mortality. There was significant clinical heterogeneity 
and further work addressing optimum cell type, cell dose and administration 
time are still required before large scale clinical trials are commenced. 
 
Mobilisation of stem cells 
Production of stem cells derived from bone marrow is stimulated by hormones 
called colony stimulating factors (CSFs). Stem cell factor (SCF) regulates 
differentiation of CD34+ stem cells; granulocyte-colony stimulating factor (G-
CSF) Ð neutrophils; erythropoietin (EPO) Ð red blood cells; granulocyte-
macrophage-colony stimulating factor (GM-CSF) Ð macrophages and 
neutrophils; macrophage-colony stimulating factor (M-CSF or CSF-1) Ð 
monocytes; and thrombopoietin (TPO) Ð platelets. SCF, G-CSF, EPO, GM-CSF 
and M-CSF have all been evaluated in pre-clinical models of ischaemic stroke; 
229-233 studies using G-CSF and EPO have advanced to human stroke trials. 
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Intentional recruitment of haematopoietic CD34+ stem cells from bone marrow 
to peripheral blood with G-CSF is a clinical process termed peripheral blood 
stem cell (PBSC) mobilisation. Although the mechanism is poorly understood, 
G-CSF alone or with chemotherapy is used routinely in clinical practise to 
reduce the duration of neutropenia in patients with haematological disease, or 
for mobilising and harvesting PBSCs for subsequent autologous or allogenic 
infusion. Its use in stroke is novel and under investigation in both animals and 
humans. For therapeutic purposes, autologous marrow stem cells could be 
obtained but this is unattractive in view of the need for multiple marrow 
punctures.  
 
The mechanisms of action of G-CSF are probably multimodal. Work on the 
effects of G-CSF revealed that neurons and adult neural stem cells express a 
G-CSF receptor and its expression is induced by ischaemia.137 It is thought that 
the neuroprotective effect of G-CSF is mediated by anti-apoptotic activity via 
up-regulation of Stat 3 (signal transducer and activator of transcription 3) and 
the JAK/STAT signaling pathway.234 Pre-clinical studies also show that G-CSF 
may have an anti-inflammatory role as it causes suppression of inducible nitric 
oxide synthase (iNOS) 234 and other inflammatory mediators such as 
interleukin-1 beta.138 If G-CSF is administered subacutely then mechanisms of 
recovery are more likely to relate to PBSC cell migration, enhancing neurorepair 
via angiogenesis and neurogenesis. Despite the paucity of preclinical studies 
addressing this time-window of drug administration, G-CSF has been shown to 
be effective in promoting long-term functional recovery at various time points up 
to one week post stroke.235, 236 These mechanisms should be distinguished from 
stem cell trials assessing direct intracerebral implantation since it is not clear 
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that mobilised PBSCs target, migrate and remain in the stroke lesion, although 
it has been observed in animal models following intravenous administration of 
CD34 cells 48 hours post-stroke.161 
 
In rodent models of ischaemic stroke, a number of groups have demonstrated 
G-CSF to be neuroprotective at various doses,237 in the presence of 
thrombolysis, 238, 239 induce functional recovery 231, 240 and promote 
angiogenesis 235, 240, 241 and neurogenesis.137, 240, 241 All have illustrated that G-
CSF causes a reduction in stroke lesion volume. However, G-CSF can also 
lead to impaired behavioural function 167 and may have no benefit when given in 
the chronic phase of stroke 242 or in global ischaemic models.243 Interestingly, 
G-CSF deficient mice have larger infarcts and these effects are reversed by G-
CSF administration.244 G-CSF induced improvements in functional outcome 
appeared to be preserved in aged stroke rats.245 No deleterious effects were 
seen with co-administration of thrombolysis in one study.246 Although G-CSF 
increased total leukocyte counts, there was no evidence of neutrophils 
infiltrating the stroke lesion, important since this might lead to microvessel 
occlusion and the release of free radicals and interleukins.237 G-CSF improved 
sensorimotor recovery in a rat model of cerebral haemorrhage 247 and, in vitro 
can protect human cerebral neurons from ischaemia.248 G-CSF is a candidate 
treatment for stroke 249 and is being assessed in phase III clinical trials. 
 
SCF is a haemopoietic cytokine produced by bone marrow (BM) stromal cells. It 
has limited clonogenic activity when used alone but augments the other colony 
stimulating factors, including G-CSF.250 When administered following middle 
cerebral artery occlusion in pre-clinical studies, SCF induced neuroproliferation 
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and neurogenesis,229 the former by a combination of inducing migration of BM 
derived cells to the peri-infarct area and stimulating proliferation of intrinsic 
neural progenitor cells.251 Alone and in combination with G-CSF, SCF can 
reduce infarct size and induce functional improvement in rat models of acute 
stroke.252 Similarly, in experimental chronic stroke (3.5 months post ictus), SCF 
+ G-CSF treated rats had an improved outcome and reduced infarct volume 
when compared to control.242 
 
EPO controls red cell production and has been available in recombinant form 
since 1985; it has been utilised for the treatment of anaemia in patients with 
end-stage renal disease since 1988. EPO was neuroprotective in experimental 
stroke 230 and increased functional recovery,253 effects possibly mediated by 
inhibiting apoptosis in the penumbra.254 In a small clinical trial, EPO was safe 
and well tolerated 255 but in the following phase III trial safety concerns were 
raised.256 Derivatives of EPO, which do not alter red cell kinetics but retain their 
neuroprotective activity, have been developed;257, 258 clinical studies of these 
have yet to be reported. 
 
GM-CSF can be used to mobilise stem cells (CD34+) and activate 
macrophages, and has been shown to induce vascular proliferation. GM-CSF 
improved collateral flow in patients with coronary artery disease.259 In stroke 
patients, baseline GM-CSF levels have been seen to be higher when compared 
to control, but no correlation has been found with clinical or neurological 
outcome.260 Pre-clinical studies have found that GM-CSF stimulates 
arteriogenesis, improves cerebral blood flow,261 and protects against 
haemodynamic injury in a rat model of cerebral artery occlusion.262 Intra-carotid 
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injection of GM-CSF increased numbers of activated microglial cells and 
protected against neuronal apoptosis after transient middle cerebral artery 
ischaemia in rats;263 GM-CSF given intravenously crossed the blood-brain 
barrier and counteracts programmed cell death,264 and intra-peritoneal 
administration decreased infarct volume and improved locomotor recovery in 
rats with ischaemic stroke.265 
 
M-CSF (colony stimulating factor-1, CSF-1) selectively stimulates the 
proliferation and differentiation of monocytes, as well as granulocytes and 
platelets, indirectly through the generation of interleukin-6 and G-CSF. M-CSF 
has also been reported to prevent the progression of atherosclerosis. Serum 
levels of M-CSF were elevated in patients with previous cerebral infarction 
compared with healthy people.266 In vitro, M-CSF is neuroprotective, inhibiting 
excitotoxic neuronal apoptosis.233 In mice, recombinant M-CSF increased 
neuronal survival and reduced the size of the cerebral infarct.267 
 
Development of stroke trials using stem cells 
Although many studies assessing stem cells in pre-clinical stroke have been 
reported, and limited clinical trial data are now available, many questions 
remain unanswered. It is also important to recognise the lack of published 
studies reporting a negative or neutral outcome. This publication bias can 
perpetuate the development of inappropriate clinical trials that will not answer 
the uncertainties that remain in this field.268 It is vital that future experimental 
studies are of high quality (for example, conforming to the STAIR criteria 269) 
and have standardised protocols and outcome measures so that they can be 
fairly compared. 
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One possible advantage of treating stroke with stem cells is their potentially 
wide therapeutic window. The optimal time of administration post stroke may 
relate to the micro-environment of the damaged area, i.e. should stem cells be 
administered during the acute phase of stroke (exerting a neuroprotective 
effect) at a time when inflammatory responses are maximal or will delayed 
treatment be effective at a time when scar tissue has formed? The inflammatory 
response can last up to several weeks and it may be that stem cells could 
exacerbate or attenuate this process. It may be that stem cells will work by 
directly replacing damaged neurons and supporting cells, or, more likely, by 
stimulation of endogenous regeneration through secretion of growth factors. It 
may therefore be of benefit to transplant cells when the initial inflammatory 
response has settled giving the cells an opportunity to survive and integrate 
with the host tissue.  A recent study, evaluating aged stroke rats (24 months 
old) with distal MCA occlusion,270 transplanted human-embryonic stem cell 
derived neural precursor cells intracerebrally as late as 3 weeks post infarct and 
still induced a reduction in infarct volume and an improvement in functional 
outcome. Another study assessed human neural stem cells transplanted as 
neurospheres into a rat model of ischaemic stroke at various time points post-
ictus;271 cells transplanted 48 hours after stroke demonstrated better survival 
than those grafted at 6 weeks, although the delay did not appear to cause any 
difference in magnitude of cell proliferation, differentiation and migration (it is 
not clear, however, that increased cell survival translates into functional 
benefit). Further preclinical stroke studies designed specifically to address 
timing of administration of stem cells are therefore required. 
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The ideal route for stem cell delivery is also unclear. One pre-clinical study 
compared intra-striatal, intra-ventricular and intravenous administration of 
neural precursor cells to rats with cerebral ischaemia. All routes of delivery were 
associated with cells targeting the lesion.272 Other studies have found benefit 
from intravenous delivery of stem cells;273 in a rodent MCAo model, intravenous 
administration of human umbilical tissue-derived cells improved neurological 
severity scores when compared to control at doses > 3 x106 cells/injection up to 
30 days post stroke. In contrast, a study assessing intravenous administration 
of human umbilical cord cells in stroke rats did not detect any evidence of stem 
cells in the target lesion.274 Furthermore, concern has been raised with intra-
arterial administration of cells leading to an increased risk of vascular events, 
potentially caused by clumping of cells and micro-emboli formation. The STEPS 
(Stem Cell Therapy as an Emerging Paradigm for Stroke) reports have called 
for more research into this area.275, 276 If intracerebral administration is the most 
efficient route 272 (though probably the most hazardous) then should cells be 
transplanted directly into the ischaemic lesion or distant to it (reducing the 
chance of damaging vital structures) and relying on spontaneous stem cell 
migration?163, 277, 278 Existing human safety trials used intracerebral injections of 
stem cells directly into the peri-infarct area,279, 280 a decision appearing not to be 
based on any substantial pre-clinical work. The role of immunosupression in 
such exogenous transplants also remains unclear.  
 
Relatively few studies have assessed the effects of stem cells in intracerebral 
haemorrhage (ICH). A reduction in inflammation was observed in one study 
using intravenous human neural stem cells in experimental ICH;281 the majority 
of the transplanted cells were detected in the marginal zones of the spleen with 
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only very few seen in the brain sections. Adipose derived stem cells (ASCs) 
have also been trialled in experimental ICH,282 and again, a reduction in the 
inflammatory response was seen but ASCs did not reveal any evidence of 
neuronal transdifferentiation. In contrast, allogenic bone marrow stromal cells 
(BMSC) transplanted into female rats subjected to ICH expressed neuronal 
phenotypes;283 the rats receiving BMSCs 2 months post-ICH improved 
neurologically compared to rats receiving saline only. Further work is needed to 
explore the role of stem cells in treating human ICH. 
 
Clinical trials of stem cell transplantation after stroke 
There have been no large-scale clinical trials of stem cell transplantation in 
stroke. However, a number of safety studies have been reported (table 6). 
 
In one non-controlled study, cultured neuronal cells, derived from an 
immortalised cell-line (LBS-Neurons), were transplanted into 12 patients (age 
44-75) with stroke (primarily involving basal ganglia).280 Patients received one 
of 2 doses of cells via CT-guided, stereotactic-targeting of cell implants; 
immunosuppression was achieved with intravenous methylprednisolone (during 
surgery) and then cyclosporine for 8 weeks. Although functional outcome could 
not be assessed since the study was too small and had no control group, 
positron emission tomography (PET) in 6 patients showed increased metabolic 
activity, suggesting either cell viability or the presence of inflammatory cells.280 
   
Table 6. Summary of observational and randomised controlled trials involving stem cells after stroke 
Author, year Cells Patients  
(active / 
control) 
Stroke type Administration Immunosuppression Comments 
Kondziolka   
2000 
280
 
Immortalised 
neuronal 
12 / 0 Basal ganglia 
infarct 
Stereotactic 
transplantation into 
region of the stroke 
Methylprednisolone during 
surgery. 
Cyclosporine 1 week prior to 
surgery and continued for 8 
weeks 
No effect on functional 
outcome. PET showed 
increased metabolic 
activity. 
Kondziolka  
2005 
279
 
Immortalised 
neuronal 
14 / 4 Basal ganglia 
infarct 
Stereotactic 
transplantation into 
region of the stroke 
Methylprednisolone during 
surgery. 
Cyclosporine 1 week prior to 
surgery and continued for 6 
months 
No effect on functional 
outcome. 
Savitz       
2005 
284
 
Foetal porcine 5 (of planned 
12) / 0 
MCA infarct Stereotactic 
transplantation into 
region of the stroke 
None (cells pre-treated with 
anti-MHC antibody) 
Study stopped early after 2 
SAEs 
Bang        
2005 
285
 
Autologous, 
mesenchymal 
5 / 25 MCA infarct 
 
Intravenous None Questionable study 
quality, e.g. 10 patients 
lost to follow-up 
Rabinovich 
2005 
286
 
Human foetal 10 / 11 Ischaemic and 
haemorrhagic 
stroke 
Intra-thecal None Improvement in Ôquality of 
lifeÕ in treated group. Poor 
quality report 
Suarez-
Monteagudo 
2009 
287
 
Autologous, 
mesenchymal 
5 / 0 Ischaemic and 
haemorrhagic 
stroke 
Stereotactic 
transplantation into 
region of the stroke 
None Open label. No adverse 
events. Timing of implant 
unclear 
Lee          
2010 
288
 
Autologous, 
mesenchymal 
16 / 36 MCA infarct 
 
Intravenous None Open label, observer 
blinded. 
Honmou   
2011 
289
 
Autologous, 
mesenchymal 
12 / 0 MCA infarct Intravenous None Open label. No adverse 
events 
PET, positron emission tomograpgy; MCA Middle Cerebral Artery; SAE Serious Adverse Event; BI Barthel Index 
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Interestingly, detailed histopathological study of the brain from one of the study 
patients who died at 18 months after cell implantation identified survival of 
transplanted neuronal cells with no evidence of malignancy.290 The potential for 
de-differentiation of transplanted cells back to a malignant state is a theoretical 
concern with the use of transformed stem cells derived from tumours, although 
pre-clinical studies in mice with this cell line (NT2) have demonstrated no 
toxicity or tumourgenicity.291  
 
Subsequent to this study, the same researchers performed a phase two 
randomised trial, using the same cell line, in 18 patients.279 Patients were 
between 18 and 75 years and had a fixed motor deficit that was stable for at 
least 2 months. The treated group (n=14) received one of two doses of 
implanted cell and a rehabilitation programme; the control group (n=4) had 
rehabilitation alone. The primary outcome measure, the change in the 
European Stroke Scale motor score at 6 months, did not differ between the two 
groups.279 
 
A safety and feasibility study of the use of foetal porcine cells in patients 1.5-10 
years after a middle cerebral artery infarct (affecting the striatum) has also been 
performed.284 To prevent rejection, cells were pre-treated with anti-MHC1 
antibody and no immunosuppressive drugs were given to the patients. Of the 
12 planned patients, only 5 patients entered the study following which the US 
Federal Drug Administration halted the trial prematurely as 2 patients 
developed serious adverse events. One patient suffered a cortical vein 
occlusion secondary to the surgical procedure, and the other experienced 
generalised and partial seizures while hyperglycaemic.   Such observations 
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highlight the potential risks with intracranial transplantation of stem cells and 
suggest that other modes of administration should be considered. 
 
One such alternative is to use autologous stem cells intravenously. A recent 
randomised controlled trial tested mesenchymal stem cells (MSCs) in patients 
with middle cerebral artery territory infarction.285 5 patients with persistent 
neurological deficit 7 days after their ischaemic stroke were allocated to receive 
intravenous MSCs and 25 patients acted as controls (no additional intervention 
and no sham procedure). MSCs were acquired from bone marrow aspirates and 
then cultured ex vivo to obtain sufficient quantities before re-injection into each 
patient 4-6 and then 7-9 weeks after symptom onset. At 1 year, 10 patients in 
the control group were lost to follow-up but no serious adverse events such as 
infection or tumour formation were reported. The study has demonstrated 
feasibility in administering ex-vivo cultured MSCs but the authors were heavily 
criticised for both its methods and conclusions reached 292 and have since 
issued an apology for having plagiarised sections of their discussion.293 More 
recently, the same authors have completed a long-term randomised controlled 
observer-blinded safety trial using the same cell isolation and administration 
methods in 16 patients with MCA infarct (day 7 NIHSS > 7) compared to 36 
controls.288 Mean follow up was 118 weeks during which time there were no 
significant concerns regarding tumour formation or adverse events related to 
cell delivery, and improved survival and functional outcome in the MSC treated 
group. Autologous bone marrow stem cells have also been assessed in an 
open study of 5 patients where cells were stereotactically implanted 
intraparenchymally 287 and in a further trial of 12 patients receiving 1 x108 cells 
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intravenously 36-133 days post ischaemic stroke;289 again, no significant 
adverse events related to cell delivery or tumour formation occurred in either. 
 
Yet another potential route of cell administration was reported in a Russian 
study, in which 2 x108 human foetal cells obtained from spontaneous or 
prostaglandin-induced abortions were injected intra-thecally into 10 patients 
with ischaemic or haemorrhagic stroke.286 A significant improvement in Ôquality 
of lifeÕ (as measured by a Karnofsky score) in the treatment group was 
reported. No significant adverse events were described although Òsome patients 
developed meningism and feverÓ during the 48 hours post transplantation.286 
Unfortunately, the quality of the publication is questionable as important details 
are missing including the timing of administration of stem cells and a description 
of adverse events. 
 
G-CSF in clinical stroke 
Five small, randomised controlled trials have assessed the safety of 
recombinant G-CSF after ischaemic stroke (table 7). A recently completed 
phase IIa dose-escalation trial assessed G-CSF in 36 patients (G-CSF, n=24; 
placebo, n=12) with sub-acute ischaemic stroke.294 Patients were treated 
between 7-30 days post ictus with increasing doses of G-CSF (1-10µg/kg given 
either once or daily for 5 days) given subcutaneously. G-CSF increased 
circulating CD34+ counts 10-fold (as measured by flow cytometry) in a dose- 
dependent manner and with the peak level occurring at day 5. 
 
  
Table 7. Summary of human clinical trials in G-CSF and ischaemic stroke 
Author / year Trial Design G-CSF Regimen Time after 
stroke 
Patients 
(active / 
control) 
Comments 
Shyu 2006 295 Single-blind 
controlled 
15!g/kg/day s/c 
For 5 days 
Within 7 days 7 / 3 No thrombotic complications. 
Improved outcome in G-CSF 
group but a majority of lacunar 
strokes 
Sprigg 2006 294 Double-blind 
placebo-controlled 
Dose escalation 
1-10!g/kg s/c 
For 1 or 5 days 
7-30 days post 
ictus 
24 / 12 No difference in SAEs 
although non-significant 
increase in infection rates in 
active group 
Zhang 2006 296 Double-blind 
placebo-controlled 
2 !g/kg/day s/c 
For 5 days 
Within 7 days 15 / 45 No difference in adverse 
events reported. Significant 
reduction in NIHSS 
Shabitz 2010 297 Double-blind 
placebo-controlled 
Dose escalation 
30-180!g/kg iv 
Over 3 days 
Within 12 hours 30 / 14 No difference in adverse 
events reported 
Floel 2011 298 Double-blind 
placebo-controlled 
10!g/kg s/c 
For 10 days 
>4 months 21 / 20 Feasible and tolerated. No 
effect on efficacy 
SAE serious adverse event; s/c subcutaneous; iv; intravenous; NIHSS National Institutes of Health Stroke Scale 
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A dose-dependent increase in white cell count at day 3 and decrease in platelet 
count also occurred (expected effects of G-CSF). Serious adverse event rates 
did not differ, although the frequency of infection was non-significantly higher in 
G-CSF treated patients (29% vs. 25%); stroke recurrence rates did not differ 
between the treatment groups. 
 
In a second trial, 10 patients with a NIHSS score between 9 and 20 and within 7 
days of stroke onset were randomised to 5 days of G-CSF (15 !g/kg per day, 
n=7) or control (routine care, n=3).295 Over a 12-month follow-up, patients who 
received G-CSF had a significantly greater improvement in neurological function 
and less disability than those in the control group. There was no aggravation of 
stroke symptoms or thrombotic complications. Unfortunately, the results are 
confounded since many patients receiving G-CSF had a lacunar infarction, a 
type of stroke that often improves spontaneously. In a third trial, 15 patients 
were randomized within 1 week of stroke onset to receive G-CSF and 30 to 
placebo 296. A non-significant reduction in NIHSS was noted at day 10, which 
became significant at day 20. 
 
In a Cochrane systematic review (2006) of these trials of G-CSF (as well as 
other colony stimulating factors) for stroke, G-CSF did not significantly alter 
functional outcome although there was a trend to reduced impairment.299 
Furthermore, G-CSF was well tolerated and appeared to be safe, and 
significantly increased white cell count.299 More recently, the AXIS (AX200 for 
the treatment of Ischemic Stroke) trial has assessed hyperacute intravenous 
administration of G-CSF in 44 patients, using doses between 30!g/kg and 
180!g/kg over 3 days within 12 hours of ischaemic stroke in the middle cerebral 
artery.297 G-CSF was well tolerated and there were no reported concerns 
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regarding safety even at the higher doses. Similarly, no safety issues were 
raised in a randomised placebo controlled trial of G-CSF (10 !g/kg 
subcutaneously od for 10 days) in 41 patients (21 G-CSF, 20 placebo) with 
chronic stroke (4 months post ictus).298 The primary efficacy outcome, hand 
motor function, was not affected by treatment.  
 
The long term safety of G-CSF has been monitored in 101 normal donors who 
received G-CSF for the purpose of mobilising PBSCs prior to allogenic 
transplantation; there were no obvious adverse effects over a 3-6 year follow-up 
period and, in particular, the rates of cancer and vascular disease were not 
increased.300 Nevertheless, G-CSF may cause a hypercoagulable state,301 a 
potential mechanism for increasing the risk of recurrent stroke. In healthy 
donors receiving G-CSF, in vitro bleeding time is decreased with increased 
levels of Factor VIII and fibrinogen, and reduced protein C and S activity.301 
 
Further trials of G-CSF are underway, including a phase III efficacy trial 
(hyperacute),302 a safety trial of acute administration (within 48 hours, n=20),303 
and STEMS-2, a phase IIb randomised placebo-controlled trial of subacute 
treatment with G-CSF (n=60),304 described in full detail in subsequent chapters.  
Data from completed and ongoing trials will suggest whether larger phase III 
trials of G-CSF in subacute stroke are warranted. Although other colony 
stimulating factors such as stem cell factor (SCF), granulocyte-macrophage-
colony stimulating factor (GM-CSF) and macrophage-colony stimulating factor 
(M-CSF or CSF-1) also mobilise bone marrow-derived stem cells (and 
recombinant forms are available), trials in patients with stroke have not been 
reported.299 
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Outcome Measures 
There is no single accepted outcome measure after stroke that encompasses 
assessment of all its potential consequences. Several tools are therefore 
required to measure multiple outcomes including motor and sensory function, 
vision, language, cognition, affect and function. This lack of consensus 
regarding the best choice of primary outcome measure, which affects the 
design, interpretation and comparison of all stroke trials.305 A number of 
measures used in subsequent chapters are discussed below. 
An outcome measure needs to be reliable, reproducible, standardised, valid 
(measure what it intends to measure) and sensitive. Examples of such tools 
includes the National Institutes of Health Stroke Scale (NIHSS) 306 and 
Scandinavian Neurological Stroke Score (SNSS or SSS) 307 which measure 
specific neurological deficits. They are reproducible, easy and quick to perform 
and are useful in predicting outcome.307, 308  
 
The NIHSS is a 15-item scale providing key components of the neurological 
examination (table 8). It offers quick and accurate assessments of patients with 
stroke and can be implemented by all types of health care provider.306 Video 
and online training is available, important for standardisation for multi-centre 
clinical trials. Both intra- and inter-observer reliability are excellent 309 and it 
yields high correlation coefficients with infarct volume (one measure of 
validity).310 However, for equivalent NIHSS scores, stroke volume in the right 
hemisphere may be larger when compared to the left hemisphere.311 The 
scoring system also favours the left hemisphere. Of a total of 42 points, 7 are 
dedicated to language function, whilst there is only a maximum of 2 for neglect. 
Another pitfall is the lack of detailed assessment of the cranial nerves Ð patients 
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with brainstem or cerebellar infarcts can be quite disabled yet produce a 
relatively low NIHSS score. Nonetheless, baseline NIHSS scores strongly 
predict outcome at both 7 days and at 3 months.312 
 
Table 8. The National Institutes of Health Stroke Scale 
1a Level of consciousness 
0=Alert 
1=Not alert, arousable 
2=Not alert, obtunded 
3=Unresponsive 
1b Questions 
0=Answers both correctly 
1=Answers one correctly 
2=Answers neither correctly 
1c Commands 
0=Performs both tasks 
correctly 
1=Performs one task 
correctly 
2=Performs neither task 
2 Gaze 
0=Normal 
1=Partial gaze palsy 
2=Total gaze palsy 
3 Visual fields 
0=No visual loss 
1=Partial hemianopia 
2=Complete hemianopia 
3=Bilateral hemianopia 
4 Facial palsy
 
0=Normal 
1=Minor paralysis 
2=Partial paralysis 
3=Complete paralysis 
5a Left motor arm 
0=No drift 
1=Drift before 10 s 
2=Falls before 10 s 
3=No effort against gravity 
4=No movement 
5b Right motor arm 
0=No drift 
1=Drift before 10 s 
2=Falls before 10 s 
3=No effort against gravity 
4=No movement 
6a Left motor leg 
0=No drift 
1=Drift before 5 s 
2=Falls before 5 s 
3=No effort against gravity 
4=No movement 
6b Right motor leg 
0=No drift 
1=Drift before 5 s 
2=Falls before 5 s 
3=No effort against gravity 
4=No movement 
7 Ataxia 
0=Absent 
1=One limb 
2=Two limbs 
8 Sensory 
0=Normal 
1=Mild loss 
2=Severe loss 
9 Language 
0=Normal 
1=Mild aphasia 
2=Severe aphasia 
3=Mute or global aphasia 
10 Dysarthria 
0=Normal 
1=Mild 
2=Severe 
11 Extinction 
0=Normal 
1=Mild 
2=Severe 
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The Scandinavian Stroke Scale was developed following a trial of 
haemodilution in ischaemic stroke.313 The maximum score is 48 (table 9), and 
unlike the NIHSS, the higher the score, the better the outcome. Scores correlate 
well with 3-month outcome.307 Inter-observer agreement is very good but 
disadvantages include the absence of assessing neglect and it was initially 
intended for use in conscious patients.313 Motor power is assessed on the 
affected side only. 
 
Table 9. The Scandinavian Stroke Scale 
Consciousness 
6=fully conscious 
4=somnolent, can be 
awaked to full 
consciousness 
2=reacts to verbal command, 
but is not fully conscious 
0=unconscious 
Eye movement: 
4=no gaze palsy  
2=gaze palsy present  
0=conjugate eye deviation 
Speech:  
10=no aphasia  
6=limited vocabulary or 
incoherent speech  
3=more than yes/no, but 
not longer sentences  
0=only yes/no or less 
Arm, motor power 
6=raises arm with normal 
strength 
5=raises arm with reduced 
strength 
4=raises arm with flexion in 
elbow  
2=can move, but not against 
gravity  
0=paralysis 
Leg, motor power 
6=normal strength  
5=raises straight leg with 
reduced strength  
4=raises leg with flexion of 
knee  
2=can move, but not 
against gravity  
0=paralysis 
Hand, motor power 
6=normal strength  
4=reduced strength  
2=some movement, 
fingertips do not reach 
palm  
0=paralysis 
Gait 
12=walks 5 m without aids 
9=walks with aids  
6=walks with help of another 
person 
3=sits without support 
0=bedridden/wheelchair  
Orientation 
6=correct for time, place 
and person   
4=two of these 
2=one of these 
0= completely disorientated 
Facial palsy:  
2=none/dubious 
0=present 
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The Barthel Index (BI) assesses activities of daily living (ADLs) and is a 
commonly used, validated, primary outcome measure in stroke trials.314 It is a 
10-item scale assessing feeding, bathing, personal grooming, bowel and 
bladder control, toileting, transfers, ambulation and stair climbing.  
 
Table 10. The Barthel Index 
Bowels 
0=Incontinent (or needs to 
be given enema) 
5=Occasional accident 
(once/week) 
10=Continent 
Bladder 
0=Incontinent, or 
catheterised and unable to 
manage 
5=Occasional accident (max 
once per 24 h) 
10=Continent  
Transfer 
0=Unable, no sitting balance 
5=Major help (one or two 
people, physical), can sit 
10=Minor help (verbal or 
physical) 
15=Independent 
Toilet use 
0=Dependent 
5=Needs some help, but can 
do something alone 
10=Independent (on and off, 
dressing, wiping) 
Feeding 
0=Unable 
5=Needs help cutting, 
spreading butter, etc 
10=Independent (food 
provided in reach) 
Stairs 
0=Unable 
5=Needs help (verbal, 
physical, carrying aid) 
10=Independent up and down 
Mobility 
0=Immobile 
5=Wheelchair independent, 
including corners, etc. 
10=Walks with help of one 
person (verbal or physical) 
15=Independent (but may 
use any aidÑeg, stick) 
Dressing 
0=Dependent 
5=Needs help, but can do 
about half unaided 
10=Independent (including 
buttons, zips, laces, etc) 
 
Grooming 
0=Needs help with personal 
care 
5=Independent 
face/hair/teeth/shaving 
(implements provided)  
Bathing 
0=Dependent 
5=Independent (or in shower) 
 
Again, it is simple to use but it does not help to discriminate between patients at 
the upper end of the scale; that is a maximum score can be reached before 
functional improvement has stopped (a ÔceilingÕ effect). This can be overcome 
with more detailed functional assessments such as the Nottingham Extended 
Activities of Daily Living (NEADL), which is validated and sensitive to an 
effective therapeutic intervention.315, 316 The BI can also be susceptible to the 
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Ôfloor effectÕ in the setting of acute stroke Ð patients with minor stroke are often 
bed-bound in the first few hours and will score very low on the BI. In addition, 
many aspects of functional living are not included in the BI, such as language, 
vision and emotional impairment. For example, a patient with severe aphasia 
may sore a maximum BI but is unable to function at home without assistance. 
 
The modified Rankin Score (mRS) 317 is now the commonest assessment tool 
used in stroke trials and is a measure of disability and dependency on a 7 level 
ordinal scale ranging from no symptoms to death (shown below).  
 
Table 11. The modified Rankin scale 
0=no symptoms  
1=no significant disability, despite symptoms Able to perform all usual duties and activities 
2=slight disability Unable to perform all previous activities but 
able to look after own affairs without 
assistance 
3=moderate disability Requires some help, but able to walk without 
assistance 
4=moderately severe disability 
 
Unable to walk without assistance and 
unable to attend to own bodily needs without 
assistance 
5=severe disability Bedridden, incontinent, and requires constant 
nursing care and attention 
6=dead  
 
Its simplicity allows it to be applied to multi-centre trials with consistent results. 
Compared to the Barthel Index, the mRS is a better instrument for 
differentiating between changes in mild-moderate disability; it may also reflect 
disability from an emotional context.318 However, it is subject to Ôinterpretation 
variabilityÕ,319 especially in the middle of the scale, which could potentially lead 
to reporting negative or neutral trials that are actually positive. Training 
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programmes (DVD or internet based) and centralised adjudication are 
strategies that may reduce interpretation variability. A structured interview can 
also improve reliability, with agreement in 81% of cases.320 Attempts to 
measure the mRS by telephone will significantly reduce reliability and is not 
recommended.321 Other disadvantages include the scaleÕs lack of specificity, 
not including domains such as cognition, vision and language, but also the 
source of disability. If a patient is bed-bound due to a hip fracture, they will 
score highly on the mRS even if their stroke is minor. 
 
The incidence of dementia is high after ischaemic stroke 322 and the Mini-mental 
State Examination (MMSE) is a 30 point questionnaire assessing orientation, 
memory, language, attention, and construction. It is a valid tool and correlated 
with educational level.323, 324 Depression is also common after stroke 325 and is 
often difficult to distinguish from dementia. Various tools can be utilised to 
measure its severity including the Geriatric Depression Scale 326 and the Zung 
depression scale.327 These scales are not stroke specific and suffer when 
patients with aphasia or visual disturbance are included. More specific 
depression assessment tools for patients with aphasia have also been 
developed; the SADQ-H10 (10-item Hospital version of the Stroke Aphasic 
Depression Questionnaire is valid and reliable in measuring depressive 
symptoms in stroke patients with aphasia.328 
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Systematic review and meta-analysis methodology 
Three of the subsequent chapters are based on systematic review and meta-
analysis and a review of its methodology is described.  
Traditional review articles summarise the medical literature in a particular field, 
forming a narrative of the existing evidence. This approach is subject to a 
biased interpretation since the overview of the primary studies is unlikely to 
have been approached in a thorough, objective and standardised way. A 
systematic review attempts to reduce bias and offers the following 
advantages:329 
¥ Explicit methods reduce bias in study identification. 
¥ More reliable and accurate conclusions. 
¥ Accumulation and summary of large amounts of information. 
¥ May reduce the delay between identification of an effective strategy and its 
implementation. 
¥ In studies of generalisable results (lack of heterogeneity), findings can be 
formally compared. 
¥ Identification of reasons for heterogeneity 
¥ Subgroup hypothesis generation 
¥ Quantitative assessment (meta-analysis) can increase the precision of the 
result 
 
Systematic reviews can be performed on any important clinical question, which 
must be defined precisely, so papers identified following a literature search can 
be explicitly included or excluded. The figure below, derived from the Cochrane 
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Collaboration Handbook (http://www.cochrane-handbook.org), identifies the 
methods for a systematic review of randomised controlled trials. 
 
Figure 6. Methodology for systematic review of randomised controlled trials 329 
 
 
The search clearly needs to be comprehensive, and attempts made to identify 
studies that may be missed by standard database search engines, including 
reviewing references of published articles, searching conference proceedings 
and Ôgrey literatureÕ (e.g. pharmaceutical industry files), and attaining 
unpublished sources of information via personal communication. Once 
selected, the quality of the studies should be assessed. Various systems can be 
used, for example the Jadad scoring system for RCTs, which provides an 
overall score for evidence of randomisation and blinding (and their methods) 
and how data is managed following participant withdrawals.330 Cochrane review 
methods also take into account evidence of Ôreporting biasÕ (evidence of 
selective outcome reporting). 
  88 
Comparable data from selected studies can be extracted, tabulated, 
synthesised and meta-analysed. A pictorial representation of this data is a 
Ôforest plotÕ, an example of which is shown in figure 7. The data are comparing 
the effects of stroke ward care versus a general ward on stroke patient outcome 
(death by the end of scheduled follow up). The horizontal lines represent each 
trial, the square in the middle is the point estimate of the difference between the 
groups, and the width of the line is the 95% confidence interval of the estimate. 
If the confidence interval (CI) crosses the Ôline of no effectÕ (the vertical line 
down the middle) then either there is no difference between groups or the 
sample size is too small to be confident of where the true result lies. The 
diamond at the bottom of the plot represents the pooled data of all of the trials 
and will have a narrower CI. In this particular example, data from the pooled 
trials shows stroke ward care reduces death, odds ratio 0.83 (95% CI 0.71-
0.96); this translates to a number needed to treat (NNT) of 25. 
Figure 7. Example of a forest plot. Effects of stroke ward care versus general 
ward care on death (by the end of scheduled follow up).331 
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One of the main problems with meta-analysis is comparing studies of different 
designs (Ôcomparing apples with pearsÕ), resulting in heterogeneity. Statistical 
software will measure statistical (not clinical) heterogeneity using the "2 and the 
!
2 tests. "2 tests whether there is greater spread of results between studies than 
is due to chance, and a value of <0.1 usually suggests this. The !2 test tries to 
quantify any heterogeneity present, a value of >40% usually suggests this.332 In 
the example forest plot above there is no statistical heterogeneity. If it is 
present, sources of heterogeneity should be sought. Furthermore, if clinical 
heterogeneity is thought to be present then a Ôrandom-effectsÕ model of analysis 
should be used; this model assumes that individual studies are estimating 
different treatment effects and that there is variability of distribution around a 
central value. In contrast, a fixed-effect model assumes a single common effect 
of every study with no statistical heterogeneity. Sensitivity analyses can also be 
performed on meta-analysis results, which tests whether the findings are robust. 
This can be done by removing certain studies from the analysis (e.g. those of 
poor quality) and reviewing the effect on the overall result. 
An additional factor to take into account is the potential presence of publication 
bias, i.e. studies that are negative or neutral are less likely to be published. This 
can be visualised on a funnel plot (or EggerÕs plot) which plots the precision of 
the estimate of each study (such as the standard error) on the vertical axis 
against the treatment effect on the horizontal axis. If there is no publication bias, 
the studies will be distributed uniformly within a ÔVÕ shape (in the absence of 
heterogeneity, 95% of the trials should lie within the funnel). If there is bias, 
funnel plots will appear asymmetrical.333, 334 Funnel plots can be misleading, 
however, since the scale of the y-axis will change the appearance of the chart. 
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AIMS: THE CURRENT INVESTIGATION 
The potential application for stem cell therapy is vast and its development for 
use in stroke is still in its infancy. Trials are also underway evaluating 
haematopoietic precursors mobilised with G-CSF, an approach offering an 
autologous means of administrating stem cells for therapeutic purposes. This 
thesis will concentrate on the use of G-CSF in stroke with the following aims: 
1. To systematically analyse the use of granulocyte-colony stimulating 
factor in experimental stroke and its effects on infarct size and functional 
outcome. 
2. To systematically review stem cell labelling with iron based techniques in 
the context of experimental ischaemic stroke. 
3. To perform a pilot randomised placebo-controlled trial assessing the use 
of granulocyte-colony stimulating factor in mobilising bone marrow stem 
cells in sub-acute stroke. 
4. To update a systematic review assessing the use of colony stimulating 
factors (including erythropoietin, granulocyte colony stimulating factor 
and analogues) for stroke. 
5. To assess the potential for stem cell migration using paramagnetic 
labelling of CD34+ haematopoietic cells and their identification using MRI 
after stroke. 
6. To assess CD34+ cell uptake of superparamagnetic iron oxide (SPIO) 
with and without a transfection agent. 
7. To determine the histopathological characteristics of stroke brain post 
treatment with G-CSF. 
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CHAPTER 2 
GRANULOCYTE-COLONY STIMULATING FACTOR IN 
EXPERIMENTAL STROKE AND ITS EFFECTS ON INFARCT SIZE 
AND FUNCTIONAL OUTCOME: A SYSTEMATIC REVIEW. 
 
Publications contributing to this chapter: 
 
England TJ, Gibson CL, Bath PM. Granulocyte-colony stimulating factor in 
experimental stroke and its effects on infarct size and functional outcome: A 
systematic review. Brain Res Rev. 2009;62(1):71-82 
 
ABSTRACT 
 
Background 
Granulocyte-colony stimulating factor (G-CSF) shows promise as a treatment 
for stroke. This systematic review assesses G-CSF in experimental ischaemic 
stroke. 
 
Methods 
Relevant studies were identified with searches of Medline, Embase and 
PubMed. Data were extracted on stroke lesion size, neurological outcome and 
quality, and analysed using Cochrane Review Manager using random effects 
models; results are expressed as standardised mean difference (SMD) and 
odds ratio (OR). 
  92 
Results 
Data were included from 19 publications incorporating 666 animals. G-CSF 
reduced lesion size significantly in transient (SMD -1.63, p<0.00001) but not 
permanent (SMD -1.56, p=0.11) focal models of ischaemia. Lesion size was 
reduced at all doses and with treatment commenced within 4 hours of transient 
ischaemia. Neurological deficit (SMD -1.37, p=0.0004) and limb placement 
(SMD -1.88, p=0.003) improved with G-CSF; however, locomotor activity (>4 
weeks post ischaemia) did not (SMD 0.76, p=0.35). Death (OR 0.27, p<0.0001) 
was reduced with G-CSF. Median study quality was 4 (range 0-7/8); EggerÕs 
test suggested significant publication bias (p<0.001). 
 
Conclusions 
G-CSF significantly reduced lesion size in transient but not permanent models 
of ischaemic stroke. Motor impairment and death were also reduced. Further 
studies assessing dose-response, administration time, length of ischaemia and 
long-term functional recovery are needed. 
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INTRODUCTION 
Stroke has enormous consequences both for the individual and society. Finding 
an effective treatment for this burden is proving challenging and protection of 
the neurovascular unit 335 might be achieved through enhancing reperfusion, 
modifying neuronal activity and augmenting neurorepair. Of these, reperfusion 
is effective with alteplase 336 whilst neuroprotection has not been shown to be 
effective to date.88, 176, 337 One neuroprotectant showing promise is recombinant 
granulocyte colony stimulating factor (G-CSF). Its pharmacological and side 
effect profile is well known since G-CSF is already licensed for use in other 
indications in humans. 
 
G-CSF is a 207 amino acid glycoprotein cloned more than 20 years ago.338 Its 
recombinant form is usually administered to patients with neutropenia to reduce 
the risk of sepsis, or to volunteers willing to donate haematopoietic stem cells 
(mobilised by G-CSF) for allogenic or autologous infusion. Endogenous G-CSF 
is produced by numerous cell types including monocytes 339 (the most abundant 
source), fibroblasts,340 mesothelial and endothelial cells.341 G-CSF and its 
receptor are expressed in the penumbral region of ischaemic stroke 137 and 
recent studies have highlighted its neuroprotectant properties as a possible 
therapy for cerebrovascular disease. G-CSF also stimulates the release of stem 
cells from the bone marrow and it could, therefore, also promote neurorepair.342 
 
In light of ongoing human clinical trials assessing G-CSF in stroke, the purpose 
of this chapter is to review systematically the effects of G-CSF in experimental 
stroke and, in particular, its effect on infarct size, motor impairment and death. 
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MATERIALS AND METHODS 
Experimental (non-human) studies assessing the effects of G-CSF in ischaemic 
models of stroke (any species, age, sex and model) were sought with searches 
of Medline, Pubmed and Embase; search keywords included: ÔstrokeÕ, 
ÔcerebrovascularÕ, ÔthrombosisÕ, ÔbrainÕ, ÔcerebralÕ, ÔcerebellumÕ, Ômiddle cerebral 
arteryÕ, ÔischaemiaÕ, ÔembolismÕ and ÔG-CSFÕ. Searches were limited to animal 
studies. The reference lists of included articles and review articles were 
searched, and abstracts used to select relevant articles. Pre-specified exclusion 
criteria were used to aid selection and prevent bias and studies were included if 
the following were met: (i) a focal ischaemic stroke model, not global; (ii) 
treatment was in the acute/subacute phase i.e. <7 days, not chronic; (iii) no 
other potential neuroprotectants were administered with G-CSF (i.e. 
confounded); (iv) measures on infarct size or functional outcome were 
performed; (v) there was a control group; and (vi) data were from an original 
article, not a letter or review article. Decisions on study inclusion and exclusion 
were made by TE and PB. 
 
Data Extraction 
Summary data on total infarct size, measured as volume or area (mm3, 
percentage of normal brain, or mm2) were extracted from all eligible papers up 
to June 2009. If given, infarct volume from total brain, cortex and subcortex was 
obtained separately. Volumes corrected for oedema were chosen in preference 
to uncorrected data. Similarly, information on vital status, weight (grams), 
Rotarod test (time spent on Rotarod expressed in seconds or percentage 
compared to baseline), motor impairment (low scores indicate a better 
outcome), foot fault (number of errors and percentage of total errors made), 
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limb placement test (neurological scores) and locomotion (vertical movement 
and rearing) were also collected. If published studies used multiple groups (e.g. 
to assess dose-response relationships) then the number of animals in the 
control group was divided by the number of comparison groups. When 
numerical values were not available and contacted authors were unable to 
provide necessary information, published graphs were enlarged from the article 
and the size of axes and position of data points estimated using Grab (version 
1.3.1) on an Apple Mac. Methodological quality was assessed using methods 
previously described 343, 344 based on an eight-point STAIR criteria with one 
point given for evidence of each of the following:152 presence of randomisation, 
monitoring of temperature (not just maintenance), assessment of effect by G-
CSF dose, assessment of effect by time between stroke onset and treatment, 
masked outcome measurement, assessment of outcome at days 1Ð3, 
assessment of outcome at days 7Ð30, and assessment of outcome other than 
just lesion size. Two authors (TE and CG) independently assessed 
methodological quality and data extraction. 
 
Analysis 
Data were grouped before analysis by (i) model type (permanent or transient 
ischaemia); (ii) species; (iii) time to treatment with G-CSF; and (iv) total dose of 
G-CSF. Data from each of these groups were analysed as forest plots using the 
Cochrane Review Manager software (version 4.2.10), as used in previous 
animal meta-analyses.343, 344 Since heterogeneity was expected between study 
protocols (different species, stroke models, dose, time), random effect models 
were used. The results of continuous/ordinal data are expressed as 
standardised mean difference (SMD), with 95% confidence intervals (CI), which 
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allows data measured on different scales and in different species to be merged. 
The results of binary data are expressed as odds ratios (OR) with 95% CI. 
Studies were weighted by sample size and statistical significance was set at 
p<0.05. Publication bias was assessed by visually examining BeggÕs funnel plot 
(standard error of SMD against the SMD); asymmetry in the plot was formally 
assessed using EggerÕs test.333 
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RESULTS 
Design of Studies 
The initial search for studies identified 220 relevant publications (figure 8). Once 
pre-specified exclusion criteria were applied, a total of 19 publications were 
chosen for analysis (table 12); these came from 12 laboratories in 8 countries 
(China, France, Germany, Japan, South Korea, Taiwan, UK and USA). Only 
one negative study was identified in which G-CSF had a detrimental effect on 
behavioural function, caused brain atrophy and exaggerated the inflammatory 
response in the infarcted area.167 Studies excluded (table 13) were those 
administering G-CSF in combination with other agents such as stem cell factor 
(SCF) and those assessing chronic (i.e. >7 days post stroke) and global 
(transient bilateral common carotid artery occlusion) ischaemia. Of note, no 
functional improvement was seen with G-CSF in the studies of chronic 242 and 
global 243 ischaemia; studies co-administering SCF reduced infarct volume in 
female mice (permanent ischaemia) by 50% 345 and improved functional 
recovery in acute and subacute phases.251 
 
Of the 19 included publications, 14 studied rats, and 5 studied mice; 
hypertensive (1 of 18) and diabetic (1 of 18) rats were investigated but no 
studies in primates were identified. Some publications included more than one 
experimental condition, giving 44 studies in total (table 12). Studies included 
transient models of ischaemia (n=29) with vessel occlusion time ranging 
between 45 and 180 minutes. Permanent models were used in 12 studies; and 
a photothrombotic model, which is less likely to negatively affect survival, was 
used in 3 studies, each of which only assessed functional outcome.  
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Figure 8. Summary of trial identification process 
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Table 12. Included Studies 
 
 
 
  Study Parameters assessed [time of assessment] G-CSF dose 
(!g/kg) 
Time to Rx 
(hours) 
Species Model Route STAIR 
score 
Gibson 2005a 
Experiment 1 
Infarct volume (mm
3
) [48 hours] 
50 1 
Adult male CL57 
BL/6 mice  
T 60mins s.c. 6 
Experiment 2 
Rotarod, foot fault [daily for 7 days],  
Morris water maze [days 15 to 20] 
Gibson 2005b Infarct volume (mm
3
) [48 hours], survival 50 0 
Adult male CL57 
BL/6 mice  
P s.c. 4 
Han 2008  
Experiments 1-3 
Infarct volume (mm
3
) [4, 16 and 24 hours] 60 0.5 Male Wistar rats T 60mins i.v. 3 
Kobayashi 2006  
Experiments 1-2 
Infarct volume (mm
3
), neurological deficit (0-3 scale) [24 and 
72 hours] 
50 0.5 
Adult male CL57 
BL/6 mice 
T 60mins i.v. 4 
Lan 2008  
Experiment 1-3 
Infarct volume (mm
3
), NSS (0-18 scale) [days 7, 14 and 21] 
50 for 7, 14 and 
21 days 
0 
Male Sprague 
Dawley diabetic 
rats 
P s.c. 4 
Lee 2005  
Experiment 1 
Infarct volume (mm
3
) [day 1] 
50 for 3 days 
2 
Male Sprague 
Dawley rats 
T 90mins i.p. 7 
Experiments 2-4 
 
Rotarod (% of baseline), MLPT (0-7 scale) [1 week before 
and weekly  for 5 weeks post ischaemia] 
2, 24, 96 and 
168 
Schneider 2005  
Experiment 1 Infarct volume (mm
3
), survival  60 2 
Male Wistar rats 
T 90mins 
i.v. 5 Experiment 2 
Infarct volume (mm
3
), Rotarod (seconds and AUC), NSS* 
(0-16 scale) [72 hours] 
50 1 T 180mins 
Experiment 3 
Rotarod (seconds and AUC), NSS* (0-16 scale) [weekly, 2 
to 6 weeks post-ischaemia] 
15 for 5 days 1 
Photo-
thrombotic 
Schneider 2006  
Experiment 1 Infarct volume (mm
3
) [24 hours] 
60 4 
Male Wistar rats 
T 90mins 
i.v. 6 
Experiments 2-3 
Rotarod (seconds and AUC) [weekly, 1 to 6 weeks post 
ischaemia] 
10 for 10 days 24 and 72 
Photo-
thrombotic 
Schabitz 2003  Infarct volume (mm
3
) [24 hours], survival 60 0.5 Male Wistar rats T 90mins i.v. 4 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T, transient ischaemia; P, permanent ischaemia; s.c., subcutaneous; i.v., intravenous; i.p., intraperitoneal; NSS, neurological severity score; AUC, area under the curve; MLPT, modified limb placement test 
  
Sehara 2007a  
Experiment 1 
Infarct volume (mm
3
) [72 hours] 
50 1.5 
Adult male Wistar 
rats 
T 90mins s.c. 4 
Experiment 2 Neurological deficit (0-3 scale) [24 and 72 hours] 
Sehara 2007b  Infarct area (mm
2
) [day 7] 
 
50 
1.5 
Adult male Wistar 
rats 
T 90mins s.c. 2 
Sevimli 2009 
Experiment 1 
Infarct volume (mm
3
) [48 hours] 
250 bd for 6 days -96 
G-CSF deficient 
female C57BL/6 
mice 
T 45mins s.c. 5 
Experiment 2 Neurological deficit (0-5 scale) [24 and 48 hours] 
Experiment 3 Rotarod (seconds), survival 
Shyu 2004 
Experiment 1  Infarct volume (mm
3
) [day 7], 
50 for 5 days 24 
Adult Sprague 
Dawley male rats 
T 90mins s.c. 4 
Experiment 2 
Body swing test (% recovery) and locomotor activity  
(vertical movement)  [days 1 to 28] 
Six 2002  Infarct volume (mm
3
) [4 days], survival 50 24 
Male CL57 BL/6 
Mice 
T 60mins s.c. 0 
Solaroglu 2006  
Experiment 1 Infarct volume (mm
3
) [24 hours] 
50 
1.5 
Adult male 
Sprague Dawley 
rats 
T 90mins s.c. 5 
Experiment 2 Infarct volume (mm
3
) [72 hours]  50 for 2 days 
Experiment 3 Neurological deficit [24, 48 and 72 hours] 50 for 2 days 
Solaroglu 2009 
Experiment 1 
Infarct volume (mm
3
) [24 hours] 50 1.5 
Adult male 
Sprague Dawley 
rats 
T 90 mins s.c. 5 
Experiment 2 Neurological score (scale 3-18) [24 hours]       
Taguchi 2007 
Experiment 1  Infarct area (mm
2
) [72 hours] 
50 for 3 days 24 CB-17 mice P s.c. 6 
Experiments 2-3 
 Locomotor activity (rearing) and neurological deficit [35 
days] 
0.5, 5, 50 or 250 
for 3 days 
     
Yanqing 2006 
Experiments 1-3 
Infarct volume (mm
3
), survival, NSS (0-18 scale) [7, 14 and 
21 days] 
10 for 5 days 5 
Male Sprague 
Dawley rats 
T 60mins s.c. 4 
Zhao 2007b 
Experiment 1 Infarct volume (%) [12 weeks] 
50 for 7 days 3 
Male hypertensive 
rats 
P s.c. 4 
Experiments 2-3  Foot fault, limb placement test [1, 4, 7 and 10 weeks]       
  
Table 13. Excluded studies 
Study Reason for exclusion and comments.  
Toth 2008 
345
 G-CSF given in combination with SCF in a permanent MCAo mouse model. Treatment induced infarct volume reduction and 
enhanced angiogenesis. 
Morita 2007 
346
 Assessed inflammatory marker expression in mice with permanent ischaemia treated with a combination of G-CSF and SCF in 
acute (1 to 10 days) and subacute (11 to 20 days) phases. No assessment on functional recovery or infarct volume 
Zhao 2007a 
242
 Treatment given to rats with chronic ischaemia (3.5 months post stroke). No benefit seen in functional outcome in rats given G-CSF 
alone. SCF alone and in combination with G-CSF improved functional outcome. 
Yata 2007 
347
 
Kim 2008 
348
 
Rat models of neonatal hypoxia. No assessments of infarct volume or functional recovery. Treatment with G-CSF improved 
quantitative brain weight 
347
 and inhibited apoptosis 
348
. 
Kawada 2006 
251
 G-CSF given in combination with SCF acutely and subacutely. Permanent MCAo model used. Reduction in infarct volume and 
enhanced functional recovery. 
Matchett 2007 
243
 Effect of G-CSF on global cerebral ischaemia. No long-term (2 weeks) protection seen in neurobehavioural studies. 
Zhoa 2007b 
349
 Observed that G-CSF and SCF pass through an intact blood-brain barrier in intact rats. No stroke induced. 
Chen 2005 
350
 Article in Chinese and unable to acquire to translate. 
Willing 2003
351
 Transplanted peripheral blood progenitor cells (mobilised by G-CSF) and human umbilical cord-blood derived stem cells in rats 24 
hours after permanent MCAo. Compared to control, a reduced stroke-induced hyperactivity was observed in the transplanted 
animals. 
Hokari 2009 
352
 Bone marrow stromal cells (BMSC), pre-treated with G-CSF, transplanted into mouse stroke brain, enhanced motor function earlier 
than mice treated with Ônon-treatedÕ BMSC. 
Muller 2009 
353
  Compared neurotransmitter profile in rats subjected to photothrombotic ischaemia treated with either G-CSF or brain derived 
neurotrophic factor (BDNF). No infarct volumes or functional outcome measures. 
Sehara 2007b 
354
 In a rat model of transient MCAo, G-CSF enhanced cell proliferation in the dentate gyrus. No measures of infarct volume or 
functional outcome.  
SCF Stem Cell Factor; MCAo middle cerebral artery occlusion 
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All photothrombotic models used direct illumination of the cortex after 
sensitisation with the dye rose bengal to produce a focal infarct. G-CSF was 
given via various routes (subcutaneously n=30, intravenously n=12, and intra-
peritoneum n=4) and at various dose regimens (total dose range 50 to 3000 
mcg/kg) and time from onset of ischaemia (range from -96 hours to 1 week with 
68% of animals having ischaemia for <2 hours). Infarct size was measured 
either histologically (staining with triphenyltetrazolium chloride [TTC], toluidine 
blue, haematoxylin and eosin or cresyl violet) or with MRI evaluation (T2 
weighted images). 
 
Infarct Size 
26 studies from 19 publications (table 14) assessed the effects of G-CSF on 
lesion size in a total of 412 animals (318 rats, 94 mice). All studies measuring 
infarct volume had protocols which required that G-CSF be administered within 
24 hours. 22 of 26 studies measured these effects following transient ischaemia 
(table 14, figure 9). The presence of publication bias is suggested by a positive 
EggerÕs test of asymmetry (p<0.001, figure 10). Overall, G-CSF significantly 
reduced lesion size in transient ischaemia (SMD -1.63, 95% CI -2.14 to -1.11, 
p<0.00001). In the 4 studies using a permanent model (56 animals), G-CSF did 
not significantly reduce lesion size (SMD -1.53, 95% CI -3.42 to 0.36, p=0.11). 
Significant reductions in lesion size were seen in both rats and mice in transient 
(figure 9) but not permanent ischaemia. When only including the 21 studies that 
reported lesion volume (in mm3) in transient ischaemia, the weighted mean 
difference was -62.32 (95% CI -79.6 to -45.1); equivalent to a SMD of -1.59 
(95% CI -2.12 to -1.06). 
  
Table 14. Effect of G-CSF on lesion volume, functional outcome and survival  
(SMD, standardised mean difference; OR, odds ratio; 95% CI, 95% confidence interval; IS, ischaemic stroke) 
 
 N
o
 of Studies N
o
 of Animals SMD 95% CI p-value 
Lesion Volume 
Transient IS 22 356 -1.63 (-2.14, -1.11) < 0.00001 
Permanent IS 4 56 -1.53 (-3.42, 0.36) 0.11 
Mice 7 94 -1.61 (-2.81, -0.40) 0.009 
Rats 19 318 -1.58 (-2.12, -1.04) < 0.00001 
Motor Impairment 
Neurological deficit 11 108 -1.37 (-2.13, -0.61)  0.0004 
Rotarod (<1 week post IS) 5 87 1.11 (0.16, 2.06) 0.02 
Rotarod (5 weeks post IS) 6 115 3.24 (1.63, 4.85) < 0.0001 
Foot fault (1 week post IS) 2 32 -0.45 (-2.10, 1.19) 0.59 
Limb placement (1 week post IS) 5 95 -0.97 (-1.91, -0.04) 0.04 
Limb placement (4 weeks post IS) 5 95 -2.17 (-3.61, -0.72) 0.003 
Locomotor activity (>4 weeks post IS) 5 54 1.75 (-1.89, 5.38) 0.35 
 
N
o
 of 
Studies 
N
o
 of Animals OR 95% CI p-value 
Survival 
Transient ischaemia 6 230 0.27 (0.14, 0.451) < 0.0001 
  
  
Figure 9. Effect of G-CSF on lesion volume in transient middle cerebral artery occlusion. 
 
(N, number of animals; SMD, standardised mean difference; 95% CI, 95% confidence interval; SD, standard deviation; MCAo, middle cerebral artery occlusion) 
  
  
Figure 10. BeggÕs funnel plot. 
The relationship between lesion volume (standardised mean difference, SMD) and standard error of SMD. Smaller neutral or negative 
studies (i.e. where lesion volume was not altered by G-CSF or increased with it) are missing suggesting the presence of publication bias 
(EggerÕs test p<0.001). 
 
  
  
Figure 11. Effect of total G-CSF dose (logged) on lesion volume in models of transient ischaemia.  
Data expressed as standardised mean difference (SMD) and 95% confidence intervals. Significant reductions in lesion volume: * p<0.05; 
** p<0.001, # p<0.0001, ## p<0.00001 
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Motor Impairment 
G-CSF significantly reduced neurological deficit (SMD -1.37, 95% CI -2.13 to -
0.61, p=0.0004) in 11 studies.167, 234, 244, 355-357 Impairment was measured at 
various time points post stroke (1, 2, 3, 7, 14, 21 and 35 days); beneficial 
effects of G-CSF were seen at all times but there was no correlation between 
reduction in impairment and time to measurement (rs= 0.37, p=0.47). G-CSF 
increased time that animals stayed on a Rotarod 231, 235, 236, 244 (table 14) at 1 
and 5 weeks post ischaemia. Similarly, improvements were seen in limb 
function as assessed by limb placement tests at 1 and 4 weeks post stroke. 
This was not reflected, however, in locomotor activity (at 4 and 5 weeks), as 
assessed by vertical movements / rearing, where there was no difference 
between G-CSF and control (SMD 0.76, 95% CI -0.98 to 2.51, p=0.35).167, 240 
 
Survival 
Data on vital status were available in 6 studies;137, 231, 237, 244, 355, 358 G-CSF 
reduced the odds of dying almost 4-fold (OR 0.27, 95% CI 0.14 to 0.51, 
p<0.0001). 
 
Total G-CSF dose 
G-CSF administration varied considerably between studies: in studies using 
higher doses, regimens divided the G-CSF dose over a number of days. In an 
indirect comparison assessing total administered dose in transient ischaemia, a 
significant reduction in lesion size occurred at all doses (dose range 50 to 3000 
mcg/kg) (figure 11). None of the doses used in permanent ischaemia (50 to 350 
mcg/kg) had a significant effect on infarct size. No studies compared lesion size 
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with 2 or more doses of G-CSF but one study displayed impaired behavioural 
function with increasing doses of G-CSF (0.5 to 250 mcg/kg).167 
 
Timing of treatment 
G-CSF was administered pre-ischaemia in one study 244 and only one study 
compared time to treatment.235 Significant reductions in lesion size in transient 
models of ischaemia were seen with treatment started within 4 hours post-
ischaemia; trends to efficacy were also seen with commencement at 5 and 24 
hours post-onset of ischaemia (data not shown).  
 
Study Quality 
The median study quality score was 4 (out of 8) with range 0 to 7. The majority 
of included studies were randomised 137, 138, 231, 234-237, 241, 244, 252, 355-357, 359-361 
and used blinded outcome assessments 137, 138, 167, 231, 234-237, 240, 244, 252, 355-357, 
359, 360 and although each study varied in G-CSF dose regimen, only one study 
specifically addressed the optimal time window of drug administration.235 One 
study assessed dose response.167 After adjusting for the number of animals in 
each study, the effect of G-CSF on lesion size was not related with study quality 
(SpearmanÕs rank correlation, rs=-0.16, p=0.7). 
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DISCUSSION 
This systematic review finds that G-CSF reduces lesion size in transient 
ischaemia within 4 hours of administration, motor impairment (neurological 
severity and limb function) and death in experimental stroke. No significant 
effects were seen in permanent ischaemic models or in long term locomotor 
activity. Of note, the identified studies are biased towards those which might be 
expected to be positive, that is most studies assessed transient (32 
experiments) rather than permanent (12 experiments) ischaemia, and short 
rather than long ischaemia. 
 
The mechanisms of action of these potential effects are under investigation and 
are probably multi-factorial. First, neuroprotective activity may be secondary to 
suppression of oedema formation,138 reduction of inflammation 138, 235, 356 
(although G-CSF has also been reported to exacerbate the inflammatory 
response within the peri-infarct area 167), and anti-apoptotic effects (with 
reduced cell death in the ischaemic penumbra).137, 234, 360 Second, CD34+ 
haematopoietic stem cells (which are mobilised by G-CSF) are able to migrate 
to the site of injury when administered either intracerebrally or intravenously.362, 
363 Transplanted human bone marrow cells have been shown to generate 
neurons and astrocytes 364 but the ability of migratory stem cells to help restore 
functional and structural recovery post stroke has been questioned; in one 
study, bone marrow derived cells spontaneously fused, in vivo, with recipient 
Purkinje neurons in the cerebellum with no evidence of transdifferentiation.365 
Neurogenesis 137, 240, 241 needs to be sufficient and angiogenesis 235, 240, 241 is 
also necessary. In rats, G-CSF is able to cross the blood brain barrier when 
administered exogenously 137 and both G-CSF and its receptor are widely 
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expressed from neurons in the CNS.137 In addition, a recent post mortem series 
highlighted G-CSF receptor upregulation in human ischaemic stroke.366 Though 
these findings are encouraging, species differences in the expression profile of 
G-CSF should be considered which could alter the effect it has on infarct 
volume reduction and functional recovery.  
 
The optimal time of administration of G-CSF relative to stroke onset (0-4 hours) 
supports a role of neuroprotective mechanisms. Whether neuroreparative 
actions occur is far less clear, since only trends to efficacy were seen between 
5 and 24 hours. However, these data were limited and neurorepair may need 
stimulation after 24 hours when inflammatory responses have declined.367 With 
the exception of 2 studies, 235, 236 pre-clinical experiments of G-CSF did not 
assess the effects of the drug given beyond 24 hours, which has implications on 
human trials; the AXIS study group are assessing hyperacute administration,368 
whereas all other human safety trials administer the drug during the sub-acute 
phase.294, 295, 303, 304 Further studies are thus required to determine the extent of 
the therapeutic window. Moreover, the most appropriate G-CSF dose and 
administration regimen still needs to be established. A positive correlation was 
seen between total G-CSF dose and lesion size reduction but the true dose-
response relationship requires confirmation in a study designed to answer this. 
 
Furthermore, the infarct type (transient or permanent ischaemia) requires 
consideration. Our analysis confirms efficacy of G-CSF in rodents with transient 
ischaemia within 4 hours of administration but a better model for treatment in 
the majority of human stroke would be a permanent ischaemic model treated 
beyond 4 hours Ð a combination without evidence in this review. However, the 
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data are limited and the smaller number of animals tested in the permanent 
ischaemic model may account for the lack of significance.  
 
Human stroke is also increasingly treated with thrombolytic agents and no 
articles were identified (except for one abstract 239) assessing G-CSF in 
combination with tissue plasminogen activator (t-PA). This is especially 
important for potential neuroprotective agents which have to be administered 
early. The paucity of the number of publications assessing a combination of t-
PA and G-CSF is likely to be related to the difficulty of reproducing embolic pre-
clinical models. The procedure is technically very difficult to perform (in only a 
few laboratories worldwide) and the resulting infarct from embolism can be very 
inconsistent. Other stroke models could also influence lesion volume and 
recovery, for example, the presence of co-morbidities such as diabetes, 
hypertension, hypercholesterolaemia, female gender and increasing age. 
Ideally, all should be tested for their confounding effects.155 
 
It is important to note that the potential beneficial effects observed here could 
be artefactual in view of the presence of potential publication bias, detected for 
the effect of G-CSF on lesion size caused by transient ischaemic models. This 
suggests that neutral or negative studies were not published, or at least not 
identified despite using a comprehensive search strategy. It is possible that 
these studies have been published in a journal not included in Medline or 
Embase, or that investigators deliberately did not publish neutral/negative data, 
or that such studies are not attractive to journal reviewers and editors. 
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We assessed study quality on the basis of methodological recommendations 
derived from the STAIR consortium 152 and found no relationship between study 
quality and effect on lesion size. STAIR standards have been developed by an 
expert panel to address why so many clinical trials of neuroprotectants have 
failed, and we have previously used this scale in other meta-analyses of 
experimental regimes for stroke.343, 344 Although the majority of studies in this 
review had written evidence of randomisation (16/19 publications) and blinded 
outcome assessment (16/19), important sources of bias if unused,369, 370 other 
key methodological criteria were missing, including assessment of dose-
response (1/19) and time-response (2/19). It is, of course, possible that these 
criteria were not reported rather than not being performed. Furthermore, the 
majority of studies reporting randomisation and blinded outcome assessment 
was significantly higher than in other stroke reviews 371 and may explain why no 
study quality effect was observed here. It is also important to highlight, 
however, that absence some of the ÔqualityÕ items do not necessarily mean that 
the study was carried out to a poor standard; criteria such as randomisation, 
blinding and monitoring temperature are likely to reflect the standard to a 
greater degree than, for example, assessment of lesion volume and outcome at 
two different time-points.  
 
Research involving animals is subject to strict regulation and adhering to the 
high standards is increasingly difficult in the context of the Ô3 RsÕ. ÔReductionÕ of 
the number of animals in each experiment is encouraged by the use of sample 
size calculations and avoiding inefficient use of animals. ÔRefinementÕ methods 
are alternatives that minimise distress and pain as to improve animal well-being, 
for example, ensuring use of adequate analgesia, proper handling and 
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appropriately sized caging. ÔReplacementÕ involves utilising other methods such 
as computer simulation and in-vitro studies; human volunteer studies are also 
encouraged. The NC3Rs (National Centre for the Replacement, Refinement 
and Reduction of Animals in Research) have recently published the ARRIVE 
guidelines (Animial Research: Reporting In Vivo Experiments) to help improve 
the quality of reporting pre-clinical experiments, similar to the CONSORT 
(Consolidated Standards of Reporting Trials) statement for reporting 
randomised controlled trials.372 ARRIVE guidelines contain a 20-item checklist 
describing the minimum information required in a publication to allow accurate 
critical review of methods, results and conclusions.  
 
Meta-analysis methodology has a number of limitations and there are several 
caveats for this review. First, its findings depend on the success of identifying all 
relevant studies; the non-inclusion of some studies, perhaps due to non-
publication (Ôpublication biasÕ) means that the estimated treatment effects may 
be an over- or an under-estimate. Second, the results depend on study quality 
(so assignment and observer bias are minimised). Third, study design 
determines what data are available for each included study; e.g. Rotarod and 
limb placement assessments largely came from one study 235 thereby restricting 
interpretation. Fourth, differences in methodology and study quality limit 
interpretation and introduce heterogeneity in findings, a problem that is 
addressed, in part, by using random effects models; e.g. analysing using 
standardised mean differences allows for comparison of infarct size whether 
measured by volume, area or percentage. Last, the selection process of 
suitable publications has the potential to introduce its own bias. 
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Of note, a similar systematic review was published whilst this one was being 
written. The former observed a 0.8% reduction in infarct volume per 1 µg/kg 
increase in G-CSF dose.373 However, it included fewer articles (13 publications), 
excluded studies appropriate for analysis 167, 241, 374 and found no evidence of 
publication bias.  
 
In summary, G-CSF appears to have neuroprotective qualities, although the 
evidence is limited in nature and potentially biased. Nonetheless, G-CSF offers 
a potential multimodal therapy for ischaemic stroke and it is possible that 
meaningful reductions in infarct volume and improvements in functional 
recovery may be translated into human trials. However, further experimental 
studies are required; in particular, to assess permanent models of ischaemia, 
length of ischaemia, other species (such as primates), both sexes, and animals 
with other co-morbidities and of increasing age (mimicking patients with 
stroke).155 Studies also need to address optimal dose and route regimens, and 
elucidation of time responses. Acquiring this information is key since clinical 
trials assessing the safety of G-CSF in human stroke are already underway.294, 
295, 299
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CHAPTER 3 
TRACKING IRON LABELLED STEM CELLS IN STROKE: A 
SYSTEMATIC REVIEW 
 
Publications contributing to this chapter: 
 
England TJ, Sprigg N, Bath PMW. Tracking iron labelled stem cells in stroke: a 
systematic review. International Journal of Stroke 2010;5(s3):43.  
(Abstract poster presentation at UK Stroke Forum) 
 
ABSTRACT 
 
Background 
Labelling stem cells with iron and tracking their movement with non-invasive 
magnetic resonance imaging (MRI) may help improve our understanding of the 
mechanism of action of stem cells. This review identifies iron-labelling 
techniques used in experimental stroke models and their potential application to 
human clinical trials. 
 
Methods 
Two authors independently searched Medline and Embase (to June 2010) for 
studies examining experimental stroke with iron-labelled stem cells. Data were 
collected on label technique, administration regimen (cell type, time post ictus, 
dose, route), stroke type (transient, permanent, photothrombotic) and outcome 
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(evidence of migration, transdifferentiation, function, lesion volume). Study 
quality was assessed using an 8-point scale. 
 
Results 
17 publications containing 25 experimental paradigms were identified. 
Mesenchymal stem cells (MSC) (n=11) and neural progenitor cells (n=8) were 
used most commonly and the majority were labelled with ferumoxide (n=16); 
the use of a transfection agent (e.g. protamine sulphate) was inconsistent. Iron 
labelled MSCs did not appear to transdifferentiate into neurons or glia. Study 
quality was low so potentially introduced significant bias; no studies reported 
blinded outcome assessments and only one utilised randomisation for animal 
selection. 
 
Conclusion 
Ferumoxide is useful for tracking stem cells, is already licensed for humans, 
and could be used in clinical studies. Protamine sulphate may be used as a 
transfection agent. Further research is needed using higher quality 
experimental models that mimic human stroke. The incorporation of iron into the 
cell to provide sufficient MRI contrast needs to be balanced with its potential 
negative effects on cell viability and function. 
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INTRODUCTION 
Stem cells offer therapeutic potential for ischaemic stroke, a condition with few 
effective interventions. Numerous animal experiments have suggested 
functional benefit following treatment with a variety of stem cell types, but the 
mechanisms of action underlying improvements are poorly understood.367 It is 
likely that the role of a stem cell is multifactorial orchestrating neurogenesis, 
angiogenesis and supporting the neurovascular unit via secretion of 
chemokines and growth factors; whether stems cells contribute directly to 
neuronal replacement remains unclear. One growing area of interest in helping 
to understand stem cell function during cerebral ischaemia is establishing stem 
cell migration patterns and tracking their movement with non-invasive MR 
imaging. 
 
The majority of animal stroke models assessing stem cells determine the fate of 
a particular cell by using histological Ôsnap-shotÕ assessments. In contrast, the 
potential advantage of MRI in cell tracking is to provide near real-time cell 
movements. This can be achieved by labelling the cells of interest with an iron-
containing contrast agent which will Ônegatively enhanceÕ T2* weighted 
images.375 Numerous techniques are used, each with varying degrees of 
success; some of the agents applied in these experiments are already licensed 
for use in humans and therefore could be applicable to clinical studies. 
 
The aim of this systematic review is to assess stem cell labelling with iron based 
techniques in the context of experimental ischaemic stroke. 
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METHODS 
Search strategy and selection 
Experimental models of stem cell labelling and ischaemic stroke were sought by 
systematically searching Medline and Embase (June 2010) using keywords 
Ôstem cellÕ, Ôprogenitor cellÕ, ÔtrackingÕ, ÔmigrationÕ, ÔMRIÕ, ÔstrokeÕ, 
ÔcerebrovascularÕ, ÔthrombosisÕ, ÔbrainÕ, ÔcerebralÕ, ÔcerebellumÕ, Ômiddle cerebral 
arteryÕ, ÔischaemiaÕ and ÔembolismÕ. Two independent authors (TE, NS) 
reviewed each article and their reference list, and articles were included in the 
analysis providing they met the following criteria: (i) stroke model involving 
transient or permanent ischaemia; and (ii) analysis of stem/progenitor cells 
labelled with iron. There were no limitations on species, timing of administration 
relative to stroke ictus, or whether there was a control group. 
 
Data Collection 
Information was gathered on cell labelling technique, cell type and number, 
route of administration and differentiation capacity. Where available, data on 
functional outcome was collected, specifically the adhesive tape removal test 
(time in seconds, less time indicating better function) and foot fault test (number 
of faults expressed as a percentage of the total number of steps). When 
numerical values were not available, published graphs were enlarged and the 
size of axes and position of data points estimated using Grab (version 1.3.1) on 
an Apple Mac.376 Meta-analysis was performed with Review Manager (version 
5.0.21); continuous data is expressed as a weighted mean difference (WMD) 
with 95% confidence intervals (95% CI) and random effects models were used 
due to expected heterogeneity between studies. Median and interquartile range 
are given for non parametric data. Statistical significance was set at p<0.05. 
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Quality 
The quality of the included studies was assessed using an 8-point scoring 
system based on the STAIR report,152 as previously used in systematic 
reviews.343, 376 Each publication scored one point for evidence of (i) 
randomisation, (ii) monitoring (not measuring) physiological parameters (i.e. 
temperature), (iii) assessment of dose-response, (iv) assessment of optimal 
time of administration, (v) blinded outcome assessments, (vi) assessment of 
outcome at days 1 to 3, (vii) assessment of outcome at days 7 to 30, and (viii) 
combined measurement of lesion volume and functional outcome. A higher 
score indicates a higher quality experiment. 
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RESULTS 
Study Characteristics 
The initial search up to June 2010 identified 216 articles. Once pre-specified 
exclusion criteria were applied, 17 articles (containing 25 experimental 
paradigms) were selected for analysis (figure 12). These publications were 
presented from 10 laboratories across 7 countries (USA, Korea, Singapore, 
China, Czech Republic, Belgium and Germany). A total of 291 animals were 
studied. The majority of animals used were male rats; male mice (n=10) and 
female rats (n=47) were also studied.377-379 Studies not selected for analysis 
included those assessing haemorrhagic stroke 380 and those using alternative 
labelling methods (for example, Gadolinium,240, 278 and bioluminescence 381). 
One study provided insufficient detail in two of its three in vivo experimental 
paradigms to be fully included.382 
 
The primary aim of most studies identified was qualitative, that is to determine 
migrational cell dynamics and the use of iron as a marker for non-invasive MR 
tracking. 
 
Infarct type 
Eleven of 25 experiments used a photothrombotic stroke model (table 15), a 
method that is less likely to affect the survival of the rodents concerned. Two 
studies used an embolic method whilst the remainder utilised transient models 
of ischaemia with occlusion time ranging between 1 and 3 hours. None used a 
permanent model of ischaemia. 
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Figure 12. Summary of database search 
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Table 15. Characteristics of included studies 
Article Species 
Stroke 
type 
Transplant 
time 
Cell 
type 
Cell 
No 
MRI 
field  
Active, 
Control 
Label 
TransfÕn 
agent 
Route Outcomes 
Hoehn 
2002 
Male 
Wistar rats 
T - 1 hr 2 weeks 
ESC 
(m) 
3x104 7T 11,3 Sinerem FuGENE ic 
Cell culture, IHC (GFP), cell 
viability 
Jendelova 
2003 A 
Male 
Wistar rats 
Photo-
chemical 
24 hours MSC (r) 3x105 4.7T 15,?10 
Ferumoxide -
BrdU 
- ic 
EM, IHC (GFAP, Neu N), iron 
content Jendelova 
2003 B 
Male 
Wistar rats 
Photo-
chemical 
24 hours MSC (r) 2x106 4T 12, 6 
Ferumoxide -
BrdU 
- iv 
Zhang 
2003 
Male 
Wistar rats 
Embolic 
MCA 
48 hours NPC (r) 1x105 7T 8,?2 
Ferromagneti
c gun 
- ic 
Function: foot fault test, 
adhesive removal test, body 
weight at 7 to 35 days 
Jendelova 
2004 A 
Male 
Wistar rats 
Photo-
chemical 
1 week 
ESC 
(eGFP) 
2x105 4.7T 12,3
§
 Ferumoxide - ic 
EM, IHC (GFAP, Neu N), iron 
content 
Jendelova 
2004 B 
Male 
Wistar rats 
Photo-
chemical 
1 week 
ESC 
(eGFP) 
2x106 4.7T 7,0 Ferumoxide - iv 
Jendelova 
2004 C 
Male 
Wistar rats 
Photo-
chemical 
1 week MSC (r) 2x105 4.7T 15,3
§
 
Ferumoxide -
BrdU 
- ic 
Jendelova 
2004 D 
Male 
Wistar rats 
Photo-
chemical 
1 week MSC (r) 2x106 4.7T 12,0 
Ferumoxide -
BrdU 
- iv 
Jiang 2005 Rats 
Embolic 
MCA 
48 hours NPC (r) 1x105 7T 8,0 
Ferromagneti
c gun 
- ic 
Cerebral blood flow, IHC 
(vWF) assessing 
angiogenesis, 
Jendelova 
2005 
Male 
Wistar rats 
Photo-
chemical 
1 week 
CD34+ 
(h) 
7.5x1
06 
4.7T 8,4 
Extracellular 
micro beads 
- ic 
EM, IHC (GFAP, Neu N), iron 
content 
Jiang 2006 
Male 
Wistar rats 
T - 3 hrs 48 hours 
NPC 
(h,f) 
1x106 7T 17,9  Ferumoxide Protamine ia 
Foot fault test, adhesive 
removal test at 1, 7 to 35 
days 
Li 2006 
Male 
Wistar rats 
Embolic 
MCA 
48 hours NPC (r) 1x105 7T 8,3 
Ferromagneti
c gun 
 ic 
CBF, IHC (B-tubulin, GFAP, 
nestin, vWF), lesion volume 
Rice 2007 
Male balb 
C mice 
T - 1 hr 2 weeks 
ASC 
(m) 
500 
to 
5000 
7T 8,2 Ferumoxide PLL ic IHC (GFP), cell viability 
Guzman 
2007 
Male 
Sprague 
Dawley 
rats 
T - 1 hr 7 days 
CNS-
SCns 
1x105 
(x 3) 
4.7T 10,0 Ferumoxide Protamine ic 
MRI characterisation 
IHC (GFAP, B-tubulin) 
 
  
Guzman 
2008 
Male 
Sprague 
Dawley 
rats 
T - 1 hr 
minus 7 
days 
NPC 
(m) 
2x105 4.7T 
12,3 
(6,6)* 
Ferumoxide - 
BrdU 
Protamine ic 
Cell viability, labelling 
efficiency, DCX, B-tubulin, 
GFAP, iba-1 
Kim 2008 
Male 
Sprague 
Dawley 
rats 
T - 
unclear 
7 days 
MSC 
(h) 
1x105 4.7T 11
 
,2 Ferumoxide Protamine ic 
MRI characterisation 
IHC (human specific nuclei, 
nestin, tubulin, MAP2, GFAP) 
Walczak 
2008 A 
Adult 
female 
Wistar rats 
T - 2 hrs 0.5 hrs MSC (r) 1x106 4.7T 17,4
$
 
Ferumoxide -
BrdU 
PLL ia 
IHC (BrdU), survival 
Walczak 
2008 B 
Adult 
female 
Wistar rats 
T - 2 hrs 0.5 hrs MSC (r) 1x106 4.7T 4,4
$
 
Ferumoxide -
BrdU 
PLL iv 
Zhu 2008 Rats T- 1 hr 2 weeks NPC (r) 2x106 4.7T unknown 
Ferumoxide -
BrdU 
PLL ic IHC (GFAP, Map2, BrdU) 
Song 2009 
A 
Male 
Sprague 
Dawley 
rats 
T - 2 hrs 24 hours NPC (h) 4x105 1.5T 3,3 Fe-BrdU - ic 
Viability, proliferation, iron 
content, IHC (Neu N, GFAP, 
MHC class II) 
Song 2009 
B 
Male 
Sprague 
Dawley 
rats 
T - 2 hrs 24 hours NPC (h) 4x106 1.5T 3,3 Fe-BrdU - iv 
Lee 2009 A 
Female 
Wistar rats 
Photo-
chemical 
48 hours 
MSC 
(h,f) 
2x104 1.5T 9,7
!
 MGIO - ic 
IHC (Vimentin, ED1), cell 
characterisation, iron 
content, viability 
Lee 2009 B 
Female 
Wistar rats 
Photo-
chemical 
48 hours 
MSC 
(h,f) 
2x104 1.5T 4,7
!
 Ferucarbotran - ic 
Lee 2009 C 
Female 
Wistar rats 
Photo-
chemical 
48 hours 
MSC 
(h,f) 
2x106 1.5T 2,7
!
 MGIO - iv 
Crabbe 
2010 
Male Fisher 
rats 
Photo-
chemical 
24 hours 
MAPC 
(r) 
1x105 9.4T 8,?0 Ferucarbotran PLL ic MRI characterisation, IHC 
T, transient; MCA, middle cerebral artery; MSC, mesenchymal stem cell; ESC, embryonic stem cell; NPC, neural progenitor cell; ASC, adipose stem cell; CNS-SCns, central 
nervous system stem cell neurospheres; MAPC, multipotent adult progenitor cells; (m) murine; (r), rat; (h) human; f (foetal);
 
PLL, poly-L-lysine; MGIO, microgel iron oxide; 
BrdU, Bromodeoxyuridine; ic, intracerebral; ia, intra-arterial; iv, intravenous; EM, electron microscopy; IHC, immunohistochemistry.
 
*
12,3 - cells v placebo (6,6 - stroke v non-stroke) 
 
6 ipsilateral, 5 contralateral to the stroke; 
§,$,!
 same control 
 
  
Stem cell type 
Real-time tracking using iron labelled cells and MRI was assessed in 
experimental stroke using CD34+ haematopoietic stem cells (HSC) (n=1),362 
rodent and human mesenchymal stem cells (MSC) (n=10),378, 379, 383-385 rodent 
and human neural stem/progenitor cells (NSC) (n=8),386-391 embryonic stem 
cells (ESC) (n=3),277, 384 adult progenitor cells (n=1),382 adipose derived stem 
cells (n=1) 377 and human CNS neurospheres (n=1).392  
 
Dose, route and time of administration  
The total number of cells injected ranged between 500 and 7.5 x 106. Assuming 
an average rat weight of 300g, this is an equivalent dose of between 1.7 x 103 
and 2.5 x 107 cells per kilogram. Most studies injected the cells via a direct 
intracerebral route (n=17), whilst the remainder used intravascular routes 
(intravenous, n=6; intra-arterial, n=2). There was marked variation in the time of 
administration with cells injected between minus 7 days and 2 weeks post 
stroke ictus, though this did not appear to affect cell migration as all studies 
analysed detected positive evidence of this. Median time of cell administration 
was 48 hours. 
 
Label type 
Cells were labelled with ferumoxide (superparamagnetic iron oxide 
nanoparticles, SPIO, particle size 120-150nm containing a crystal 
approximately 5nm in size) in 16 experiments; ferumoxtran (ultrasmall 
superparamagnetic iron oxide, USPIO, particle diameter 20-40nm) in one 
experiment;277 ferucarbotran (particle diameter 60nm) in two; or a ferromagnetic 
gun (which ÔshootsÕ dye-coated iron into clusters of cells using compressed gas 
  
and a nylon filter) in three studies.387, 388, 393 Only one publication directly 
compared two different labels, a larger 600nm particle (microgel iron oxide, 
MGIO) and the smaller ferucarbotran.379 Extracellular microbeads attached to 
human CD34+ cells were also evaluated as an effective iron label but this 
required 7.5 x 106 cells, the highest number, injected intracerebrally to produce 
a weak hypointense signal on 4.7 Tesla (T) MRI.362 MRI strengths ranged from 
1.5T to 9.4T. In 8 experiments, a co-label (bromodeoxyuridine, BrdU, a 
thymidine analogue that labels cells in the S-phase of the cell cycle) was used 
to aid identification of migrating cells. 
 
Eight studies used a transfection agent such as protamine sulphate (n=4) or 
poly-l-lysine (PLL) (n=5) to enhance cellular uptake during incubation. 
Transfection agents were not consistently required. For example, both MSCs 
and NPCs were assessed with and without a transfection agent (table 15). 
 
Outcomes 
All experiments confirmed that cell migration was detectable with MRI using iron 
labelled stem cells Ð there were no negative studies. Quantification of 
differentiated iron labelled stem cells (into neurons or glia) was measured in 8 of 
25 experiments, and assessed but not quantified in 4 more. Interestingly, iron 
labelled MSCs did not appear to produce any response in developing new 
neurons or glia,383, 385 whereas 70% of iron labelled ESCs differentiated into 
astrocytes, 5% into neurons and, ominously, 10% produced tumour-like cells.384 
13% of labelled NPCs produced detectable new neuron formation and human 
CNS neurospheres produced neurons and glia in vitro (56% and 19% 
  
respectively).392 Labelled CD34+ cell differentiation was not observed in one 
study.362 
 
Lesion volume was evaluated in one study only.393 Functional outcome 
measures were evaluated in 2 studies;387, 389 labelled SVCs 387 and NPCs 389 
improved both the tape adhesion test (WMD -22.14, 95% CI -31.12 to -13.16, 
p<0.00001) and foot fault test (WMD -4.67, 95% CI -8.15 to -1.2, p=0.008) 
(figure 13). Only one study reported survival in which a higher mortality was 
observed in the group treated with intra-arterial MSCs when compared to 
control (67% vs 7%).378 Conversely, the other study assessing intra-arterial 
delivery (of NPCs) showed an improvement in functional outcome.389  
 
Quality  
Control groups were not provided in 5 of 25 experiments (and may not have 
been present in another 382). Only one study reported that the animals were 
randomised into treatment or placebo groups.389 No studies specified that 
outcome assessments were blinded to treatment allocation. Assessment of 
dose-response and optimal time of therapeutic administration was not assessed 
in any of the identified studies, although this may not be surprising considering 
that the main outcome assessments were not focused on function or infarct 
volume analysis (these are key parameters in experimental stroke studies 152). 
Overall the median quality score was 2 (interquartile range 2-3). The low quality 
scores suggest that significant bias may be present and findings should be 
treated with caution. 
  
Figure 13. The effects of iron labelled stem cells on functional outcome: (a) the adhesive tape removal test and (b) the foot fault test. 
 
 
(a) 
 
 
(b) 
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DISCUSSION 
Stem cell labelling with iron based compounds allows real-time tracking of migration 
patterns of implanted cells. The primary intention of this review was to describe 
labelling techniques used in experimental stroke models with a view to considering 
whether such labelling methods could be translated into clinical practice. However, 
none of the articles analysed reported a failure to display migration capacity and 
hence it would be challenging to select a superior technique based on this outcome 
alone. The absence of negative studies suggests the presence of publication bias. 
 
The most commonly used compound was ferumoxide (n=16), a dextran-coated 
superparamagnetic iron oxide nanoparticle (SPIO), which is commercially available 
and licensed for human use. Its particle size is in the region of 120-150nm, 
containing a crystal approximately 5nm in size. Incorporation into stem cells can be 
enhanced using a transfection agent such as poly-L-lysine (PLL) or protamine 
sulphate, which works by altering electrostatic interactions across the cell 
membrane and transferrin receptor. Protamine sulphate is also licensed for human 
use (for reversal of the effects of heparin) and it is apparent that its combination with 
ferumoxide is increasingly used in labelling experiments. However, it is evident from 
this review that there has been inconsistency in the type of transfection agent used 
across cell types or even whether a transfection agent has been used at all.378, 384, 
385 
 
Loading a cell with internal iron can potentially attenuate its function by interfering 
with cell signalling pathways; an adequate cell iron concentration for maximum 
tissue contrast on MR imaging is desirable but it must be balanced with its effects on 
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cell viability and differentiation capacity.394 MSCs labelled with ferumoxide 383, 385 
and implanted intravenously or intracerebrally in ischaemic stroke models failed to 
demonstrate significant cell differentiation into neurons or glia suggesting either the 
cells cannot differentiate into neural-type cells or they have impaired function. 
Nevertheless, other non-stroke studies have shown that labelling MSCs with SPIO 
may not inhibit cell differentiation but can cause subtle yet significant cell 
phenotypical alterations.395 Bone marrow stem cells are capable of adopting neural 
characteristics 396 but it has been suggested that they simply fuse with recipient cells 
and adopt their phenotype.222 
 
With the exception of one, all studies in this review utilised intracellular iron labelling 
techniques. The remaining study used an extracellular CD34+ antibody containing 
iron oxide nanobeads.362 In vitro, it was observed that 6050 cells/!l were required to 
produce a visible contrast difference on 4T MR scanning, each cell containing, on 
average, 0.275 pg of iron. Higher cell numbers were transplanted intracerebrally in 
vivo in this particular study (7.5x106 cells).362 In contrast, much smaller doses of 
cells were used in studies using intracellular labelling; ESCs containing 13.6 pg of 
iron per cell required only 315 cells/!l (17 cells per voxel) to be visualised with 7T 
MRI (in vitro). The higher the cellular iron concentration, the more likely it is to effect 
cell viability, function and differentiation capacity. If a cellÕs functional capacity were 
limited to a significant degree, cell labelling experiments in human clinical trials 
would have to be designed with Ôproof of conceptÕ in mind rather than as an 
assessment of the cells for therapeutic purposes, since it would be unethical to 
transplant dysfunctional cells. However, the two studies in this review that observed 
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improved functional outcome when using labelled cells suggest that the potential 
therapeutic benefit is unaffected. 
 
One major concern is the high mortality rate in one study transplanting cells via the 
intra-arterial route,378 an issue also highlighted in the ÔStem Cell Therapies as an 
Emerging Paradigm in StrokeÕ (STEPS) report.276 A suggested mechanism for 
excess mortality could be intercellular adhesion, forming microemboli to cause 
recurrent stroke, a factor also influenced by total cell dose. The least invasive, and 
therefore preferable, route of administration is intravenous, but more cells must be 
injected for adequate numbers to reach the cerebral infarct.272 Further concern has 
also been raised in a study that assessed transplanted MHP36 labelled neural stem 
cells in a rat MCAo model.397 Cells labelled with the contrast agent GRID 
(Gadolinium-Rhodamine Dextran conjugate) did not significantly improve functional 
behavior compared to animals transplanted with the same cells labelled with a red 
florescent dye. In addition, the GRID-labelled group demonstrated an increase in 
lesion volume growth over 1 year; it is possible that GRID mediated inflammation 
leads to exacerbation of the stroke lesion, effects that are not seen in the short term 
or in vitro.397 The same authors have also demonstrated that transplantation of dead 
stem cells can lead to an increase in lesion volume.398 These results highlight the 
need more for studies assessing labelled stem cell grafts in the chronic phases of 
stroke and the significant implications for clinical studies. Labelling cells may affect 
their function and potential therapeutic benefit but they may also cause harm. 
Ethical and regulatory authorities are likely to view a labelled cell as a different 
therapy compared to the same unlabelled cell and therefore expect equivalent 
demonstrations of preclinical safety and efficacy before human clinical trials. 
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This systematic review has limitations. First, it is important to recognise that studies 
were only included if they described ischaemic stroke models and iron based stem 
cell labelling; no conclusions can therefore be drawn on the treatment effects of 
stem cells in stroke models. Moreover, non-iron labelling studies such as those 
assessing gadolinium cell labelling (providing MRI contrast on T1-weighted 
images),278, 399 were not included but these methods still offer the potential to label 
cells in a human clinical trial setting. Second, heterogeneity between the 
methodologies of studies such as timing of administration and dose of cells 
transplanted makes comparison challenging. In particular, only transient or 
photochemical models of stroke were included. A alternative paradigm for human 
stroke would be to use a permanent model of ischaemia in addition to hypertensive, 
diabetic and aged rodent models. Third, the ÔqualityÕ of the studies was low and 
important methodological quality markers (randomisation and masked outcome 
assessment) were notably absent, or at least not reported. As a result, significant 
selection, measurement, and publication bias may be present.371 Finally, it may be 
that iron based cell tracking techniques will be inappropriate in human stroke. Up to 
85% of ischaemic strokes can undergo haemorrhagic transformation.400 Iron 
contained in blood will show as hypodense regions on MR gradient echo imaging 
and will significantly confound scan interpretation. 
 
In summary, it is currently unclear which labelling technique is best to translate into 
human trials, and further research is required using consistent stroke models in 
higher quality studies. It would be sensible to use agents with established 
pharmacological profiles in humans, such as ferumoxide or ferucarbotran (SPIOs), 
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and protamine sulphate as a transfection agent if required. The incorporation of iron 
into the cell to provide sufficient MRI contrast needs to be balanced with cell viability 
and function. 
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CHAPTER 4 
STEM CELL TRIAL OF RECOVERY ENHANCEMENT AFTER STROKE 
2 (STEMS-2): PILOT RANDOMISED PLACEBO-CONTROLLED TRIAL 
OF GRANULOCYTE-COLONY STIMULATING FACTOR IN 
MOBILISING BONE MARROW STEM CELLS IN SUB-ACUTE 
STROKE. 
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ABSTRACT 
Background 
Granulocyte-colony stimulating factor (G-CSF) is neuroprotective in 
experimental stroke, and mobilises CD34+ peripheral blood stem cells into the 
circulation. We assessed the safety of G-CSF in recent stroke in a phase IIb 
single-centre randomised controlled trial. 
 
Methods 
G-CSF (Filgrastim 10 !g/kg [=1x106 U/kg]) or placebo (ratio 2:1) was given 
subcutaneously for 5 days to 60 patients 3-30 days after ischaemic or 
haemorrhagic stroke. The primary outcome was the frequency of serious 
adverse events (SAE). Peripheral blood counts, CD34+ count and functional 
outcome were measured. MRI assessed stroke lesion volume and atrophy. 
 
Results 
60 patients were recruited at mean 8 days (SD 5) post ictus, with mean age 71 
(12) years, and 53% male. In Ôon-treatmentÕ analysis, the groups were well 
matched for baseline minimisation/prognostic factors. There were no significant 
differences between groups in the number of participants with a SAE: G-CSF 
15/38 (40%) versus placebo 7/22 (32%), death or dependency (modified Rankin 
Scale: G-CSF 3 (IQR 2-4), placebo 3 (IQR 2-4)) at 90 days, or the number of 
injections received. G-CSF increased CD34+ and total white cell counts 9.5 and 
4.2-fold respectively. There was a trend towards reduction in MRI ischaemic 
lesion volume with respect to change from baseline in G-CSF treated patients 
(p=0.06).  
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Conclusions 
This randomised double-blind placebo-controlled trial suggests that G-CSF is 
safe when administered sub-acutely.  
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INTRODUCTION 
Few interventions aid recovery for patients with acute stroke and although 
earlier trials of putative neuroprotectants failed (e.g. NXY-059 88), new studies 
are ongoing, including focussing on colony stimulating factors such as 
granulocyte-colony stimulating factor (G-CSF) and erythropoietin where 
promising data exist in pre-clinical experimental models of stroke.376 
 
G-CSF is a glycoprotein hormone encoded by a single gene located on 
chromosome 17 q11-22;401 it plays a key role in the regulation of granulopoiesis 
and is responsible for the terminal maturation of neutrophils. Recombinant G-
CSF is used for treatment of neutropenia and for production of CD34+ 
haematopoietic stem cells (HSC) for bone marrow transplantation. When 
considering G-CSF as a potential treatment for stroke, the mechanisms of 
action appear to be multimodal. Experimentally, neuroprotection occurs by 
reducing apoptosis in the ischaemic penumbra and attenuating the 
inflammatory cascade.137 It also appears to be neuroreparative through 
potentiating angiogenesis 235 and neurogenesis,137 in part by activating brain 
endothelial cells 402 and mobilising HSCs to migrate to the ischaemic lesion.362 
More contentiously, bone marrow derived stem cells have been shown to 
differentiate into neurons and glia 222 and experimental transplants of 
haematopoietic stem cells have been observed to improve outcome post-
stroke.403  
 
The purpose of the present trial, STEMS-2, was to further evaluate the safety of 
G-CSF in stroke with emphasis on its effects on bone marrow derived HSCs 
and their fate in the brain. 
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METHODS 
Design 
We performed a prospective, single-centre, double blind, randomised, placebo-
controlled, phase IIb trial of G-CSF in patients with subacute stroke. The trial 
was conducted in accordance with the Declaration of Helsinki and the 
International Conference of Harmonisation of Good Clinical Practice (ICH-
GCP), received authorisation from the Medicines and Healthcare products 
Regulatory Agency (EudraCT 2006-005345-11), the Local Research Ethics 
Committee and was a registered clinical trial (International Standard 
Randomised Controlled Trial Number 63336619). 
 
Patients 
Patients 3-30 days post ischaemic and haemorrhagic stroke were recruited from 
the stroke service at Nottingham Universities Hospital NHS Trust from July 
2007 to January 2010 (see table 16 for inclusion and exclusion criteria). Written 
informed consent was obtained from each patient. If the patient was unable to 
consent (e.g. due to confusion or dysphasia), proxy consent was obtained from 
a relative or carer. 
 
Intervention 
Participants were randomised 2:1 to receive subcutaneous human recombinant 
G-CSF (1x106 units/kg, equivalent to 10!g/kg, Neupogen, Amgen, the 
maximum dose in STEMS-1 294) or matching subcutaneous saline once per day 
for 5 days. Treatment was prepared centrally and both the participants and 
those administering the injections were blinded to treatment and its assignment. 
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Randomisation involved computerised minimisation (table 16) and randomised 
treatment was administered in addition to best medical care. 
 
Table 16. Inclusion and exclusion criteria for STEMS-2 and computerised 
minimisation factors used for randomisation. 
 
Inclusion criteria 
Age > 18 
Clinical diagnosis of stroke 
Limb weakness present at randomisation (SNSS score in arm and/or leg <4) 
Brain scan compatible with ischaemic or haemorrhagic stroke 
Time from ictus 3-30 days 
 
Exclusion criteria 
Pre-morbid dependency (modified Rankin scale, mRS >3), 
Coma (SNSS consciousness <4) 
Dementia 
Malignancy 
Sickle cell disease 
Pregnancy 
Neutropenia 
 
Computerised minimisation factors 
Age (<70, >70 years) 
Sex 
Time since stroke (<8, >8 days) 
Stroke type (ischaemic, haemorrhage) 
Stroke severity (SNSS <30, >30), 
Cortical signs (cortical, sub-cortical) 
Presence of infection 
Intention to perform MRI 
SNSS, Scandinavian Neurological Stroke Score 
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Clinical outcomes 
The primary outcome measure was safety, assessed as the number of 
participants having a serious adverse event (SAE) by day 90. Clinical 
secondary outcomes included tolerability, feasibility, impairment (NIHSS), grip 
strength, dependency (mRS), disability (Nottingham Extended Activities of Daily 
Living, NEADL; Barthel Index, BI), cognition (Mini Mental State Examination, 
MMSE) and mood (Zung depression score); measurements were made at days 
10 and 90. All assessments were blinded to treatment assignment. The Data 
Monitoring Committee assessed unblinded safety data after recruiting 20 and 
40 patients into the trial. 
 
Laboratory Measures 
Peripheral blood CD34+ cell count was measured at day 5 using flow cytometry 
(FACScalibur, Becton Dickinson, Oxford, UK) and complied with ISHAGE 
guidelines.404 Full blood counts and putative markers of neuroprotection efficacy 
(D-dimer, B-natriuretic peptide (BNP), matrix metalloproteinase-9 (MMP-9) and 
protein S-100", (Triage Stroke Panel, Biosite Inc, San Diego, US)) were 
assessed on days 0, 5 and 10. 
 
Volumetric analysis 
Magnetic resonance imaging (MRI) of the brain was performed at baseline and 
on day 90 (±7) in patients with ischaemic stroke, except in those who were 
intolerant, had contraindications to MRI, or refused imaging. The volume of 
acutely cerebral infarcted tissue was calculated at baseline by measuring DWI 
hyperintense lesion outlines at day 0 and at day 90 at which time point 
intermediately T2 weighted scans were used (table 17). Contralateral ventricular 
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volume on DWI images (including the lateral ventricles to the level of the third 
ventricle) was also assessed as an indirect measure of cerebral atrophy. Two 
assessors blinded to treatment allocation (TJE, MA) were trained by an 
experienced neuroradiologist (DPA), and measured volumes independently. 
Scans were performed on a 3T Achieva (Philips, Netherlands) using an 8-
channel phased array coil or on a 1.5T Signa Excite (GE Medical Systems, US) 
for baseline scans when participant could not be transferred for 3T imaging. 
Lesion volume was measured using semi-automated software developed locally 
(NeuRoi, Dr C Tench, Department of Clinical Neurology, Nottingham, UK 405). 
 
Table 17. MRI sequence parameters 
MRI Scan 
Sequence 
Parameter 3T Achieva 1.5T Signa 
Excite 
Diffusion  Echo Time (ms) 53 92 
weighted Repetition time (ms) 6605 8000 
(baseline, day 0) Slice thickness (mm) 3 3 
 Field of View (mm) 240#240  256x256 
 Scan Matrix 96#96 128x128 
 Voxel Size (mm) 2.5x2.5x2.5  2x2x3 
 Diffusion weighting (s/mm2) 1000  1000 
    
T2 weighted Echo Time (ms) 32 74 
 Repetition time (ms) 2000 4120 
 Slice thickness (mm) 3 3 
 Pixel size (mm) 0.38x0.38 0.47x0.47 
 
 
Statistical analysis 
The primary outcome was the number of participants with one or more SAEs; 
this was chosen since G-CSF was associated with a non-significant increase in 
SAEs in our earlier phase IIa trial.294 The sample size was calculated as 60 
assuming alpha 5%, power 80%, SAE rate G-CSF 50% vs. placebo 20%, ratio 
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G-CSF:placebo 2:1, losses 5%. Data were analysed using FisherÕs Exact test, 
Mann-Whitney U test, repeated measures ANOVA, or ANCOVA as appropriate. 
Data are presented as number (percentage), mean (± standard deviation, SD), 
or median (interquartile range, IQR) and are presented as Ôon-treatmentÕ 
analysis. Stroke lesion volume data was positively skewed; it was therefore 
transformed using log(10) to normalise the distribution and anti-logged to 
present the geometric mean. All analyses were performed using PASW 
statistics data editor (version 18.0) and MediStat; analysis was by intention-to-
treat (according to randomisation) and statistical significance was taken at 
p<0.05. 
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RESULTS 
Subjects 
Of 205 screened participants who were eligible, 60 were included and the 
groups (40 G-CSF, 20 placebo) were well matched at baseline (figure 14, table 
18). The first dose of trial drug was received, on average, 10 days after stroke 
onset. The mean number of treatment doses received was 4.5 (90.5% in total) 
in participants randomised to G-CSF, and 5 (100%) for placebo; 2 participants 
randomised to G-CSF refused any treatment (but agreed to continued follow-
up) before they received their first dose. The data for these 2 recruits were 
analysed in the placebo group. Other participants stopped treatment after 
receiving G-CSF due to lower back pain (n=1, 2 of 5 doses received), acute 
illness not related to the trial drug (n=1) and administration error (n=2, missed 
doses). One patient withdrew from the trial; whilst they refused follow-up, they 
allowed information on vital status and mRS to be obtained from the General 
Practitioner. 
 
Clinical outcomes 
No significant difference in the number of patients with SAE (the primary 
outcome) or in the mean number of SAEs and adverse events (AEs) per patient 
was observed between treatment groups (tables 19 and 20). There were 3 
deaths in the G-CSF group (pulmonary embolus, ischaemic bowel, community 
acquired pneumonia) but all occurred after the end of the treatment phase; no 
deaths occurred in the placebo group. There were no differences in vascular 
events (non-fatal stroke, non-fatal MI, pulmonary embolus, deep vein 
thrombosis) or infection rates by day 90 (table 19). 15% (6 G-CSF, 3 placebo) 
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of the participants were included with a primary intracerebral haemorrhage and 
no safety concerns were present in this subgroup (table 20). 
 
Figure 14. Flow of participants into the trial 
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Table 18. Baseline patient characteristics by treatment group 
  
Characteristic All G-CSF Placebo 
Number 60 38 22 
Age (years)   71.5 (11.8) 72.0 (12.3) 70.6 (11.1) 
Male (%)   32 (53) 20 (53) 12 (55) 
NIHSS 10 [5-15] 10 [4-15.3] 8.5 [6-15.3] 
Time to randomisation (days)   8.1 (4.8) 8.0 (4.8) 8.3 (4.8) 
Stroke type (%)      
Ischaemic 51 (85) 34 (90) 17 (77) 
Haemorrhagic 9 (15) 4 (11) 5 (23) 
Clinical syndrome (%)      
Lacunar 13 (22) 8 (21) 5 (23) 
Partial anterior circulation 19 (32) 10 (26) 9 (41) 
Total anterior circulation 27 (45) 19 (50) 8 (36) 
Posterior circulation 1 (2) 1 (3) 0 (0) 
TOAST subgroup (%) à    
Small Vessel 8 (16) 7 (18) 1 (5) 
Large Vessel 15 (29) 8 (21) 7 (32) 
Cardio-embolic 19 (37) 14 (37) 5 (23) 
Unknown 8 (16) 5 (13) 3 (14) 
Past Medical History (%)    
Hypertension 31 (52) 17 (45) 14 (64) 
Hyperlipidaemia 27 (45) 16 (42) 11 (50) 
Diabetes mellitus 6 (10) 2 (5) 4 (18) 
Atrial Fibrillation 9 (15) 5 (13) 4 (18) 
Stroke 9 (15) 5 (13) 4 (18) 
TIA 6 (10) 4 (11) 2 (9) 
Ischaemic Heart Disease 17 (28) 10 (26) 7 (31) 
Peripheral Vascular Disease 0 0 0 
Thrombolysis at admission (%) 4 (7) 3 (8) 1 (4) 
Antiplatelet treatment (%)    
 Aspirin 49 (82) 34 (90) 15 (68) 
 Dipyridamole 40 (67) 28 (74) 12 (55) 
 Clopidogrel 1 (2) 0 (0) 1 (4) 
Statin treatment (%) 48 (80) 32 (84) 16 (73) 
Infection present (%)   14 (23) 10 (26) 4 (18) 
Time stroke to first dose (days) 9.7 (4.9) 9.4 (4.9) 10.3 (4.9) 
Data: Number (%), mean (standard deviation), median [interquartile range]; NIHSS: National Institutes of 
Health Stroke Scale; TOAST (Trial of org 10172 in acute stroke treatment) classification;   minimisation 
variables; à
 
haemorrhagic stroke excluded 
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Table 19. Clinical outcome encompassing serious adverse events (primary 
outcome), functional measures and lesion volume by treatment group (Ôon-
treatmentÕ analysis) 
Event G-CSF Placebo p 
 N=38 N=22  
Mean No serious adverse events 0.6 (0.9) 0.6 (1.1) 0.91 
Mean No adverse events 1.2 (1.2) 1.0 (1.1) 0.42 
No of patients with SAE 15 (40) 7 (32) 0.59 
        Non-fatal 12 (30) 7 (35) 1.0 
        Death 3 (8) 0 (0) 0.29 
    Vascular event 6 (16) 3 (14) 1.0 
        Fatal 2 (5) 0 (0) 0.53 
        Non-fatal stroke 1 (3) 0 (0) 1.0 
        Non-fatal MI 1 (3) 1 (5) 1.0 
        Venous thromboembolism   3 (8) 2 (9) 1.0 
    All Infections 7 (18) à 5 (23) 0.74 
        Lower respiratory tract 6 (16) 2 (9) 0.70 
        Urinary tract 2 (5) 2 (9) 0.62 
        Other  0 (0) 1 (5) ¦ 0.37 
    Timing    
        During treatment/wash-out 5 (13) 5 (23) 0.47 
        During follow-up 10 (26) 2 (9) 0.18 
    
Functional measures N=38 N=22  
    Modified Rankin Scale (/6) 3 [2-4] 3 [2-4] 0.68 
    Barthel Index 75 [33-98] 75 [40-93] 0.65 
    NIHSS 4.0 [2-9] 5.0 [2.5-11] 0.38 
    ! NIHSS (Day 0 Ð Day 90) 4.0 [2-6] 4.0 [2.5-5] 0.72 
    Motoricity Index (/100) 77 [13-100] 67 [18-81] 0.46 
    Grip Strength (kg) 5.5 (7.5) 4.1 (4.3) 0.45 
    NEADL (/66) 25 [5-40] 16 [4-32] 0.60 
    Zung Depression score $ 50 [40-64] 50 [38-63] 0.95 
    MMSE $ 27 [20-29] 24.5 [21-29] 0.87 
    
Stroke Lesion volume (cm3)    N=14 N=6  
    Day 0 (DWI)  9.8 (9.0) 26.9 (4.2) 0.32 
    Day 90 (T2-weighted) 5.2 (10.2) 27.6 (4.0) 0.51 
    Difference (day 90 - day 0) % -1.9 (2.0) 1.03 (1.2) 0.06 
    
Contralateral ventricular vol (cm3)    
    Day 0 (DWI) 23.1 (12.6) 22.7 (8.2) 0.96 
    Day 90 (DWI) 24.3 (13.5) 23.2 (8.9) 0.87 
    Difference (day 90 Ð day 0) % 1.2 (1.8) 0.5 (2.0) 0.47 
Number (%), mean (standard deviation); comparison by FisherÕs Exact Test, Mann-Whitney U test, t-test, 
or Analysis of Covariance. 
%
 adjusted for baseline lesion volume (ANCOVA). NEADL, Nottingham 
Extended Activities of Daily Living; MMSE, Mini-Mental State Examination; SNSS, Scandinavian 
Neurological Stroke Scale; DWI: Diffusion weighted imaging;   Includes deep vein thrombosis and 
pulmonary embolism; à One participant had both urinary tract and lower respiratory tract infections; ¦ 
Clostridium difficile diarrhoea; $
 
Dysphasic participants who were unable to answer questions were 
excluded; 
   
geometric means and SD. 
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Table 20. (i) Serious adverse events (SAE) and (ii) adverse events (AE) by 
treatment group and their relationship to study drug (blinded adjudication). 
 
(i) 
Group Subject 
No 
Serious Adverse Event Days post 
Rx 
Relationship to 
drug 
Placebo 9 UTI 15 Unlikely 
  10 Aspiration pneumonia 2 Possible 
  17 Functional weakness 8 Possible 
   Clostridium difficile diarrhoea 16 Not related 
  30 UTI 0 Not related 
   Urinary retention 4 Unlikely 
   Lower GI bleed 17 Unlikely 
   DVT 70 Unlikely 
  31 Aspiration pneumonia 8 Possible 
  36 Neurological deterioration 6 Possible 
   PE 9 Possible 
   DVT 20 Possible 
  37   STEMI 15 Unrelated 
   Seizure 66 Possible 
G-CSF 5 Aspiration pneumonia 26 Not related 
  6 ARF 2o to outflow obstruction 15 Possible 
    UTI 16 Possible 
    Post stroke psychosis 7 Possible 
    NSTEMI 11 Possible 
  7 Muscular chest pain 58 Not related 
    Ischaemic stroke 62 Not related 
  8 Aspiration pneumonia 0 Not related 
    DVT 17 Unlikely 
  13 Cardiac arrest 20 to massive PE 15 Unlikely 
  14 Admission for inguinal hernia  11 Not related 
  15   Aspiration pneumonia 2 Unlikely 
  20 Aspiration pneumonia 1 Possible 
    UTI 44 Not related 
  23 Anaemia under investigation 13 Possible 
  25   DVT 22 Not related 
    PE 26 Not related 
  26 Community pneumonia causing 
death 
86 Not related 
  35 Ischaemic bowel causing death 24 Unlikely 
  41 UTI 31 Unlikely 
    Aspiration pneumonia 49 Unlikely 
  45 Admitted for investigation of PE  26 Not related 
  46 Hyperaesthesia 6 Unlikely 
  Haemorrhagic stroke; UTI, urinary tract infection; DVT, deep vein thrombosis; PE 
pulmonary embolus; STEMI, ST elevation myocardial infarction; ARF, acute renal failure; 
NSTEMI, non-ST elevation myocardial infarction. 
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(ii) 
Group Subject 
No 
Adverse Event (not 
serious) 
Days post 
Rx 
Relationship to 
drug 
Placebo 4 Depression 18 Unlikely 
  10 Neuropathic pain 7 Unlikely 
    Depression 20 Unlikely 
  11 Exacerbation COPD 34 Not related 
    Oral candidiasis 45 Not related 
  17 Angina 4 Possible 
    Functional weakness 75 Not related 
    Functional weakness 80 Not related 
  19 UTI 17 Unlikely 
  22 Abdominal bruising 0 Definite 
  24 Hypokalaemia 20 to 
thiazide 
5 Unrelated 
    UTI 7 Possible 
    Neuropathic pain 22 Not related 
    Spasticity 56 Not related 
  30 LRTI 10 Possible 
    LRTI 67 Not related 
  31 Hypothyroidism 5 Not related 
  40   Intertrigo 5 Possible 
    Back pain 67 Not related 
  52 Bad dreams 4 Unlikely 
G-CSF 2 Minor epistaxis 20 
anticoagulation 
8 Unlikely 
    UTI 18 Unlikely 
    Hypokalaemia  20 to 
thiazide 
24 Not related 
    Statin induced rise in 
liver enzymes 
25 Not related 
  3 Back pain post trial 
drug injections 
0 Probably 
  8 Dizziness post 
injection 
0 Probable 
    Oral candidiasis 5 Possible 
    Abdo pain 20 
constipation 
16 Unlikely 
  12 UTI 53 Not related 
    Vasovagal syncope 41 Not related 
  13 Abdominal bruising 0 Definite 
  16 Headache after 3rd 
dose only 
2 Possible 
  18   Viral diarrhoea 21 Not related 
  20 UTI 52 Not related 
  21   UTI 7 Possible 
    UTI 46 Not related 
    UTI and haematuria 67 Not related 
  21 Deranged LFTs 67 Not related 
  25   Deranged LFTs 9 Possible 
    Oral Candidiasis 15 Possible 
  29   Muscular shoulder 
pain 
55 Not related 
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  32 UTI 3 Possible 
  38 UTI 6 Possible 
    Abdominal bruising 1 Definite 
  39 Transient hypotension 5 Possible 
  41 UTI 89 Not related 
  43 Back pain 0 Probable 
    Frozen shoulder 66 Not related 
    Swollen hand 20 to 
osteoarthritis 
40 Not related 
  45 Thrombocytopenia 7 Probable 
    Leucopoenia 18 Possible 
  46 UTI 6 Possible 
    UTI 20 Unlikely 
  49 UTI 10 Possible 
    Transient left arm 
pain 
4 Possible 
  50 Epistaxis 8 Possible 
    UTI with renal 
impairment 
12 Possible 
    UTI 33 Not related 
  51 Simple fall 9 Unlikely 
  54 Photopsia 4 Possible 
    Muscular chest pain 6 Unlikely 
    Allergic rash to 
morphine 
7 Unrelated 
  55 Dizziness 3 Possible 
  57 Neuropathic pain 19 Unlikely 
    UTI 26 Unlikely 
    Deranged LFTs 33 Unlikely 
  58 Gout 90 Not related 
  Haemorrhagic stroke; UTI, urinary tract infection; COPD, chronic obstructive pulmonary 
disease; LFT, liver function tests. 
 
No significant difference emerged between treatment and placebo groups in 
respect of measurements of dependency (mRS) (figure 15), disability (BI, 
NEADL), impairment (NIHSS, Motoricity index, grip strength), cognition (MMSE) 
or mood (Zung depression score) (table 19). When mRS is dichotomised (poor 
outcome >2), no difference is observed between groups (G-CSF 27/38 vs 
placebo 15/22, p=0.82). 
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Figure 15. Distribution of the modified Rankin scale (mRS) by treatment group 
(Ôon-treatmentÕ analysis) 
 
 
Volumetric analysis 
Stroke lesion volume was analysed at baseline and day 90 in 20 participants 
(14 G-CSF, 6 placebo) (table 19). Scans were not indicated in 9 recruits 
(primary haemorrhage) and not performed due to patient refusal (n=17), 
contraindication (n=4), scan intolerance (n=1) and severe illness or death (n=5). 
It was not possible to analyse 4 scans due to poor quality and the acute lesion 
becoming embedded in chronic ischaemic change. Stroke lesion territory and 
size varied considerably but there was no significant difference in baseline DWI 
lesion volume (table 19) between placebo and treatment groups. When 
adjusted for baseline DWI lesion volume, a trend towards reduced lesion 
volume at day 90 was present in G-CSF treated patients (ANCOVA, p=0.06). 
With respect to change in ventricular volume over 90 days, no significant 
difference was seen between groups (table 19). 
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Laboratory measures 
In comparison with placebo, G-CSF significantly elevated CD34+ cell count 
(peak 31.4 versus 3.3 cells/!L), white cell count (peak 40.2x109 vs 9.5x109 
cells/L), and white cell components including neutrophils (peak 34.1x109 vs 
6.9x109 cells/L), at day 5 (table 21, figure 16). By day 10, counts were returning 
to normal. There were apparent absolute differences between groups in 
baseline values in BNP and D-dimer but they did not reach statistical 
significance (p=0.08 and 0.07 respectively). Change in haemoglobin, platelet 
count, red cell count, haematocrit, D-dimer, BNP, MMP-9 and protein S100-" 
did not differ significantly between the treatment groups. 
   
 
Table 21. Laboratory measures by treatment group: G-CSF versus placebo.  
Mean (standard deviation); comparison by repeated measures analysis of variance 
  G-CSF   Placebo  ANOVA 
Day of treatment 0 5 10 0 5 10 p 
Haemoglobin (g/dL) 13.6 (1.9) 13.4 (1.8) 13.4 (1.9) 14.1 (1.2) 13.8 (1.4) 13.6 (1.3) 0.49 
White cells (x109/L) 9.45 (2.8) 40.2 (14.3) 10.41 (3.4) 9.26 (2.2) 8.56 (2.3) 9.26 (3.2) <0.001 
Neutrophils (x109/L) 6.88 (2.4) 34.1 (13.2) 8.03 (3.3) 6.46 (2.3) 5.84 (1.9) 6.29 (2.5) <0.001 
Lymphocytes (x109/L) 1.56 (0.5) 2.74 (0.9) 1.58 (0.6) 1.81 (0.5) 1.80 (0.4) 1.85 (0.5) 0.22 
Monocytes (x109/L) 0.79 (0.3) 2.39 (1.1) 0.78 (0.9) 0.77 (0.2) 0.71 (0.3) 0.76 (0.3) <0.001 
Eosinophils (x109/L) 0.15 (0.2) 0.36 (0.4) 0.15 (0.1) 0.23 (0.2) 0.22 (0.2) 0.20 (0.1) 0.99 
Basophils (x109/L) 0.02 (0.04) 0.07 (0.16) 0.01 (0.03) 0.02 (0.04) 0.03 (0.05) 0.03 (0.05) 0.61 
CD34+ (/!L) 3.27 (1.9) 31.40 (31.1) 3.74 (1.9) 2.78 (1.8) 3.59 (3.3) 3.97 (3.2) <0.001 
Platelets (x109/L) 240 (93) 279 (89) 238 (93) 260 (63) 272 (42) 302 (61) 0.17 
Red cell count (x1012/L) 4.53 (0.6) 4.43 (0.6) 4.51 (0.6) 4.55 (0.5) 4.46 (0.5) 4.22 (1.0) 0.63 
Haematocrit (L/L) 0.41 (0.05) 0.41 (0.05) 0.40 (0.05) 0.42 (0.04) 0.41 (0.04) 0.41 (0.04) 0.51 
D-dimer (ng/ml)   2952 (2009) 2560 (1819) 2440 (1811) 1844 (1682) 1635 (1768) 1586 (1789) 0.10 
BNP (pg/ml)   281.9 (501.6) 219.9 (315.9) 206.8 (303.4) 89.9 (101.7) 97.1 (102.5) 118.1 (134.6) 0.15 
MMP-9 (ng/ml)   284.2 (325.3) 259.1 (265.3) 231.6 (174.4) 374.8 (407.4) 202.5 (204.1) 163.9 (102.8) 0.87 
S100-" (pg/ml)   107.4 (30.7) 105.5 (17.0) 113.0 (34.0) 103.1 (11.1) 109.1 (31.0) 104.9 (18.8) 0.60 
BNP: §-natriuretic peptide; MMP-9: matrix metalloproteinase-9.  , n=41 (G-CSF 26, placebo 15) 
  
   
 
Figure 16. CD34+ cell, white cell and neutrophil count at days 0, 5 and 10 by treatment group.  
Mean (standard deviation). Analysis by repeated measures ANOVA, p<0.001 for a, b and c. 
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DISCUSSION 
The STEMS-2 trial was designed to test the safety of G-CSF and explore 
mechanisms by which it might work in patients with subacute stroke. There 
were no significant differences in serious adverse events (primary outcome) 
between two well-matched groups, supporting the view that treatment with G-
CSF is safe. Of note, there were no differences in either the number of patients 
with a SAE or the average number of SAEs per patient. The inclusion of 9 
haemorrhagic strokes also provides initial safety data, though further phase II 
trials designed specifically for this subgroup are warranted. The majority of 
subcutaneous injections were received suggesting that the treatment is also 
feasible to administer, at least when given subacutely. Adverse events 
experienced that were probably or definitely related to the study drug were 
expected side effects of G-CSF (musculoskeletal pain, dizziness). Despite 
significant increases in white cell count, no difference in the frequency of 
vascular events (arterial and venous) or infection, were seen. Two of three 
deaths in the G-CSF group were vascular in nature and did not appear to be 
secondary to active treatment; the overall vascular event rate was identical in 
each group (15%). 
 
Although no significant differences between groups were seen with respect to 
functional outcome (and the trial was not powered to detect this), a trend 
towards improvement was observed in NIHSS at 90 days in G-CSF treated 
subjects. This is consistent with other measured clinical parameters (motoricity 
index, grip strength, NEADL) whereby the median value in the G-CSF group 
was non-significantly better when compared to placebo. Further phase III trials 
are therefore required to test efficacy of G-CSF. Similarly, a trend to reduced 
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stroke lesion volume and growth in the G-CSF group was observed. This is 
unexpected considering G-CSF administration in the subacute phase is thought 
to improve outcome via promotion of neurogenesis 137 and angiogenesis 235 
rather than through neuroprotection. Such volume differences should be 
interpreted with caution due to the small sample size and heterogeneity of case 
mix, though these were accounted for, in part, by adjusting for baseline stroke 
volume. In addition, preclinical concern about the effects of G-CSF on cerebral 
atrophy 167 was not borne out here; subgroup analysis revealed no significant 
difference between groups in change in contralateral ventricular volume, though 
the numbers are small and 90 days may be an insufficient follow-up period. 
 
Altogether, four trials have been published evaluating G-CSF in ischaemic 
stroke Ð this and the first STEMS study, and two others.295, 368 Of these, the first 
assessed 10 patients (7 in the G-CSF arm dosed at 15!g/kg od for 5 days, 3 in 
the control arm) randomised within 7 days of ictus and no safety concerns were 
raised.295 In the AXIS trial (n=44), where treatment was instituted with 12 hours 
of stroke onset at a cumulative dose range of 30 to 180 µg/kg,368 there was no 
significant difference between treatment groups in respect of serious adverse 
events and thromboembolic complications. Although G-CSF transiently 
increases total white cell count and therefore has potential to lead to vascular 
complications, there is currently no evidence to suggest that G-CSF causes 
thomboembolic events or aggravates stroke symptoms.299 Each of the four trials 
was too small individually to assess the effect of G-CSF on functional outcome; 
when data from the four trials are aggregated, no safety concern is obvious 
(odds ratio 1.11, 95% confidence intervals 0.38 to 3.25, figure 17). In light of the 
above evidence and a recent negative trial assessing administration of EPO 
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(another colony stimulating factor 249) within 6 hours of ischaemic stroke 256 
further phase II/III trials are required to evaluate the safety and efficacy of G-
CSF. 
 
Figure 17. Meta-analysis of the effect of G-CSF on functional outcome events 
assessed as dependency (modified Rankin score>2 or Barthel index<60) 
 
 
 
Whilst the trial provides robust clinical data on the safety of G-CSF in stroke, a 
number of limitations need to be taken into account. First, the small sample size 
means that any findings may be due to chance; although there are no 
significant safety concerns in the current investigation, trends that are present 
here (e.g. higher number of deaths in the G-CSF group, though not thought to 
be related to treatment) may become significant in a larger phase II/III trial. 
Another caveat is the wide time-window of inclusion post stroke onset, which 
has implications on interpreting stroke lesion volume and serum biomarker 
results. The variable time of inclusion (between 3 and 30 days) leads to 
heterogeneity within the trial and it becomes difficult, therefore, to make fair 
comparisons between groups. Since patients were enrolled into the trial during 
the subacute phase of stroke (mean time to first dose of 10 days), any potential 
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effects of treatment on biomarker expression may have been missed; the peak 
serum levels of S100β occur within 2-3 days, and MMP-9 within early hours 
after a stroke, and are both related to infarct volume.406, 407 The trial was 
designed, however, to evaluate the potential ÔneuroreparativeÕ qualities of G-
CSF (via CD34 cell migration) and not early neuroprotective mechanisms. 
 
In summary, this randomised double-blind placebo-controlled trial suggests that 
G-CSF is safe when administered in sub-acute stroke.  
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CHAPTER 5 
COLONY STIMULATING FACTORS (INCLUDING ERYTHROPOIETIN, 
GRANULOCYTE COLONY STIMULATING FACTOR AND 
ANALOGUES) FOR STROKE 
 
Publications contributing to this chapter:  
 
Bath PM, Sprigg N. Colony stimulating factors (including erythropoietin, 
granulocyte colony stimulating factor and analogues) for stroke. Cochrane 
Database of Systematic Reviews. 2006;3:CD005207 
 
This chapter is an update of the above review and has been submitted for 
publication. The chapter is laid out in the CDSR format. 
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ABSTRACT   
Background   
Colony stimulating factors (CSFs), also called haematopoietic growth factors, 
regulate bone marrow production of circulating red and white cells, and 
platelets. They have been shown to be neuroprotective in experimental stroke. 
Some CSFs also mobilise the release of bone marrow stem cells into the 
circulation. 
 
Objectives   
To assess the effects of CSFs on functional outcome and haematology 
measures in patients with acute or subacute stroke. 
 
Search methods   
We searched the Cochrane Stroke Group Trials Register (last searched 
December 2010), the Cochrane Central Register of Controlled Trials 
(CENTRAL) (The Cochrane Library Issue 2, 2006), MEDLINE (1985 to 
December 2010), EMBASE (1985 to December 2010), and Science Citation 
Index (1985 to December 2010). In an attempt to identify further published, 
unpublished and ongoing trials we contacted manufacturers and principal 
investigators of trials (last contacted January 2011). We also searched 
reference lists of relevant articles and reviews. 
 
Selection criteria   
Unconfounded randomised controlled trials recruiting patients with acute or 
subacute ischaemic or haemorrhagic stroke were included. CSFs included stem 
cell factor (SCF), erythropoietin (EPO), granulocyte colony stimulating factor (G-
CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), 
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macrophage-colony stimulating factor (M-CSF, CSF-1), and thrombopoietin 
(TPO), or analogues of these. The primary outcome was functional outcome 
(assessed as combined death or disability and dependency using scales such 
as the modified Rankin Scale or Barthel Index) at the end of the trial. Secondary 
outcomes included safety at the end of treatment (death, impairment, 
deterioration, extension or recurrence, serious adverse events, infection), death 
at the end of follow up, infarct volume and haematology measures (blood 
counts after treatment had been completed). Two review authors (TE and NS) 
independently extracted data and assessed trial quality. Study authors were 
contacted for additional information. 
 
Results   
In two trials (n=562), EPO therapy was significantly associated with death by 
the end of the trial (odds ratio 1.98, 95% confidence interval 1.17 to 3.33, 
p=0.01) and a non-significant increase in serious adverse events. EPO 
significantly increased red cell count with no effect on platelet or white cell 
count, or infarct volume.  Two small trials of carbamylated EPO have been 
completed but have yet to be reported. In six small trials (n=215), G-CSF was 
associated with a non-significant reduction in early impairment and early death 
but had no effect on functional outcome at end of trial. G-CSF significantly 
elevated white cell count and CD34+ cell count, but had no effect on infarct 
volume. Further trials of G-CSF are ongoing. 
 
Authors' conclusions   
No large trials of EPO, G-CSF or other colony stimulating factors have been 
performed and it is too early to know whether CSFs improve functional 
outcome.  
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BACKGROUND   
Colony stimulating factors (CSFs), also called haemopoietic growth factors, 
regulate the bone marrow production of circulating red cells, white cells and 
platelets. CSFs act on stem cells leading to lineage specific differentiation. Stem 
cell factor (SCF) regulates differentiation of CD34+ stem cells, whilst other 
factors modulate the synthesis of more specific cell types: erythropoietin (EPO) 
for red cells; granulocyte colony stimulating factor (G-CSF) for neutrophils; 
granulocyte-macrophage colony stimulating factor (GM-CSF) for macrophages 
and neutrophils; macrophage colony stimulating factor (M-CSF, also called 
colony-stimulating factor-1 (CSF-1)) for monocytes; and thrombopoietin (TPO) 
for megakaryocyte maturation and platelet synthesis. Evidence now suggests 
that these factors may be candidate treatments for stroke, either as potential 
neuroprotectants or as neuroreparative agents.408 
 
The background to CSFs for use in stroke has been discussed in the 
introduction. Their physiological actions and positive data relating to their use in 
experimental stroke justify the assessment of recombinant haemopoietic growth 
factors in clinical stroke. This report systematically reviews the effects of CSFs 
in patients with acute or subacute stroke. 
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OBJECTIVES   
Hypothesis 
Colony stimulating factors (haemopoietic growth factors) may improve 
functional outcome after ischaemic or haemorrhagic stroke. 
 
Aims 
To assess: 
(1) the safety and efficacy of CSFs in patients with acute or subacute ischaemic 
or haemorrhagic stroke; 
(2) the effect of CSFs on circulating stem and blood cell counts. 
 
METHODS   
Types of studies: unconfounded randomised controlled trials. 
 
Types of participants: People with recent (within 30 days of onset) ischaemic or 
haemorrhagic stroke. This time period allows studies investigating either acute 
neuroprotection (for example, through possible anti-inflammatory or anti-
apoptotic effects) or recovery enhancement (for example, through putative stem 
cell mediated events) to be included. 
 
Types of interventions: we considered unconfounded trials of: 
¥ stem cell factor (SCF) or analogue versus control; 
¥ erythropoietin (EPO) or analogue versus control; 
¥ granulocyte colony stimulating factor (G-CSF) or analogue versus control; 
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¥ granulocyte-macrophage colony stimulating factor (GM-CSF) or analogue 
versus control; 
¥ macrophage-colony stimulating factor (M-CSF, CSF-1) or analogue versus 
control; and 
¥ thrombopoietin (TPO) or analogue versus control. 
 
Types of outcome measures:   
Primary outcome 
¥ Functional outcome at end of follow up, assessed as combined death or 
disability and dependency (using scales including the modified Rankin Scale 
and Barthel Index). 
Secondary outcomes 
¥ At the end of treatment: death; impairment (using a stroke severity scale, for 
example, the Scandinavian Stroke Scale or the National Institute of Health 
Stroke Scale); deterioration (death or worsening in stroke severity scale); 
extension or recurrence; number of patients with a serious adverse event; 
number of patients with an infection; stroke lesion volume. 
¥ At the end of follow up: death. 
¥ Haematology measures (during or soon after treatment): CD34+ count; red 
cell count (RCC); white cell count (WCC); platelet count. 
 
Search methods for identification of studies   
We searched the Cochrane Stroke Group Trials Register, which was last 
searched by the Review Group Co-ordinator in December 2010. In addition, we 
performed electronic searches of the Cochrane Central Register of Controlled 
Trials (CENTRAL) (The Cochrane Library Issue 12, 2010), MEDLINE (1985 to 
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December 2010), EMBASE (1985 to December 2010), and Science Citation 
Index (1985 to December 2010) (Appendix 1). These searches commenced 
from 1985, the date when EPO (the first recombinant CSF) became available. 
Additionally, we contacted the manufacturers of SCF, EPO, G-CSF, GM-CSF, 
M-CSF and CSF-1, and TPO and the principal investigators of any identified 
trials (last contacted January 2011). Finally, we searched the reference lists of 
relevant articles and clinical reviews of these colony stimulating factors. 
 
We used the following search strategy for MEDLINE and adapted it for the other 
databases. 
 
1. Hematopoietic Cell Growth Factors/ 
2. Colony-stimulating factors/ or exp colony stimulating factors, recombinant/ or 
exp erythropoietin/ or exp granulocyte colony-stimulating factor/ or exp 
granulocyte-macrophage colony-stimulating factor/ or interleukin-3/ or 
macrophage colony-stimulating factor/ 
3. Stem Cell Factor/ 
4. Thrombopoietin/ 
5. (Haematopoieti$ or hematopoieti$ or erythropoietin or epoetin or darbepoetin 
or colony stimulating factor or colony-stimulating factor or interleukin-3 or 
Filgrastim or thrombopoietin or stem cell factor).tw. 
6. (G-CSF or M-CSF or GM-CSF or CSF-1 or HGFs or IL-3 or MGI-1 or TPO or 
SCF or E21R).tw. 
7. or/1-6 
8. Cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or 
exp brain ischemia/ or exp carotid artery diseases/ or exp cerebrovascular 
accident/ or exp hypoxia-ischemia, brain/ or exp intracranial arterial diseases/ or 
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intracranial arteriovenous malformations/ or exp "intracranial embolism and 
thrombosis"/ or exp intracranial hemorrhages/ or vasospasm, intracranial/ or 
vertebral artery dissection/ 
9. ((Brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ 
or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or 
anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or 
occlus$ or hypoxi$)).tw. 
10. ((Brain$ or cerebral or cerebell$ or intracranial or subarachnoid) adj5 
(haemorrhage or hemorrhage or hematoma or haematoma or bleed$ or 
aneurysm)).tw. 
11. or/8-10 
12. 7 and 11 
13. Limit 12 to human 
 
Data collection and analysis   
Selection of studies 
We independently selected trials for inclusion. Disagreements between authors 
were resolved by discussion. 
 
Quality 
We assessed the methodological quality of trials using standard Cochrane 
criteria including determining methods of randomisation, concealment of 
allocation, blinding of outcome assessment, analysis by intention to treat, and 
participants lost to follow up. An intended sensitivity analysis assessing the 
primary outcome in high quality trials alone was not performed since only two 
EPO trials and six G-CSF trials had been completed. 
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Data extraction 
We independently extracted data from publications on quality parameters (as 
above), drug, dose, route and timing, the numbers of events or status at end of 
treatment and end of follow up (including death, dependency), and 
haematological measures. If necessary, we sought additional information from 
the chief investigators of identified trials and pharmaceutical companies. We 
defined the primary outcome to be poor if there was a modified Rankin score of 
>2 (7 of 8 trials) or Barthel Index <60 (1 trial 295). To enable comparison of 
neurological impairment, data from one trial 294 was converted from the 
Scandinavian Neurological Stroke Score to the National Institutes of Health 
Stroke Score using a recognised formula.409 Early neurological impairment 
included data collected between 3 and 10 days post randomisation and data 
extracted on mortality was defined as early (within 14 days of randomisation) or 
'end of trial'. 
 
Data synthesis 
We analysed data by intention to treat where available, tested for heterogeneity 
using I-squared (I2), and planned to calculate a weighted estimate of the typical 
treatment effect across trials. Random-effects models were used since 
between-trial sources of heterogeneity were expected, for example, due to 
biological differences in CSFs, and clinical and statistical differences in the 
trials. Treatment effects were determined using the odds ratio for dichotomous 
data and weighted or standardised mean difference for continuous data. The 
Cochrane Collaboration's Review Manager software, Review Manager 5 (Apple 
Mac), was used for data entry and analysis. 
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RESULTS   
Description of studies  
Erythropoietin 
Two completed trials of EPO were identified (table 24). The first involved 40 
participants with hyperacute (less than seven hours of onset) ischaemic stroke; 
data from 13 participants treated in an uncontrolled phase of this study were 
excluded.255 A further phase III trial of EPO included 522 patients with middle 
cerebral artery ischaemic stroke.256 Two small safety trials of carbamylated 
erythropoietin, a derivative of EPO without haematopoietic activity, have been 
completed.410, 411 
 
Granulocyte-colony stimulating factor 
Six completed trials of G-CSF were found (table 22). The first involved 10 
participants within seven days of ischaemic stroke;295 STEMS-1 involved 36 
participants seven to 30 days post ischaemic stroke;294 STEMS-2 included 60 
patients three to 30 days post ischaemic or haemorrhagic stroke in a phase IIb 
trial.304 Another included 45 participants within seven days of ischaemic stroke 
but has been published in abstract form only.296 AXIS was a hyperacute trial 
(randomisation within 12 hours of ictus) involving 44 patients with ischaemic 
stroke,297 whilst STEMTHER was an unblinded safety trial with 20 
participants.303 Another more recent randomised controlled trial performed in 
Thailand was identified in abstract form but without enough information to 
include in the analysis.412 Results from an uncontrolled study of G-CSF in 20 
participants are apparently still awaited (Bogdahn 2005). 2 other trials of G-CSF 
are ongoing: a safety trial assessing 20 patients with non-dominant hemisphere 
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stroke,413 and a larger hyperacute trial with a recruitment target of 328 
patients.302 
 
Other CSFs 
No completed or ongoing studies of SCF, GM-CSF, M-CSF, or TPO in patients 
with stroke were identified. 
 
Risk of bias in included studies   
The two published trials of EPO and four of the G-CSF trials were triple blind 
with treatment compared with placebo, with adequate allocation concealment, 
and all measures were made blinded to treatment assignment (Ehrenreich 
2002; STEMS-1 2006; Zhang 2006; Ehrenreich 2009; AXIS 2010; STEMS-2 
2010).255, 256, 294, 296, 297, 304 Shyu 2006 was single blind, non-placebo controlled, 
with blinded outcome assessments.295 STEMTHER was an open label 
randomised trial with no placebo;303 the method of randomisation is unclear. In 
two trials investigators held a patent on the effects of the respective colony 
stimulating factor in the treatment of stroke (table 23).256, 297 Sample size 
justification was given in two trials.256, 304  
 
Effects of interventions   
EPO non-significantly reduced combined death or dependency, as measured 
by the modified Rankin Scale, in two trials including 562 patients,255, 256 but with 
92% of the weight resulting from the later phase III trial. Conversely, death by 
the end of the trial was significantly increased almost two-fold (odds ratio 1.98, 
95% confidence interval 1.17 to 3.33, p=0.01, table 24, figure 19, analysis 1.2). 
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There was also a non-significant trend towards increased number of serious 
adverse events in the EPO group. EPO significantly increased red cell count 
(table 24, figure 25, analysis 1.8) with no effect on platelet or white cell count. 
EPO had no discernible effect on stroke infarct volume. 
 
G-CSF did not alter combined death or dependency, early death or end of trial 
death; however, a trend to reduction in early impairment as measured by 
NIHSS was seen in G-CSF treated patients. G-CSF was associated with a non-
significant increase in serious adverse events but no effect on the rate of 
infection. G-CSF significantly increased white cell (table 24, figure 24, analysis 
1.7) and CD34+ count (table 24, figure 27, analysis 1.10) but had no effect on 
other blood count variables (table 24, figures 25 and 26, analyses 1.8 and 1.9). 
G-CSF had no discernible effect on infarct volume (table 24, figure 29, analysis 
1.12). 
 
. 
  
Table 22. Characteristics of included and ongoing studies 
Included studies  
Study Methods Participants Interventions Outcomes 
AXIS 2010 National, multicenter, 
randomised, placebo-
controlled dose 
escalation study 
44 patients (6 German centres) 
with acute (< 12 hours of onset) 
ischaemic MCA-territory stroke 
and diffusion/perfusion 'mismatch' 
on MRI 
G-CSF, dose-escalation (4 
levels, cumulative dose range 
between 30!g/kg and 180!g/kg 
over 3 days) versus control 
(1) Thromboembolic complications by 
day 4 
(2) Severe infection; SAEs; function 
(NIHSS, mRS, BI) at 4 weeks and 
day 90; lesion growth MRI day 90 
Ehrenreich 2002 Double-blind placebo-
controlled trial 
40 patients (1 German centre) 
with acute (< 8 hours of onset) 
ischaemic stroke 
rhEPO 3.3E4 IU iv x 3, or saline 
placebo 
(1) NIHSS, SSS, BI, mRS (day 30) 
(2) serum (EPO); impairment (NIHSS, 
SSS); function (BI, mRS); imaging 
(MRI: DWI, FLAIR); biomarkers 
Ehrenreich 2009 Randomised, double-
blind, placebo-controlled 
522 patients (German multicenter 
trial) with acute ischaemic stroke 
within 6 hours of onset. 
Epoietin-alpha 40 000 IU iv 
within 6 hours of symptom 
onset, at 24 and 48 hours 
(1) NIHSS, BI, mRS (day 30 and day 
90) 
(2) Lesion volume (MRI), adverse 
events. 
Shyu 2006 Single-blind controlled 
trial 
10 patients (1 Taiwanese centre) 
with acute ischaemic stroke within 
7 days of onset 
G-CSF (Filgrastim) 15!g/kg sc 
for 5 days 
(1) NIHSS, ESS, EMS, BI (12months) 
(2) FDG-PET 
STEMS-1 2006 Double-blind placebo-
controlled dose 
escalation trial 
36 patients (2 UK centres) with 
acute ischaemic stroke within 7 
days of onset 
G-CSF (Filgrastim) 1-10!g/kg sc 
for 1 or 5 doses 
(1) CD34+ (0 - 10 days) 
(2) Safety, clinical, efficacy; SSS (day 
10), BI, mRS (day 90) 
STEMS-2 2010 Single-centre, double-
blind, randomised, 
placebo-controlled, 
phase IIb trial 
60 patients (1 UK centre), 3 - 30 
days post ischaemic or 
haemorrhagic stroke 
G-CSF (Filgrastim) 10!g/kg 
versus control sc for 5 days 
(1) Serious adverse events 
(2) Efficacy; SNSS, mRS, BI, EADL 
at days 10 and 90 
(3) Lesion volume (MRI) at baseline 
and day 90 
STEMTHER 
2010 
Prospective, single-
centre, unmasked, 
randomised controlled 
trial 
20 patients (1 Russian centre), 
<48hours post ischaemic stroke 
G-CSF (Leukostim) 10!g/kg for 
5 days versus control (no 
placebo) 
(1) Safety 
(2) Efficacy; NIHSS, mRS, BI (day 
90) 
(3) Lesion volume (MRI) and 
laboratory measures 
Zhang 2006 Double-blind placebo-
controlled trial 
45 patients (1 Chinese centre) 
with acute ischaemic stroke within 
7 days 
G-CSF (Filgrastim) 2!g/kg sc for 
5 days 
(1) NIHSS, (2) WCC, (3) CD34+ 
  
 
Ongoing studies  
Study Methods Participants Interventions Outcomes 
AXIS-2 A multinational, 
multicenter, randomised, 
double-blind, placebo-
controlled phase II trial 
328 patients aged 18-85 with acute 
middle cerebral artery ischaemic 
stroke with lesion size on MRI DWI 
>15cm3 
G-CSF 135 mcg/kg or 
placebo (sodium chloride 
solution), short term infusion 
(20 to 30 minutes) and 
continuous infusion over 3 
days 
Primary: mRS at day 90; secondary: 
NIHSS by day 90 
CEPO 2008 Randomised, double-
blind, placebo-
controlled, single-dose, 
dose-escalation study 
16 patients aged 50-90 within 12-48 
hours of ischaemic stroke 
Dose escalation (0.005 
mcg/kg to 50.0 mcg/kg) trial 
of Lu AA24493 or placebo 
Safety, NIHSS and the mRS 
CEPO 2009 Randomised, double-
blind, placebo-
controlled, dose-
escalation study 
Patients aged 50-90 within 0-48 
hours of ischaemic stroke 
Dose escalation (0.005 
mcg/kg to 50.0 mcg/kg) trial 
of Lu AA24493 or placebo 
Safety, NIHSS and the mRS, 
pharmacokinetics, immunogenicity 
and biomarkers 
GIST 2008 Randomised, double-
blind, placebo-controlled 
trial 
20 patients with non-dominant 
ischaemic stroke (>3cm3) with 
hemiparesis 
G-CSF 10 ug/kg sc once 
daily for 4 days, repeated 
once 6 weeks later, or 
placebo (normal saline) 
Safety, feasibility, efficacy 
Shabitz 2006 Randomised, double-
blind, placebo-controlled 
trial 
180 patients with a diagnosis of 
chronic stroke or amyotrophic lateral 
sclerosis 
G-CSF for chronic stroke and 
EPO for amyotrophic lateral 
sclerosis (ALS) 
Learning success in a word learning 
model; response time in motor 
function tests 
Nilanont 2010 Block randomised 
according to stroke 
severity 
36 participants with acute ischaemic 
stroke patients within 7 days of onset 
G-CSF 15 ug/kg sc once 
daily for 5 days 
Safety and efficacy 
Studies awaiting classification  
Bogdahn 2005 Unknown 20 patients (1 German centre) with 
acute ischaemic stroke 
G-CSF given for 5 
consecutive days. Dose 
escalation up to 10ug/kg 
Unknown 
BI: Barthel index; CD34+: CD34+ cell count; DWI: diffusion weighted imaging; EADL: extended activities of daily living; EMS; European Motor Scale; ESS: European Stroke Scale; 
EPO: erythropoietin; FDG-PET: fluorodeoxyglucose positron emission tomography; FLAIR: fluid-attenuated inversion recovery; G-CSF: granulocyte-colony stimulating factor; iv: 
intravenous; MCA: middle cerebral artery; MRI: magnetic resonance imaging; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; rhEPO: recombinant 
human erythropoietin; SAE: serious adverse event; sc: subcutaneous; SSS: Scandinavian Stroke Scale; WCC: white cell count 
 
  
Table 23. Risk of bias, included studies 
Study Adequate 
sequence 
generation? 
Adequate 
allocation of 
concealment? 
Blinding? Incomplete 
outcome data 
addressed? 
Free of 
selective 
reporting? 
Free of other bias? 
AXIS 2010 Yes Yes Adequate Yes Yes Investigator holds a patent on the use of EPO for 
treatment of cerebral ischaemia 
Ehrenreich 2002 Unclear Yes Adequate Yes Yes None reported 
Ehrenreich 2009 Yes Yes Adequate Yes No Investigator holds a patent on the use of EPO for 
treatment of cerebral ischaemia 
Shyu 2006 No No Adequate Yes  Yes None reported 
STEMS-1 2006 Adequate Adequate Adequate Yes  Yes None reported 
STEMS-2 2010 Adequate Adequate Adequate Yes Yes None reported 
STEMTHER 
2010 
Inadequate Inadequate Inadequate No Yes Yes 
Zhang 2006 Adequate Adequate Adequate Unclear Unclear Unclear 
 
  
  
Table 24. Data and analyses  
  
Outcome or Subgroup Studies Participants Effect Estimate 
1.1 Functional outcome (death or dependency), end of trial   OR [95% CI] 
  1.1.1 Erythropoietin 2 562 1.01 [0.72, 1.42] 
  1.1.2 G-CSF 5 167 1.16 [0.50, 2.69] 
1.2 Death, end of trial   OR [95% CI] 
  1.2.1 Erythropoietin 2 562 1.98 [1.17, 3.33] 
  1.2.2 G-CSF 6 215 1.20 [0.36, 4.07] 
1.3 Early death   OR [95% CI] 
  1.3.1 Erythropoietin 2 562 1.50 [0.37, 6.05] 
  1.3.2 G-CSF 6 215 0.70 [0.07, 7.22] 
1.4 Early Impairment, NIHSS   WMD [95% CI] 
  1.4.1 Erythropoietin 1 40 -2.20 [-10.01, 5.61] 
  1.4.2 G-CSF 5 203 -0.40 [-1.82, 1.01] 
1.5 SAE, number of patients   OR [95% CI] 
  1.5.1 Erythropoietin 1 522 1.30 [0.89, 1.90] 
  1.5.2 G-CSF 4 160 1.31 [0.64, 2.68] 
1.6 Infection   OR [95% CI] 
  1.6.1 Erythropoietin 0 0 - 
  1.6.2 G-CSF 4 160 0.91 [0.36, 2.28] 
 
  
  
1.7 White cell count, 3 to 10 days   WMD [95% CI] 
  1.7.1 Erythropoietin 1 522 0.52 [-0.08, 1.12] 
  1.7.2 G-CSF 6 191 28.04 [23.73, 32.34] 
1.8 Red cell count, 3 to 10 days   WMD [95% CI] 
  1.8.1 Erythropoietin 2 562 0.17 [0.06, 0.27] 
  1.8.2 G-CSF 3 94 0.04 [-0.19, 0.28] 
1.9 Platelet count, 3 to 10 days   WMD [95% CI] 
  1.9.1 Erythropoietin 2 562 7.61 [-5.32, 20.55] 
  1.9.2 G-CSF 4 136 -4.21 [-35.75, 27.33] 
1.10 CD34+ count, 5 to 10 days   SMD [95% CI] 
  1.10.1 Erythropoietin 0 0 - 
  1.10.2 G-CSF 4 140 1.77 [0.91, 2.63] 
1.11 Serum S100-§, 7 to 10 days   WMD [95% CI] 
  1.11.1 Erythropoietin 1 40 0.32[-0.82, 0.18] 
  1.11.2 G-CSF 1 40 0.01 [-0.01, 0.02] 
1.12 Infarct volume, post treatment   SMD [95% CI] 
  1.12.1 Erythropoietin 2 485 -0.05 [-0.23, 0.13] 
  1.12.2 G-CSF 3 68 -0.02 [-0.52, 0.48] 
   G-CSF, granulocyte colony stimulating factor; OR, odds ratio; WMD, weighted mean difference; SMD, standardised mean difference 
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Forest plots 
Figures 18 to 29 correspond to the data in table 24 (CSF, colony stimulating factor; 
ÔrandomÕ , random effects model of analysis; M-H, MantelÐHaenszel analysis for 
repeated tests of independence, CI confidence interval) 
 
Figure 18 (Analysis 1.1). Functional outcome (death or dependency), end of trial. 
 
 
 
 
 
Figure 19 (Analysis 1.2). Death, end of trial. 
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Figure 20 (Analysis 1.3). Early death. 
 
 
 
 
 
Figure 21 (Analysis 1.4). Early Impairment, NIHSS. 
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Figure 22 (Analysis 1.5). Serious Adverse Events, number of patients. 
 
 
 
 
 
Figure 23 (Analysis 1.6). Infection. 
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Figure 24 (Analysis 1.7). White cell count, 3 to 10 days. 
 
 
 
 
 
 
 
Figure 25 (Analysis 1.8). Red cell count, 3 to 10 days. 
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Figure 26 (Analysis 1.9). Platelet count, 3 to 10 days. 
 
 
 
 
 
 
 
 
Figure 27 (Analysis 1.10). CD34+ count, 5 to 10 days. 
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Figure 28 (Analysis 1.11). Serum S100-§, 7 to 10 days. 
 
 
 
 
 
 
 
 
Figure 29 (Analysis 1.12). Infarct volume, post treatment. 
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DISCUSSION   
Although there are a number of types of colony stimulating factors, only EPO 
and G-CSF have been studied in completed trials in patients with acute or 
subacute stroke. All were small safety studies except for one phase III trial of 
EPO.256 EPO did not show a significant effect on combined death and 
dependency but there was an increase in death rate. The authors suggest that 
mortality was related to the abnormally high number of recruits receiving 
thrombolysis (63%), of which half demonstrated contraindications to rtPA 
administration. No particular mechanism of death was apparent, however, but 
an EPO-rtPA interaction could not be ruled out; additionally, the significant rise 
in red cell count caused by EPO might be a contributing factor. 
 
Non-haematopoietic derivatives of EPO, which do not increase red cell count 
and haematocrit and a subsequent procoagulant state, are in clinical 
development; two trials of carbamylated EPO have been completed and their 
results are awaited.410, 411 
 
G-CSF did not significantly alter functional outcome but its administration was 
associated with a non-significant reduction in early impairment and early death. 
G-CSF was well tolerated in all six trials and appeared to be safe, although it 
significantly increased white cell count. 
 
Further randomised controlled trials of CSFs are underway, including two with 
G-CSF, a small safety study and a larger hyperacute safety and efficacy trial.302, 
413 No trials of SCF, GM-CSF, M-CSF, TPO were identified. 
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It is apparent that at least two paradigms are being studied with CSFs in the 
treatment of stroke. First, CSFs such as EPO and G-CSF are neuroprotective in 
animal models of acute stroke and this potential mechanism is under 
investigation in patients with acute stroke.255, 256, 297, 302 Second, stem cell 
mobilising CSFs (as with SCF, G-CSF, and GM-CSF) could contribute to brain 
repair through neurogenic-related mechanisms, again as has been seen in 
experimental models of stroke; five trials have investigated this approach (Shyu 
2006; STEMS-1 2006; Zhang 2006; STEMS-2 2010; STEMTHER 2010),294-296, 
303, 304 one of which attempts to track iron-labelled CD34+ cells with MRI.304 All 
of these studies are focusing on recent stroke. No trials of CSFs in chronic 
stroke have been reported, though one is ongoing.414 
 
There are a few limitations to consider. First, despite aggregating all available 
data, the total number of included patients is small, which restricts interpretation 
of the outcomes. When further data are available and the above mechanisms of 
action are considered, analysis may need to be reviewed in subgroups of time-
window of administration, such as hyperacute, subacute and chronic. Second, 
common to most meta-analyses, the data are subject to clinical heterogeneity, 
though statistical heterogeneity was not apparent. This restriction is accounted 
for, in part, by using a random effects model of analysis. Third, there is potential 
bias in other forms, such as publication bias where all relevant studies 
completed may not be included in the analysis (e.g. due to unpublished neutral 
or negative studies). We also introduce an investigator bias since the questions 
we ask of the data are put forward after all of the trials are complete. The bias 
represented here is reduced (but not abolished) by ensuring the analysis is 
performed systematically and transparently. 
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CONCLUSIONS   
Implications for practice   
No conclusive evidence suggests that any type of CSF should be used in the 
routine management of stroke. 
 
Implications for research   
The completed trials provide evidence of the practicality and feasibility of 
administering CSFs. However, questions have arisen regarding the safety of 
EPO in the context of acute stroke, especially in patients who have received 
thrombolysis.256 The mechanism explaining an EPO-rtPA interaction is unclear; 
an increase in blood brain barrier permeability may contribute 415 but further 
experimental work on stroke models is required.  
 
Non-haematopoietic derivatives of EPO are in clinical development, including 
two ongoing trials of carbamylated EPO.410, 411  
 
The mechanisms by which CSFs might work in acute or subacute stroke are 
unclear. Although CSFs could be neuroprotective, reductions in stroke lesion 
size were not seen in trials of EPO of G-CSF. This may reflect the difficulties in 
translating experimental stroke models into clinical medicine and animal models 
not sufficiently representing human stroke.152 G-CSF may also be 
neuroreparative since its administration in the sub-acute period was associated 
with a non-significant reduction in early impairment and early death. Similar 
results have been seen in preclinical studies and mobilised stem cells could 
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enhance neurogenesis and angiogenesis. One clinical trial of G-CSF attempted 
to track the migration of CD34+ cells into the brain.304 
 
Further studies need to address mechanisms by which CSFs might work, for 
example, using alternative cell labelling techniques or cerebral perfusion 
imaging. Understanding potential mechanisms of action will help investigators 
decide when to administer treatment relative to stroke onset. There is a need 
for adequately powered phase III trials of appropriately researched CSFs. 
Whether CSFs aid recovery in chronic stroke also needs to be addressed. 
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CHAPTER 6 
PARAMAGNETIC LABELLING OF HAEMATOPOIETIC CD34+ CELLS 
AND THEIR IDENTIFICATION WITH MAGNETIC RESONANCE 
IMAGING AFTER STROKE: DATA FROM THE STEMS-2 TRIAL 
 
Publications contributing towards this chapter 
 
England TJ, Auer DP, Abaei M, Lowe J, Russell N, Walker M, Bath PMW. Stem-cell 
trial of recovery enhancement after stroke 2 (STEMS-2). Randomised placebo-
controlled trial of granulocyte-colony stimulating factor in mobilising bone marrow 
stem cells in sub-acute stroke (5th UK Stroke Forum). International Journal of 
Stroke. 2010;5 (Suppl 3):3. Oral presentation. 
 
ABSTRACT 
 
Background 
In-vivo tracking of iron labelled stem cells with serial MRI is feasible in 
experimental stroke but has never been attempted in the human stroke brain. 
 
Methods 
Patients enrolled into the Stem cell Trial of recovery EnhanceMent after Stroke 
2 (STEMS-2), a randomised double blind placebo-controlled trial assessing the 
safety of granulocyte-colony stimulating factor (G-
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were invited to partake in a CD34+ haematopoietic stem cell (HSC) labelling 
substudy. Recruits received G-CSF (10!g/kg, subcutaneously) or placebo for 5 
days 3-30 days post ictus. On day 6, mobilised HSCs were extracted from the 
patient, paramagnetically labelled and re-infused intravenously. Serial MRI T2* 
imaging (days 0, 10-12, 90) was used to track iron-labelled cells. HSC counts 
were measured using flow cytometry. 
 
Results 
8 participants (6 G-CSF, 2 placebo) with a mean age 75 (SD 7), of whom 50% 
were male, undertook cell labelling 14 days (SD 3.8) post ischaemic stroke. In 
G-CSF treated participants, between 50Ð430 x104 HSCs were harvested for re-
infusion from 100-200 ml of whole blood. HSC harvest correlated significantly 
with day 5 peripheral blood HSC count (SpearmanÕs rho 0.83, p=0.01). One 
recruit developed a hypodensity compatible with iron-deposition within the 
infarct evident on day 10 and 90 T2* scans. Three subjects had hypodensities 
in their infarct zones compatible with haemorrhagic transformation at days 0, 10 
and 90. The remaining four participants had no hypodensities in their infarct 
zones at any time point. 
 
Conclusions 
Post-stroke paramagnetic CD34+ cell labelling appears safe and feasible. 
There is suggestive evidence from one patient that labelled HSCs migrate to 
the ischaemic lesion.  
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INTRODUCTION 
Experimental stroke recovery is enhanced by cell therapy following implantation 
with a number of stem cell types.162, 221, 416, 417 It is not yet known if this 
therapeutic promise can be translated into clinical practice. Clinical trials 
assessing stem cell transplantation in human stroke are already underway 418, 
419 but there is still much to learn regarding how best to apply any potential 
treatment. Is it safe or feasible? Which stem cell and at what dose should be 
used? How, when and where should they be implanted?  
 
Insights into stem cell dynamics and migration will contribute towards our 
understanding of mechanisms underlying the recovery process. Methods often 
applied in pre-clinical stroke to track migrating cells can be toxic and are not 
suitable for human use. However, labelling with intracellular 277 and extracellular 
362 iron labels and subsequent monitoring with serial MRI has been successful 
in tracking cells in rodents for several weeks post transplantation.384 To our 
knowledge, tracking stem cells using these methods has never previously been 
attempted in the human stroke brain. 
 
Following stroke, mobilisation of CD34+ haematopoietic stem cells (HSC) into 
the peripheral circulation can be achieved with administration of granulocyte 
colony stimulating factor (G-CSF),294 a glycoprotein hormone responsible for the 
production of granulocytic neutrophils. It is used routinely for acquiring HSCs for 
bone marrow transplantation and shows promise as a treatment for stroke. 
HSCs could migrate to the stroke through injury induced chemotaxis and 
contribute towards a recovery process, enhancing neurogenesis and 
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angiogenesis.161 The Stem cell Trial of recovery EnhanceMent after Stroke 2 
was a pilot, phase IIb safety trial evaluating G-CSF for the treatment of 
stroke.304 Here we describe a substudy of STEMS-2 which aimed to determine 
the fate of mobilised HSCs using a CD34+ extracellular iron-oxide label and 
subsequent imaging with MRI. 
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METHODS 
Subjects 
STEMS-2 was a prospective, single-centre, double blind, randomised, placebo-
controlled, phase IIb trial of G-CSF in patients with subacute stroke (see 
chapter 4). Patients included were 3 to 30 days post ischaemic or haemorrhagic 
stroke and were randomised 2:1 to receive subcutaneous human recombinant 
G-CSF (1x106 units/kg, equivalent to 10!g/kg, Neupogen, Amgen) or matching 
subcutaneous saline once per day for 5 days. If there was no evidence of 
haemorrhage on baseline CT brain imaging then recruits were offered the 
opportunity to take part in the CD34+ cell labelling substudy. Recruitment for 
the main trial commenced in July 2007 and ended in January 2010. Due to 
procedural and logistical complexities, patients were recruited into the substudy 
from November 2008. 
 
Once consent or assent from an appropriate legal representative was gained, 
baseline (Day 0) observations were obtained including age, sex, stroke severity 
(Scandinavian Neurological Stroke Score, SNSS) and stroke subtype based on 
the Oxford Community Stroke Project (OCSP) 50 (total anterior circulation infarct 
[TACS], partial anterior circulation stroke [PACS], lacunar infarct [LACS] and 
posterior circulation infarct [POCS]). Follow-up by face-to-face interview was 
performed on days 10-12 and 90 (±7) (figure 30). All assessments were made 
blinded to treatment allocation. 
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Figure 30. Time scheme for the trial and CD34+ cell labelling substudy 
 
 
 
 
Stroke volume 
Two independent investigators measured baseline stroke lesion volume (MR 
diffusion weighted images, echo time (TE) 53 ms, repetition time (TR) 6605 ms, 
slice thickness 2.5 mm, diffusion weighting 1000 s/mm2, field of view (FOV) 
240"240 mm2) using semi-automated software developed locally (NeuRoi, Dr C 
Tench, Department of Clinical Neurology, Nottingham, UK 405).  
 
CD34+ cell labelling 
Between 100 and 200 ml of blood was collected on day 6 and processed in a 
HTA licensed clean room facility. CD34+ cells were immunomagnetically 
separated from the blood using a CliniMACS Separator (Miltenyi Biotec, 
Bergisch Gladbach, Germany) (Appendix A). The CD34+ antibody used for 
immunoseparation contained a dextran-coated iron-oxide nanobead, effectively 
labelling the cells and allowing visualisation with gradient echo (T2* weighted) 
imaging.362 Post labelling, the CD34+ cells were re-injected intravenously back 
into the donor patient on the same day and tracked with MR T2* imaging on day 
10 and day 90 (3T: TE 16 ms, TR 1070 ms, slice thickness 3 mm, FOV 
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230"143 mm2; 7T: TE 254 ms, TR 2500 ms, slice thickness 1.6 mm, FOV 
220"220 mm2). These images are highly sensitive to iron, and therefore to iron-
labelled cells.  
 
CD34+ cell counts were measured using flow cytometry (FACScalibur, Becton 
Dickinson, Oxford, UK) and complied with ISHAGE guidelines.404  
 
A neuroradiologist blinded to treatment allocation and cell counts interpreted pre 
and post labelling scans. Scans were performed on a 3T Achieva (Philips, 
Netherlands) and in some instances, where clinically possible and in patients 
who tolerated MRI scans well, we scanned patients using Nottingham 
UniversityÕs 7T Achieva (Philips, Netherlands).  
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RESULTS 
Eight participants (six in the G-CSF group and two placebo) with a mean age of 
74.6 (standard deviation, SD 6.9), of whom 50% were male and had moderate 
stroke severity (mean SNSS score 33.4, SD 13.2, a lower score representing a 
greater severity) underwent CD34+ cell labelling (figure 31, table 25). All stroke 
subtypes except POCS were included: 3 TACS, 2 PACS and 3 LACS with 
substantial differences in stroke lesion volume ranging between 1.2 cm3 and 
184.5 cm3. There was marked variation in each participantÕs response to G-
CSF; following 5 days of treatment, between 50Ð430 x104 cells were harvested 
from 100-200 ml of whole blood. Participants receiving placebo yielded between 
2Ð7 x104 CD34+ cells. The process of white blood cell separation and then 
immunomagnetic CD34+ cell selection yielded a low proportion of CD34+ cells 
from the original sample of donated blood (mean 24%, table 26).  The total 
quantity of CD34+ cells acquired for re-injection was positively correlated with 
patient peripheral blood CD34+ cell count on day 5, SpearmanÕs rho coefficient, 
rs = 0.83, p=0.01 (figure 32). Labelling occurred, on average, 14 (SD 3.8) days 
from stroke ictus. 
 
Phantom model 
A phantom model was used to demonstrate that iron-oxide microbead-labelled 
CD34+ cells (harvested from a volunteer) dispersed in 0.5% agar (4x103 
cells/ml) were visible on 3T T2* MR scanning; agar alone, and unlabelled 
CD34- cells were not detectable (figure 33). 
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CD34+ cell labelling 
Following review by an experienced neuroradiologist (DA), who was blinded to 
treatment assignment, the scans of one G-CSF treated participant (recruit 
number 50) developed a hypodensity compatible with iron-deposition within 
their left gangliocapsular infarct, evident on both day 10 and 90 T2* scans 
(figure 33). The hypodensity was not present at baseline and this participant 
had received the highest number (430 x 104) of labelled CD34+ cells with 
administration 14 days after stroke onset. Three (G-CSF 2, placebo 1) 
participants (recruits 30,46 and 51) had evidence of hypodensities compatible 
with haemorrhagic transformation at days 0, 10 and 90. The remaining 4 
participants receiving labelled cells had no hypodensities in their infarct zones 
at any time point (figure 34). 
 
 
   
 
Table 25. Baseline characteristics of patients undertaking CD34+ cell labelling 
 
Patient 
trial No 
Treatment 
assignment 
Age Sex Stroke Region 
(ischaemic) 
Clinical 
subtype 
Stroke 
lesion 
volume 
(cm3) 
SNSS 
(_/58) 
Day 
Labelled 
(days post 
ictus) 
Presence of 
HTI 
30 
 
Placebo 84 F Right MCA TACS 165.1 19 13 + 
52 
 
Placebo 83 M Multiple in left 
hemisphere 
PACS 1.7 42 11 - 
27 
 
G-CSF 66 M Left pontine LACS 1.2 40 13 - 
39 
 
G-CSF 81 M Right thalamic LACS Poor quality 44 20 - 
43 
 
G-CSF 71 M Right thalamo-
capsular 
LACS 1.4 43 12 - 
46 
 
G-CSF 72 F Left MCA TACS 184.5 10 19 + 
50 
 
G-CSF 69 F Left ganglio-
capsular 
PACS 56.0 26 14 - 
51 
 
G-CSF 71 F Right striatal  TACS 16.1 43 9 + 
SNSS: Scandinavian Neurological Stroke Scale; G-CSF: granulocyte-colony stimulating factor; HTI: haemorrhagic transformation of infarction; MCA, middle 
cerebral artery; TACS: total anterior circulation infarct; PACS: partial anterior circulation stroke; LACS: lacunar infarct; 
   
 
Table 26. CD34+ cell counts pre and post immunomagnetic labelling 
 
Patient 
trial 
number 
Treatment 
assignment 
Day 5 
peripheral 
blood [CD34+] 
(cells/!l) 
Total CD34+ 
count * 
(blood 
collection bag) 
Total CD34+ 
count    
(pre-
immunomagn
etic selection) 
Total CD34+ 
cell count 
(post-
immunomagn
etic selection) 
Yield % 
(from original 
blood 
collection bag) 
30 
 
Placebo 2.8 Not measured 678 x 104 2.1 x 104 - 
52 
 
Placebo 2.82 18 x 104 15.3 x 104 6.9 x 104 38.3 
27 
 
G-CSF 177.8 Not measured Not measured 246 x 104 - 
39 
 
G-CSF 46.7 503 x 104 369 x 104 125 x 104 23.9 
43 
 
G-CSF 51.6 737 x 104 610 x 104 145 x 104 20.4 
46 
 
G-CSF 22.7 555 x 104 224 x 104 45 x 104 9 
50 
 
G-CSF 47.8 1370 x 104 853 x 104 430 x 104 31.4 
51 
 
G-CSF 37.6 743 x 104 512 x 104 161 x 104 21.5 
[ ], denotes concentration; * derived from 100 Ð 200 mls of whole blood taken from the patient on Day 6;  
  post-labelling but pre-immunomagnetic selection 
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Figure 31. STEMS-2 trial flow and recruitment into CD34+ cell labelling sub 
study 
G-CSF, granulocyte colony stimulating factor
* 110 refused, 35 enrolled into another trial
Not eligible
n=2410
Refused or enrolled
into another trial *
n=145
Cell labelling sub-study
n=6
G-CSF (10!g/kg)
n=40
Cell labelling sub-study
n=2
Placebo (normal saline)
n=20
Enrolled into STEMS-2
n=60
51 ischaemic
9 haemorrhagic
Eligible
n=205
Screened
n=2615
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Figure 32. Correlation of Day 5 peripheral blood CD34+ cell count and total 
number of CD34+ cells harvested for labelling on day 6 
Correlation is statistically significant, SpearmanÕs rho coefficient, rs = 0.83, 
p=0.01) 
 
 
 
 
!"
#!"
$!!"
$#!"
%!!"
%#!"
&!!"
&#!"
'!!"
'#!"
#!!"
!" %!" '!" (!" )!" $!!" $%!" $'!" $(!" $)!" %!!"
T
o
ta
l 
C
D
3
4
+
 c
e
ll
 c
o
u
n
t 
(
x
 1
0
4
)
 (
p
o
s
t-
im
m
u
n
o
m
a
g
n
e
ti
c
 
s
e
le
c
ti
o
n
)
 
Day 5 peripheral blood [CD34+] (cells/!l) 
    
 
Figure 33. Gradient echo imaging at days (i) 0, (ii) 10, and (iii) 90 in patient 50 with left gangliocapsular infarction. (iv) 
Corresponding diffusion weighted image at day 0.  
The participant received 4.3x106 intravenous immunomagnetically-labelled CD34+ cells on day 6. Arrow indicates new area of 
negative enhancement. (v) Phantom model comparing (a) labelled CD34+ cells dispersed in 0.5% agar (4x103 cells/ml), (b) agar 
alone, (c) iron-oxide microbeads alone and (d) unlabelled CD34- cells. 
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Figure 34. Gradient echo imaging at days 0, 10, and 90 and corresponding 
diffusion weighted image at day 0 in all recruits receiving iron labelled CD34+ 
cells ( =7T MRI, all other scans performed at 3T) 
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DISCUSSION 
STEMS-2 was a high quality double blind placebo-controlled randomised trial. 
The CD34+ cell labelling substudy was designed to establish whether G-CSF 
mobilised iron-labelled CD34+ cells migrate to the site of the stroke lesion, thus 
potentially contributing to neurorepair, as seen experimentally.161, 351 The 
complexity of recovering, labelling and re-administering CD34+ cells meant that 
we studied fewer participants than desired. Nonetheless, T2* MR imaging 
suggested the presence of migrated labelled cells in one participant as 
demonstrated by new signal loss within the infarct on days 10 (4 days after 
reinjection) and 90, and without evidence of baseline haemorrhagic 
transformation (at day 14 post stroke). This followed intravenous injection of 
430 x104 labelled CD34+ cells (the highest number of cells recovered from any 
participant). There was no evidence of T2* signal loss in four participants, and 
haemorrhagic transformation occurred in three. Bone marrow derived stem cells 
have been tracked successfully in animal models of stroke by using 
extracellular and intracellular iron labels,362, 385 a method that confers visibility 
on gradient echo MR imaging. Qualitative interpretation of T2* images was 
limited by scan quality and pre-existing signal loss (e.g. due to haemosiderin 
deposition from previous bleeds). New petechial or parenchymal bleeding from 
haemorrhagic transformation further limited specificity of interpretation of new 
signal loss; haemorrhagic transformation is present in up to 85% of ischaemic 
stroke in serial MR imaging studies.400 
 
The failure to visualise MRI hypodensities compatible with CD34+ cell migration 
in more than one patient may reflect several issues. First, the total number of 
cells injected may have been too low; experimental rodent models used 3Ð750 
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x104 labelled stem cells,277, 362 a significantly higher weight-adjusted dose than 
available to us. Second, the route of administration may be suboptimal; both 
intracerebral and intra-arterial injection will deliver a greater number of cells to 
the brain.272 Nonetheless, intravenous administration has been shown to be 
capable of delivering migrating cells to the lesion of interest 384 although this 
finding is not consistent.378 Third, it is possible that the cells migrate to a site 
other than the brain, such as an area of concomitant infection, or to other 
organs including liver, spleen and bone marrow.420 Fourth, extracellular iron-
oxide microbeads may not provide adequate contrast for visualisation using 
MRI in vivo, though the in vitro phantom data argues against this since as few 
as 4 x103 cells/ml were identifiable. Fifth, the microbeads may not remain 
attached to the CD34+ cell membrane after they have been re-infused into the 
patient; they could be internalised or detach and transfer to other cells (e.g. 
macrophages). Sixth, the microbeads may interfere with CD34+ activity,362 e.g. 
attenuating cell migration. Further studies could consider the use of intracellular 
iron labels.392 Seventh, the presence of haemorrhagic transformation will have 
prevented seeing any migrated cells in 3 of our G-CSF treated participants. 
Furthermore, even if the presence of negative enhancement on MR images 
were to represent iron within a cell, then this would not provide evidence on cell 
viability, which could be achieved, for example, with positron emission scanning 
(discussed below). Eighth, the timing of cell administration could be important 
and we may have treated either too early or too late. Last, it is conceivable that 
CD34+ cells do not naturally migrate to the ischaemic lesion, in which case they 
are unlikely to influence neurorepair.  
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There are no previous clinical data published involving iron-labelled stem cells 
and stroke; reports are described in melanoma (dendritic cells),421 traumatic 
brain injury (neural stem cells),422 islet cell transplantation 423 and spinal cord 
injury (CD34+ cells).424 Other reports in stroke have attempted to address stem 
cell migration using alternative methods. In one non-controlled study, 12 
patients with chronic stroke received CT-guided implantation of stem cells 
derived from an immortalised cell line;280 follow-up FDG-PET 
(Fluorodeoxyglucose Positron Emission Tomography) scanning suggested 
either the presence of inflammation or the viability of implanted cells (FDG is an 
analogue of glucose labelled with fluorine-18 and its use as a marker for cell 
tracking is limited by its short half-life and increase of radiation exposure to the 
patient. Its uptake is also non-specific and the PET scan will be positive in cells 
with a high metabolic rate, for example, in an area of inflammation or tumour 
formation). Post mortem examination of one patient 27 months after cell 
implantation identified the survival of transplanted neuronal cells.290  
 
Another trial assessed migration of intrathecal immunomagnetically-labelled 
CD34+ cells in 10 patients with chronic spinal cord injury in comparison with 6 
controls who received intrathecal immunomagnetic beads only.424 This study 
was non-randomised, patients received between 50-120 x104 labelled cells, and 
hypointense signals were observed in 50% of lesions in the treatment group 20 
and 35 days after transplantation. An alternative labelling technique was 
employed in another non-randomised, phase I, open-label clinical trial:425 6 men 
received radio-labelled bone marrow derived mononuclear cells that had been 
cultured ex-vivo, which were intra-arterially injected into the middle cerebral 
artery between 59 and 82 days post ischaemic stroke. Whole body scintigraphy 
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and Single-Photon Emission Computed Tomography (SPECT) indicated cell 
homing to the brain at 2 hours but due to the short half-life of Technetium-99m 
(6 hours), scan interpretation was limited at 24 hours. Uptake was also seen in 
the liver, lungs, spleen and kidneys. 
 
This is the first clinical trial in stroke that has identified possible CD34+ cell 
migration post intravenous implantation, though there are a number of 
limitations as described. Whilst iron-labelling techniques offer the potential to 
track cells over a long period of time (compared to the short half-life of 
radiolabelling techniques), it still may not be an optimal technique to use in 
human stroke. The common presence of haemorrhagic transformation of 
infarction (HTI), which can occur at variable time points post-stroke, will always 
confound interpretation of cell migration. If iron labels are used then careful 
patient selection is required, that is, excluding HTI before enrolment with MRI. 
Pre-clinical models of stroke will continue to provide insights into migratory 
patterns of stem cells but cell dynamics will inevitably vary in the human clinical 
trial setting. This underlies the importance of determining their behaviour in 
humans. Further research is therefore required to investigate the feasibility and 
safety of other potential stem cell labels. 
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CHAPTER 7 
HAEMATOPOEITIC STEM CELL (CD34+) UPTAKE OF 
SUPERPARAMAGNETIC IRON OXIDE (SPIO) IS ENHANCED BUT 
NOT DEPENDENT UPON A TRANSFECTION AGENT 
 
Publications contributing to this chapter: 
TJ England, PM Bath, M Abaie, D Auer, R Jones. Haematopoeitic stem cell 
(CD34+) uptake of superparamagnetic iron oxide (SPIO) is enhanced but not 
dependent upon a transfection agent. Cerebrovascular Diseases 2012, Vol. 33, 
Suppl. 2. Poster presentation and European Stroke Conference, Lisbon 2012. 
Submitted to Cytotherapy (under review) 
 
ABSTRACT 
 
Background 
Superparamagnetic iron oxide particles (SPIO) can be internalised into stem 
cells to allow real-time tracking with gradient echo magnetic resonance (MR) 
imaging. Although there are many reports of haematopoietic stem cells being 
labelled using SPIO, there is some controversy regarding the outcomes and it is 
not clear whether undifferentiated CD34+ progenitor (stem) cells are able to 
take up iron in the absence of a transfection agent to enhance the process. 
 
Methods 
CD34+ cells were treated in vitro as follows: incubation with (i) medium only 
(control), (ii) ferumoxide (Endorem) and (iii) ferumoxide (Endorem) plus 
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exposure to a transfection agent (protamine sulphate). Cells were incubated for 
2, 4 and 24 hours & assessed for viability, differentiation capacity and visualised 
in vitro with 3T magnetic resonance imaging. The cells were also analysed 
using flow cytometry and the morphology examined by electron microscopy. 
 
Results 
CD34+ haematopoietic progenitor cells can internalise ferumoxide (Endorem) 
independently of a transfection agent. However, uptake of ferumoxide is 
enhanced following exposure to protamine sulphate. Iron labelling of CD34+ 
cells in this manner does not affect cell viability and does not appear to affect 
the potential of the cells to grow in culture. Iron labelled CD34+ cells can be 
visualised in vitro on 3T MRI scanning. 
 
Conclusions 
Endorem and protamine sulphate can be combined to promote iron-oxide 
nanoparticle uptake by CD34+ cells and this methodology can potentially be 
used to track the fate of cells in a human clinical trial setting. 
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INTRODUCTION 
Stem and progenitor cells provide increasing potential for treatment of a variety 
of conditions including ParkinsonÕs disease,200 multiple sclerosis,426 spinal cord 
injury,427 and vascular diseases such as myocardial infarction and stroke.279, 428 
Despite experiences gained from (human) clinical trials, stem cell fate in the 
context of tissue repair or regeneration in vivo is relatively poorly understood. 
Particular interest has been generated in the field of autologous haematopoietic 
stem cells since these can be obtained via bone marrow aspiration (CD34+ 
cells) or via mobilisation into the circulation using granulocyte-colony stimulating 
factor (G-CSF).  
 
Labelling cells with iron and tracking them in vivo with magnetic resonance 
(MR) imaging creates the potential for Ôreal-timeÕ migration patterns to be 
established. Superparamagnetic iron oxide particles (SPIO) can be taken up 
into cells to allow tracking with gradient echo MR imaging and although it has 
been reported that Ôhaematopoietic stem cellsÕ have been labelled using 
SPIO,420, 429-431 it is not clear whether undifferentiated CD34+ cells are able to 
take up iron particles without a transfection agent (substances that efficiently 
shuttle particles into the cell). SPIOs are negatively charged and do not adhere 
to cell surface membranes, so a transfection agent could be used to 
electrostatically combine with the dextran coating of the SPIO, modifying the 
surface charge and allowing adherence to the cell membrane, with subsequent 
internalisation.  
 
However, most labelling techniques used in animal models are not applicable 
for, or are not licensed for, use in human patients. Both the SPIO, ferumoxide, 
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and protamine sulphate (which can be used as a transfection agent) are 
approved (separately) for use in humans.  Endorem is an effective labelling 
agent in other cell types,389, 391, 392 typically used as a MRI contrast reagent 
administered for detecting liver lesions.432 Protamine sulphate is a low 
molecular weight polycationic peptide used for reversing the effects of heparin 
in vivo.433 
 
The aim of this study was to determine whether human CD34+ cells are 
capable of intracellular uptake of SPIO in vitro and whether the process 
requires a transfection agent (e.g. protamine sulphate).  The use of established 
compounds such as Endorem as an intracellular label and (if required) 
protamine sulphate might facilitate the transition to human clinical trials where 
data on cell fate are required.   
   
 207 
MATERIALS AND METHODS 
Adult CD34+ cells 
CD34+ cells were purchased from a commercial supplier (Stem Cell 
Technologies, Vancouver, Canada) being originally pooled from different 
donors. The cells, prepared using immunomagnetic cell separation procedures, 
were transported from the supplier on dry ice and stored in liquid nitrogen 
(vapour phase) on receipt. When required, a frozen cell suspension was thawed 
by gentle agitation in a 37 oC water bath and the cells transferred to a sterile 
universal container. A viable cell count was performed using trypan blue 
exclusion.  The cell suspension volume was made up to 20mls in a sterile 
universal container by dropwise addition of RPMI 1640 containing 10% heat 
inactivated foetal bovine serum (FBS); the whole washed twice by 
centrifugation (200g for 15 minutes) and then resuspended in a final volume of 
1 ml (RPMI/10%FBS).  
 
Preparation of ferumoxide solutions for cell labelling 
Incubation medium contained RPMI 20% FBS and 10!l/ml glutamate (all Sigma 
Aldrich, Dorset, UK). For the SPIO-labelled cells, ferumoxide (ÔEndoremÕ, 
Guerbet, France) supplied at 11.2mg iron per ml was added to incubation 
medium at a final concentration of 100!g/ml. When required, protamine 
sulphate was also added (to the incubation medium) at a final concentration of 
5!g/ml (Fe-Pro solution).  
Equal volumes of the cell suspension (containing 106 CD34+ cells) and the 
prepared medium were combined to a final concentration of 50!g 
ferumoxide/ml (total vol. 2ml) and incubated for 2, 4 and 24 hours (37 oC, 5% 
CO2). Post incubation, the cells were washed twice in phosphate buffered saline 
   
 208 
(PBS), the second wash containing heparin (10 U/ml) to inactivate any 
protamine sulphate in extracellular Fe-Pro complexes. Cells were incubated 
with either ferumoxide alone or with ferumoxide plus protamine sulphate. As 
controls, cells were incubated with medium alone or with medium containing 
only protamine sulphate (and heparin added post incubation). After incubation, 
the cells were fixed using 0.5% formaldehyde solution for analysis using flow 
cytometry. 
 
Cell culture and viability 
After incubation with ferumoxide and/or protamine sulphate, cells were 
analysed for any impact on differentiation ability and on viability.  For growth 
and differentiation studies, 3 x 105 CD34+ cells were added to 3mls of 
haematopoietic culture medium (Methocult H4434: Stem Cell Technologies, 
Vancouver, Canada), as per the manufacturerÕs instructions and the whole 
incubated, in a humid atmosphere, at 370C, 5% CO2 for 21 days. In addition to 
haematopoietic culture, cell viability was determined using propidium iodide (PI) 
uptake, analysed via flow cytometry. PI was added to 1ml of each cell 
suspension to a final concentration of 0.5 !g/ml. PI binds to DNA in cells with a 
damaged or disrupted cell membrane, thus conveying a relatively accurate 
measure of cell viability when this is analysed using flow cytometry.  
 
MRI ÔPhantomÕ Model 
The cells derived from each experimental protocol were assessed using MRI 
(Philips Achieva at 3T, Philips, Eindhoven, NL) after dispersing in 4ml of an 
agar solution (0.5%) and allowing the whole to set. Gradient echo sequences 
were used (TE: echo time 16.1ms; TR: repetition time 643.9ms; slice thickness: 
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1mm; Field of View: 40mm x 230mm x 183.3mm, pixel size 0.5mm x 0.5mm, flip 
angle 18) since these are sensitive to iron, and are demonstrated as 
hypointense areas relative to the surrounding agar if iron is present. 
 
Electron Microscopy (EM) 
Aliquots of 3 x 106 CD34+ cells were divided equally and incubated in medium 
alone, ferumoxide or Fe-Pro for 24 hours following the methods described 
above. The resulting cells were prepared for EM by adding them to an active 
fixative solution containing 500!l 25% EM grade gluteraldehyde solution and 
5mls of 0.1M sodium cacodylate buffer, pH7.4. The cell preparations were 
evaluated using a JEOL 1010 transmission electron microscope (JEOL UK Ltd.) 
performed at 100kV. Two investigators (TE and RJ) assessed the cells for any 
structural changes and for the presence of intracellular ferumoxide. As a 
reference material, a suspension of ferumoxide alone was also evaluated using 
EM. Images were recorded using iTEM, a digital camera system (Olympus Soft 
Imaging Solutions, Olympus SIS GMBH, Germany). 
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RESULTS 
Viability of adult CD34+ cells after ferumoxide uptake 
In order to determine whether ferumoxide has a measurable effect on cell 
viability, the CD34+ cells were analysed by flow cytometry after incubation with 
ferumoxide, FePro or with medium alone for 24h.  Using propidium iodide (PI) 
as a marker of cell viability, a region was demarcated around the cell population 
showing a ÔshiftÕ in shape and size and the proportion of these non-viable cells 
(i.e. PI positive) was calculated.  Overall cell viability was unaffected by 
incubation with ferumoxide (88.9%) and Fe-Pro (90.9%) when compared with 
medium alone (91.1%). In addition, incubation with protamine sulphate alone 
did not affect cell viability (89%) compared with medium alone (91.1%).  
 
Internalisation of ferumoxide by adult CD34+ cells 
Flow cytometric analysis of the cells following incubation with medium alone 
(control), ferumoxide or Fe-Pro is shown in figure 35. The size and granularity of 
the cell population in the control group generally remained unchanged over the 
24 hour period of the study. However, as cells die within a medium they initially 
increase in size & granularity, which was evident in the small population with 
increased side scatter in the control group at 4h and at 24h (figure 35A). In the 
ferumoxide-only group, a gradual increase in side scatter (granularity) was 
apparent over the timescale of observations (2h Ð 24h: figure 35B) compared to 
the control; whereas in cells incubated with FePro granularity was pronounced 
at both 4h and 24 h (figure 35C). It is not clear whether this pattern of 
granularity was due to a subpopulation of cells undergoing apoptosis (for 
example) or whether it was due to cells taking up the iron particles. In total, 
45.3% of the CD34+ cells in the 24 hour Fe-Pro group were contained within 
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the subpopulation showing increased granularity (figure 35C), compared to 
17.3% in the control group (figure 35A) & 24.3% in the ferumoxide group (figure 
35B). Cells incubated with protamine sulphate alone showed a similar pattern to 
those from the control (medium only) Ð data not shown. Overall, these data 
suggest that although exposure to ferumoxide alone has some effect on cell 
integrity in this culture system, this effect is more marked when cells are 
incubated with Fe-Pro. 
 
CD34+ cell culture 
The cells from the experimental groups (control, ferumoxide, FePro and 
protamine sulphate) were seeded in Methocult medium (to assess 
haematopoietic potential) and incubated for 21 days.  Haematopoietic colonies 
were produced from CD34+ cells in all 4 experimental groups. Compared to the 
control culture (medium alone), there was no difference in the distribution or 
quantity of colonies derived from cells in all experimental groups (data not 
shown), indicating that there was no detriment to haematopoietic lineage 
commitment after incubation of the CD34+ cells with ferumoxide, FePro or with 
protamine sulphate alone. 
 
Electron Microscopy (EM) 
EM images of the ferumoxide preparation alone showed clusters of iron 
particles ranging between 216nm and 310nm in diameter with the dextran 
polymer coating surrounding the ferumoxide particles also visualised (figure 
36a). The CD34+ cell preparation was evidently undergoing apparent ÔapoptoticÕ 
transformation (figure 36b-d), with filaments protruding from the membrane and 
with some cytoplasmic vacuolation. When incubated with ferumoxide alone 
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(figure 36c) it was noted that particles were internalized to some extent (by the 
cells) - but that there was variation between cells. Cells incubated with FePro 
(ferumoxide plus protamine sulphate) showed a greater uptake of particles but 
there was also an increase in the number of vacuoles within the cells (figure 
36d). These vacuoles were mostly empty but there were also some liposomes 
containing coalescent material suggestive of degraded ferumoxide particles. 
 
MRI Phantom Model 
The cells from each 24h experiment (medium alone, ferumoxide, Fe-Pro and 
protamine sulphate alone) were assessed with MRI at 3T (Philips Achieva, 
Philips, Eindhoven, NL) after dispersal in 4ml of 0.5% agar solution. An area of 
negative enhancement was observed in the cells incubated with ferumoxide 
and protamine sulphate, indicating the presence of iron (figure 37). Cells 
incubated in ferumoxide alone showed no such contrast difference. 
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Figure 35. Flow cytometric analysis of bone marrow-derived CD34+ve cells. 
Incubated with (A) medium alone (control), (B) ferumoxide, and (C) ferumoxide-
protamine sulphate (Fe-Pro) complexes for 2h, 4h and 24h. The data show 
forward vs side scatter and indicate relative granularity of the cell populations. 
At 24h, there is a change in granularity in the control cells (A: 17.3% in region 
R1) which is more pronounced in cells incubated with ferumoxide (B: 24.3% in 
region R1) and is marked in cells incubated with ferumoxide-protamine sulphate 
complexes (C: 45.3% in region R1).   
 
 
 
 
 
   
  
Figure . Electron micrographs of labelled CD34+ cells. 
(a) Ferumoxide (Endorem) particle, (b) CD34+ cells incubated with medium alone, (c) CD34+ cells incubated with ferumoxide alone and 
(d) CD34+ve cells incubated with ferumoxide + protamine sulphate (Fe-Pro). Arrows indicate areas where ferumoxide has been taken 
up into the cell. Cells exposed to Fe-Pro (d) show coalescent material within liposomes, suggesting possible compromise of cell 
metabolism.  
 
  
   
  
Figure . Gradient echo MRI of labelled CD34+ cells. 
CD34+ve cells incubated for 24 hours with (a) medium alone, (b) protamine sulphate, (c) ferumoxide + protamine sulphate (Fe-Pro) and 
(d) ferumoxide alone. Each circle represents a vial containing 2x105 CD34+ve cells dispersed in 4mls of agar. 
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DISCUSSION 
We have demonstrated that CD34+ve haematopoietic progenitor cells can 
internalise superparamagnetic iron oxide particles (SPIO) in culture medium 
over a 24 hour period, and that the process of internalisation is enhanced when 
protamine sulphate is added to the medium. SPIO labelling, with or without 
protamine sulphate, does not affect cell viability and does not appear to affect 
the potential of the cells to differentiate in haematopoietic culture medium in 
vitro. Further, we have confirmed that CD34+ve cells labelled in vitro in this way 
can be visualised on 3T MRI scanning. 
 
Other groups have previously addressed haematopoietic stem cell (HSC) 
labelling with iron-containing compounds (SPIO) of varying composition (such 
as ferumoxide or ferumoxtran) but the majority of studies have not labelled 
CD34+ve cells specifically; in those studies cells were incubated for a number 
of days 431 or weeks, before labelling 434 or were grown in culture until sufficient 
numbers were obtained.430 Haematopoietic progenitor (CD34+ve) cells are 
likely to have differentiated (some to end-stage cells) during time spent in 
culture and the ability to take up SPIOs could, therefore, be expected to have 
altered. One study used mixed cell populations (CD34+ve with CD34- cells) 
obtained from cord blood,429 making it unclear which cells were actually 
internalising the iron particles. Another study, using human cord blood as a 
source of HSCs, demonstrated that CD34+ve cells cannot take up iron without 
a transfection agent (P7228 with liposome).435 However, since CD34+ve cells 
were separated from CD34- cells after the labelling process, it is possible that 
iron was internalised preferentially into one cell type.  In the current study, a 
single defined cell population was selected and labelled, and this process 
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revealed that CD34+ve cells can internalise iron in the form of a SPIO 
(ferumoxide; Endorem), both with and without the addition of protamine 
sulphate.  
 
Flow cytometric analysis of the CD34+ve cells at 24 hours incubation in the 
ferumoxide group identified a distinct cell subpopulation, presumably cells 
containing the iron particles. The uptake of SPIO was confirmed using electron 
microscopy (preferred to Prussian blue staining since the CD34+ve cells had 
been harvested by immunomagnetic selection and therefore had iron-containing 
particles on the cell membrane). It was noted that that cellular uptake of SPIO is 
far from uniform Ð ranging from 17.3% to 45.3% - indicating that not all of the 
CD34+ve cells internalise the ferumoxide. This observation is consistent with a 
previous report that used iron particle uptake by CD34+ve cells to assess cell 
migration, post infusion, in immunodeficient mice;436 cells labelled with Endorem 
and Resovist (a carbodextran-coated SPIO with a diameter of 60nm) 
accumulated iron in 61% and 49% of cells respectively. Of interest, freshly 
isolated cells were compared with frozen/thawed cells and demonstrated up to 
85% labelling efficiency if fresh cells were used.436 Using quantification with 
spectrometry, other groups have indicated that the use of protamine sulphate 
and other transfection agents will load a CD34+ve cell with between 1.1pg/cell 
and 3pg/cell but using high concentrations of ferumoxide during incubation in 
culture medium.420, 435 In contrast, lower levels of iron uptake have been 
observed in (unspecified) peripheral blood progenitor cells (0.8pg/cell) and 
CD34+ cells (0.01pg/cell) without the use of a transfection agent.420, 435 In our 
study, we were unable to quantify the SPIO uptake and therefore cannot 
directly compare these data with these other reports.   
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Uptake of iron particles by cells in vitro is dependent upon incubation time (and 
iron concentration) with longer incubation times having a detrimental effect on 
cell viability.429, 430 We did not observe this problem: after 24 hours in culture 
medium, the CD34+ve cells were ~90% viable (using propidium iodide). Despite 
this high level of viability, electron microscopy revealed the cells to be under 
stress, raising concerns about the labelling (or thawing) process on cell 
function. Nonetheless, when compared to unlabelled cells, it was clear that the 
SPIO-containing cells were able to form similar numbers of colony forming units 
in culture. Phenotype and migration capacity of HSCs also appears to be 
unaffected by ferumoxide- or FePro- labelling.430, 434 However, the effect of 
SPIO uptake on function remains a controversial point as it has been reported 
to impede CD34+ve cell differentiation 436 or alter cell surface marker 
expression in, for example, mesenchymal stem cells.395, 437 Electron micrograph 
(EM) data from our study indicate that although protamine sulphate enhanced 
SPIO uptake, this group of CD34+ve cells had intracellular changes not evident 
in the ferumoxide group.  Since such changes only occurred in the Fe-Pro 
group (exposure to protamine sulphate without ferumoxide is comparable to 
medium alone), we suggest that protamine sulphate may enhance SPIO uptake 
but that the increased iron loading of the cells may ultimately compromise 
function.   
 
The current study has a number of limitations. First, the commercially sourced 
CD34+ve cells were immunomagnetically selected, potentially influencing 
analysis of the iron content of the cells. It was not clear whether the iron 
containing microbeads on the cell membrane would either degrade or be 
internalised by the cell. The control groups did not reveal any indication of 
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internalised iron on EM images, though only a limited number of the cells were 
assessed. Second, the quantity of internalised iron oxide was not calculated, 
although analysis by flow cytometry indicated that there is considerable 
variability in cellular uptake of SPIO. Third, despite confirmation with EM that 
iron particles were internalised in the ferumoxide group, the magnetic 
resonance images revealed that only the cells incubated with ferumoxide plus 
protamine sulphate together were detectable on gradient echo imaging. The 
detection limit will clearly depend upon magnet field strength, cell number, iron 
label (size and quantity), site (in vitro or in vivo) and the level of dispersion of 
cells (concentration). The detection limit and iron load must be balanced with 
cell viability and functional capability: it is a process still undergoing 
optimisation.394 Previously reported studies have shown that as few as 2.5 x 105 
Fe-Pro labelled cells are needed to be visualised on 1.5T MRI 429 compared to 
2 x 105 with 3T MRI in the current study.  
 
In summary, the two products Endorem (ferumoxide) and protamine sulphate, 
individually licensed for human use (for other indications), can be combined to 
promote iron-oxide nanoparticle uptake by CD34+ve cells uptake without 
significantly affecting cell viability and proliferative capacity. Further, although 
the process is enhanced but is not dependent upon the use of protamine 
sulphate, it would be necessary to carry out further investigations in vivo to 
determine the fate of cells labelled in this way. However, these results suggest 
that, with adequate cellular concentrations, gradient echo MRI could visualise 
and therefore potentially track iron (SPIO)-containing cells in a human clinical 
trial setting. 
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CHAPTER 8  
HISTOPATHOLOGICAL CHARACTERISTICS OF STROKE BRAIN 
POST TREATMENT WITH GRANULOCYTE COLONY STIMULATING 
FACTOR: DATA FROM THE STEMS-2 TRIAL 
 
Publications contributing towards this chapter 
 
England TJ, Auer DP, Abaei M, Lowe J, Russell N, Walker M, Bath PMW. Stem-cell 
trial of recovery enhancement after stroke 2 (STEMS-2). Randomised placebo-
controlled trial of granulocyte-colony stimulating factor in mobilising bone marrow 
stem cells in sub-acute stroke (5th UK Stroke Forum). International Journal of 
Stroke. 2010;5 (Suppl 3):3. Oral presentation. 
 
ABSTRACT 
 
Background 
Granulocyte colony stimulating factor (G-CSF) shows promise as a treatment 
for stroke through neuroprotection or neurorepair (via mobilisation of 
haematopoietic CD34+ stem cells). The expression of G-CSF protein, its 
receptor (G-CSFR) and CD34 has never been evaluated in the human brain 
following treatment with G-CSF. 
 
Methods 
In the event of death, patients from the Stem cell Trial of recovery 
EnhanceMent after Stroke 2 (STEMS-2), a randomised controlled trial 
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assessing the safety of G-CSF administration 3-30 day post stroke, were 
eligible to take part in a post mortem substudy. Lesion morphology from 
histological samples was described qualitatively by a consultant 
neuropathologist blinded to treatment. Immunohistochemical characterisation 
for astrocytes (GFAP), microglia (CD68) and cell proliferation (Mib-1) was 
performed in addition to CD34, G-CSF protein and G-CSFR. ÔNon-trialÕ stroke 
brains were used as control cases.  
 
Results 
The brains of 3 patients treated with G-CSF were compared to 3 control brains 
(mean age 76 and 64 respectively) analysing areas of acute, subacute and 
chronic infarction. There was no discernable difference in immunoreactivity 
between groups for CD34 (weakly staining endothelium), G-CSF (also positive 
in endothelium) and G-CSFR (evident in neurons in acute stroke and microglia 
in chronic stroke). Mib-1 was positive in endothelium in acute infarction 
indicating ongoing angiogenesis. 
 
Conclusions 
G-CSF treatment did not clearly alter the cellular profile of ischaemic brain 
tissue though the sample size was small. Areas of angiogenesis and expression 
of G-CSFR in acute and chronic infarction suggest potential targets for therapy. 
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INTRODUCTION 
Experimental stroke studies assessing the effects of granulocyte colony 
stimulating factor (G-CSF), a polypeptide glycoprotein hormone that regulates 
the production of neutrophilic granulocytes,438 have demonstrated promise in 
developing the drug as a potential treatment for ischaemic stroke.137 If 
administered hyperacutely, reductions in infarct volume suggest that 
improvements in recovery could be due to neuroprotection.376 Furthermore, G-
CSF induced mobilisation of haematopoietic (CD34+) stem cells migrating to 
the infarcted brain could explain why enhanced functional recovery is also 
observed when G-CSF is given beyond 24 hours post ictus 161, 235, 236, 439 
(though fewer published studies have addressed this). G-CSF can cross the 
blood-brain barrier, reduces apoptosis in the ischaemic penumbra via 
upregulation of a neuronal G-CSF receptor and augments the neurovascular 
microenvironment via new vessel and neuron formation.137, 235 G-CSF receptor 
is expressed on a number of haematopoietic (platelets, myeloid and lymphoid 
cell lines 440) and non-haematopoietic cell types including neurons in the central 
nervous system 137 and endothelial cells.402 
 
Despite the accumulating wealth of evidence, very little has been established 
about the expression of G-CSF and its receptor in human ischaemic brain 
tissue. One autopsy series of 21 stroke brains revealed evidence of G-CSF 
receptor expression on neurons in acute stroke, microglia and macrophages in 
subacute stroke and astrocytic expression in chronic infarction.366 No studies 
have shown how the cellular profile alters following treatment with G-CSF. As 
part of the Stem cell Trial of recovery EnhanceMent after Stroke 2 (STEMS-2), 
which assessed the safety and feasibility of G-CSF treatment for subacute 
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stroke, 304 we aimed to establish the cellular profile in cerebral infarction in 
patients treated recently with recombinant G-CSF (Filgrastim), with reference to 
CD34, G-CSF and G-CSF receptor expression in the brain. 
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METHODS 
Subjects 
Patients were recruited as part of a substudy of the STEMS-2 trial. These 
methods are covered in earlier chapters. Briefly, STEMS-2 was a double blind, 
randomised placebo-controlled trial assessing the safety and feasibility of G-
CSF in subacute stroke.304 Patients received either 10!g/kg G-CSF or placebo 
(normal saline) subcutaneously once per day for 5 days and were followed up 
for 90 (±7) days. Participants were given the option to donate their brain to the 
trial in the event of their death for post mortem examination. 
 
Ethics 
Full ethical approval was obtained during the original application for the main 
trial (Local Research Ethics Committee, Nottingham LREC 22nd May 2007). 
Patients were approached once they had enrolled into the main part of the 
study and information on brain donation was left with them to consider 
involvement. Fully informed consent or assent from a legal representative was 
gained in cooperation with the Pathology Department, QueenÕs Medical Centre, 
Nottingham. In order to develop immunohistochemical techniques, we used 
brain retained from post mortem examinations performed under normal ongoing 
Trust diagnostic activities; the cases came with consent for use of retained 
organs and tissues for research and teaching in addition to the diagnostic 
component of the post mortem. For control cases, the standard post mortem 
consent form was used, which is aligned to the nationally advised form and 
complies with requirements under the Human Tissues Act. 
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Immunohistochemistry (IHC) 
Brain slices were examined following formalin fixation. Histological samples 
were taken from representative brain areas to include both macroscopically 
pathological and normal tissue. Pathology was characterised using 
conventional histological techniques using formalin-fixed, wax-embedded 
tissue; the tissue was cut on a microtome set at 3!m and floated on to a water 
bath (45 oC) to iron out any creases. Sections were picked up on charged slides 
and drained for 20 minutes before baking at 60 oC for 2 hours prior to staining 
(this minimises the risk of sections lifting off the slide). IHC staining was 
performed using a panel of antibodies applied in accordance with the 
manufacturers recommendations using BondMax staining machines (Leica 
Microsystems). IHC characterisation was carried out using standard markers for 
astroglial (GFAP, 1/4000) and microglial (CD68, 1/2000) phenotypes.290 
Immunostaining for CD34 was performed as well as Mib-1 labelling to look for 
cell proliferation in neuronal and vascular cells.290 In addition, staining and 
characterisation for G-CSF protein (1/50, Santa Cruz Biotechnology, Inc) and its 
receptor (G-CSFR, 1/50, Santa Cruz Biotechnology, Inc) were carried out.366 
Lesion morphology was described qualitatively and age of the infarct 
categorised into acute, subacute or chronic. Slides were interpreted by a 
consultant neuropathologist (JL) blinded to treatment allocation.  
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RESULTS 
Subjects 
6 patients donated their brain for analysis (figure 38), 3 in the G-CSF group (1 
male and 2 female) and 3 non-trial controls (1 male and 2 female); mean age 
was 76 and 64 years respectively. The time of death from onset of neurological 
symptoms ranged between 5 and 92 days (table 27). Infarcts within the 
hippocampus (acute), cortex (subacute and chronic), cerebellum (chronic) and 
basal ganglia (chronic) were studied. In 3 patients, the cause of death was 
secondary to stroke or complications from it (aspiration pneumonia); the other 3 
cases died from community acquired pneumonia, ischaemic bowel and 
hydrocephalus. 
 
Immunohistochemistry 
Regions of infarct were initially studied using H&E sections, markers for 
astrocytes (GFAP) and microglia (CD68) were used to further determine these 
areas. It became evident that ÔnormalÕ H&E sections demonstrated an abnormal 
GFAP pattern, indicating GFAP a more sensitive marker for ischaemia (figure 
39). 
 
Across all cases (table 28, figures 40-46), CD34 immunoreactivity was weak, 
often inconsistent, and stained endothelium in small to medium sized vessels 
within regions of infarction. No other cells were CD34 positive.   
 
In control and G-CSF treated subjects, G-CSF receptor antibodies stained 
positively in microglia (and was weakly positive in astrocytes) in areas of 
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chronic stroke with no discernable difference between treatment groups. In one 
patient in the control group with an acute area of infarction in the hippocampus 
there was strong staining for G-CSF receptor, in neurons and astrocytes (figure 
40).  
 
The G-CSF protein antibody weakly stained endothelium in small vessels in all 
except one patient in the G-CSF group. This exceptional case demonstrated, 
interestingly, strong immunoreactivity in viable vessels within the area of 
infarction (figure 45). 
 
Mib-1, which identifies proliferating cells, was consistently immunopositive in 
endothelium in one control case, indicating ongoing angiogenesis in regions of 
subacute and acute infarction (figure 46A). A proportion of cells of unclear type 
were Mib-1 immunopositive in the ischaemic border zone of the acute infarct 
(figure 46B). Cells with normal cerebral architecture in the peri-ischaemic tissue 
were Mib-1 negative. Unfortunately, the Mib-1 stain across the majority of 
remaining cases failed to highlight any proliferating cells; this may be secondary 
to modes of death (very large infarcts) and delay to post-mortem influencing 
tissue viability.  
 
 
 
   
Table . Baseline characteristics of patients in the post-mortem substudy of STEMS-2. 
NB Control patients were not part of the randomised STEMS-2 trial. 
 
Pat ent 
No 
e Sex eatment 
allocat on 
e of eat  me of at from 
et of ne ol cal 
ptom  
me from at
to a top y 
1 
 
35 M Control Cerebral infarct secondary to 
hydrocephalus and colloid cyst 
Unknown 2 days 
2 
 
81 F Control MCA infarct & aspiration 
pneumonia 
10 days 1 day 
 
 
77 F Control MCA infarct 5 days 7 days 
 
 
76 F G-CSF MCA infarct 29 days 3 days 
5 
 
70 F G-CSF Pneumonia 92 days 3 days 
6 
 
81 M G-CSF Ischaemic bowel 37 days 2 days 
  G-CSF, granulocyte colony stimulating factor; MCA, middle cerebral artery 
 
   
Table 28. Distribution of endothelial, neuronal, microglial and astrocytic CD34, G-CSF and G-CSF receptor immunoreactivity in 
ischaemic stroke brain in subjects treated with G-CSF and controls. 
 
No Brain region Group 
Infarct 
age 
Immunoreactivity 
CD34 G-CSF protein G-CSF receptor  
V N M A V N M A V N M A 
1 Hippocampus Control Acute + - - - (+) - - - - +++ - +++ 
2 Cortex Control Chronic + - - - + - - - -  + - 
3 Cerebellum Control Chronic (+) - - - + - - - - - ++ - 
4 Cortex G-CSF Chronic + - - - + - - - - - ++ + 
5 Cortex G-CSF Chronic + - - - + - (+) (+) - +§ ++ ++ 
6 Basal ganglia G-CSF Chronic ++ - - - +++ - - - - - ++ (+) 
(+), patchy immunoreactivity; +, weak immunoreactivity; ++, good immunoreactivity; +++, strong immunoreactivity; V, vascular cells 
(endothelium); N, neurons; M, microglia; A, astrocytes; §, potential cross reactivity with chromatolytic neurones 
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Figure 38. Recruitment flow in to the post-mortem substudy of ÔThe Stem cell Trial of 
recovery EnhanceMent after Stroke 2Õ (STEMS-2).  
(G-CSF, granulocyte colony stimulating factor) 
 
                  
 
 
 
 
 
 
 
 
   
Figure . GFAP immunostaining in a region of cortical infarction. 
(A) Discrete areas of infarct are apparent with reactive gliosis and dissociation of GFAP within the infarct. (B) There is preservation of 
GFAP matrix in the adjacent gyrus, in particular in peri-vascular regions. (C) Compared to the ÔnormalÕ H&E section (not shown), 
there is widespread loss of astrocytic architecture producing a washed out appearance in areas of global hypoxia. 
 
 
   
Figures 40-46. Cases correspond to recruits 1-6 in tables 27 and 28. Immunostaining for each case including haematoxylin and 
eosin (H&E), glial fibrillary acid protein (GFAP) (staining astrocytes), CD68 (microglia/macrophages), CD34, G-CSF protein and its 
receptor (G-CSFR). Magnification x4 unless otherwise stated. 
 
Figure 40. Case 1 (control group): acute infarct in the hippocampus.  
CD34 and G-CSF protein stains endothelium and neurons are immunopositive for G-CSFR. 
   
Figure 41. Case 2 (control group): chronic infarct in the cortex.  
There is peri-vascular preservation of astrocytes (GFAP) and endothelium is weakly stained by CD34 and G-CSF. Macrophages are 
positive for G-CSFR. 
 
   
Figure 42. Case 3 (control group): chronic infarct in the cerebellum with astrocytic gliosis.  
The CD34 stain is negative whilst G-CSF protein is weakly immunopositive. Microglia/macrophages are positive for G-CSFR within 
the chronic infarct. 
 
 
   
Figure 43. Case 4 (G-CSF group): chronic cortical infarct.  
Similar to case 2 (control) - endothelium is weakly stained by CD34. Macrophages are positive for G-CSFR (no stain for G-CSF 
protein performed). 
 
 
   
Figure 44. Case 5 (G-CSF group), established cortical infarct.  
Again, endothelial cells stain positively for CD34 and G-CSF protein. Interpretation of G-CSFR profile is confounded by cross 
reactivity with lipofuscin (cytoplasmic lipids, protein and carbohydrates). 
 
   
Figure 45. Case 6 (G-CSF group): chronic infarct in the basal ganglia.  
Intensity of staining for G-CSF protein was much greater in this case in comparison to all other cases. 
 
   
Figure 46. Mib-1 immunopositive stain in (A) endothelium within acute stroke indicating ongoing angiogenesis and (B) indeterminate 
cell types in the ischaemic border zone of acute infarction.  
Magnification x40. 
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DISCUSSION 
Post-mortem analysis of the brains of patients recruited into STEMS-2 provides 
information about the cellular profile within areas of cerebral infarction following 
treatment with G-CSF. Our findings are consistent with an earlier autopsy series 
of 21 stroke patients which has described G-CSF protein expression in 
endothelial cells in acute cerebral infarction and observation of G-CSF receptor 
expression in neurons (acute infarction), microglia (subacute) and reactive 
astrocytes (chronic).366 In the present study, however, G-CSF receptor was 
consistently immunopositive in CD68+ macrophages and microglia in chronic 
infarction. 
 
There were no obvious differences between the brains of subjects in our 
treatment and control groups with the exception of one patient treated with G-
CSF who had increased intensity of endothelial G-CSF protein 
immunoreactivity. It is tempting to speculate that this was secondary to 
treatment, though it could also have been due to heterogeneity in case mix 
such as mode of death or time to autopsy; the sample size is too small to draw 
any conclusions. Of note, the absence of G-CSF protein expression in cerebral, 
non-vascular, chronically ischaemic cells does not support the concept of 
endogenous G-CSF production as reported by experimental (acute) ischaemia 
where the protein is up regulated more than 100-fold.137 
 
Nonetheless, the expression of G-CSF receptor in subacute and chronic 
infarction suggests a potential mechanism underlying improvements in 
functional outcome as seen in experimental models.235 Neuronal G-CSF 
receptor stimulation in acute stroke may reduce infarct volume via the anti-
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apoptotic P13K/Akt pathway;137 the receptorÕs role in subacute and chronic 
infarction has not been investigated and is much less clear. Recovery from 
experimental subacute and chronic stroke following administration of G-CSF (in 
combination with stem cell factor, SCF) was shown in one study to augment 
functional recovery via mobilisation and migration of bone marrow derived stem 
cells,441 promoting a favourable microenvironment for neurogenesis and 
angiogenesis through up regulation of IL-10.346 Interestingly, in the same study, 
no significant changes in G-CSF and SCF expression were observed following 
co-administration of G-CSF and SCF 11 to 20 days post stroke.346  
 
Evidence of increased peripheral blood CD34+ cells post stroke,213 expression 
of G-CSF and EPO receptors in the CNS,137, 254 and expression of 
neurotransmitter receptors on CD34+ cells 442 highlight the importance of 
understanding the  Ôbrain-bone-bloodÕ axis.443 Migrating CD34+ haematopoietic 
stem cells may play a key role in orchestrating neurorepair post stroke and 
perhaps the G-CSF receptor is involved in chemotaxis, similar to other stem cell 
hormones and their receptors, for example, stromal cell derived factor (SDF-1) 
and CXCR4.444  
 
CD34 antigen has been shown to be present in CNS endothelium,445 reduced in 
inflammation and demyelination 445 and expressed in microglia on days 3 to 5 
subsequent to acute neural injury.446 Microglial cell populations expand 
following neuronal ischemia. This could be due to proliferation of resident 
microglia, migration of microglia from adjacent brain areas or, relevantly, by 
recruitment of migrating microglial progenitors from the blood.447 However, our 
results revealed no evidence of CD34 expression in cell types other than 
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endothelium (in small to medium sized vessels). Nonetheless, evidence of 
viable endothelial tissue within infarcted brain and proliferating Mib-1 
immunopositive angiogenic cells in acutely ischaemic areas suggest there are 
areas within the ischaemic brain for drugs to target and augment recovery. 
 
G-CSF and other colony stimulating factors involved in microglial proliferation 
and activation (such as macrophage colony stimulating factor (M-CSF 448) and 
granulocyte macrophage colony stimulating factor (GM-CSF 232)) are potential 
drug candidates for the treatment of stroke. The majority of work assessing G-
CSF in experimental stroke supports its use as a therapeutic agent through 
infarct volume reduction 376 and suppression of proinflammatory cytokines (e.g. 
IL-1B,138, 357 neuronal and glial tumour necrosis factor,356, 357 matrix 
metalloproteinase-9 244). However, negative effects have also been 
observed;167 in one study, a murine model of permanent stroke resulted in 
impaired behavioural function following treatment with G-CSF in association 
with an increase in inflammatory infiltrate of F4/80+ macrophages/microglia. 
This concern has not been apparent in clinical safety trials of G-CSF to date 
and further trials are ongoing.299 
 
Our study must be read with a number of caveats in mind. First, although all 
suitable patients within the STEMS-2 trial were approached, fewer subjects 
were recruited than expected. The total number of recruits who died within 90 
days was 3, all of whom were included. In order to increase recruitment, the 
follow-up period of the trial would have to be extended beyond the original 90 
days. The unpredictable nature of mortality within a trial leads to practical 
recruitment difficulties and as a consequence interpretation of data from such a 
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small sample size should be interpreted with Ôhealthy scepticismÕ. Second, there 
was a natural selection bias since it was considered clinically not appropriate to 
approach some patients and families. Third, the delay between death and post 
mortem significantly affects tissue viability and antigen expression in humans, a 
phenomenon not encountered in experimental stroke. Thus we may have 
underestimated any effects G-CSF treatment could have on the cerebral 
cellular profile. Fourth, the results are confounded by heterogeneity in case mix, 
with substantial variation in time to death post stroke onset in the G-CSF group. 
This did, however, allow different ages of stroke to be analysed. In addition, the 
control cases were not age- and sex-matched (instead selected at random), 
which has led to further confounding of the results. Finally, interpretation of 
antigen expression may have been influenced by cross-reactivity with other 
proteins, such as with cells containing lipofuscin (accumulation of lipids, 
proteins and carbohydrate granules, a common feature in aging) or 
chromatolytic neurons (ballooned, swollen neurons reacting to axonal damage) 
producing potential false positive results. 
 
Despite the above limitations, this is the first clinical study exploring the effects 
of G-CSF treatment on the human ischaemic brain and cellular expression of 
CD34, G-CSF and its receptor. 
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CHAPTER 9  
DISCUSSION 
 
Safety of G-CSF for treatment of stroke 
The primary outcome of STEMS-2, from which the body of this thesis is derived, 
has suggested that subacute administration of G-CSF in ischaemic stroke is 
safe when compared to placebo. This is also supported by evidence 
aggregated from all randomised controlled trials addressing the use of colony 
stimulating factors in stroke (see chapter 5); in 5 small trials (n=167) G-CSF had 
a neutral effect on death and dependency and there was evidence of a trend 
towards improvement in early impairment. G-CSF was well tolerated with no 
significant differences in serious adverse events when compared to placebo. 
However, future phase III efficacy trials must make safety analysis a key 
feature, particularly in light of the recent negative outcome of a trial assessing 
erythropoietin in hyperacute ischaemic stroke.256 Although this revealed a 
higher death rate in EPO treated subjects, the trial was potentially confounded 
by the unusually large number of participants who were thrombolysed. This 
should not be an issue when administering G-CSF subacutely since it is given 
at a time point beyond the wash-out period of rtPA; the subgroup of 
thrombolysed recruits in STEMS-2 (7%) did not highlight any specific safety 
concerns, though the sample size is obviously very small. 
 
The failure of numerous experimental drug therapies that could be used for 
stroke to be translated successfully into clinical research is an ongoing concern, 
and is a focus for the STAIR and STEPS committees who have produced a 
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series of recommendations and guidelines suggesting how to address the 
matter.152, 275, 276 Chapter 2, a systematic review of G-CSF in experimental 
stroke, highlights that pre-clinical studies assessing G-CSF have fulfilled only a 
proportion of these recommendations and that further evidence in permanent 
models of ischaemia, which are an additional representation of human stroke, 
are required. In addition, experimental evidence to date reports just one study 
evaluating the effects of G-CSF and thrombolysis given together - early 
combination with rtPA showed no additional benefit compared to rtPA or G-CSF 
alone and did not lead to side effects.246 Producing representative embolic 
animal models for evaluating rt-PA are technically difficult but further animal 
studies with G-CSF are still required in this area. Pre-clinical experiments 
assessing EPO in stroke also fulfilled a large proportion of the 
recommendations 449 but did not include any studies assessing an EPO/rtPA 
combination before the negative phase III trial. A subsequent experiment has 
demonstrated a hitherto unknown interaction of rtPA with EPO, in which 
vascular permeability is promoted and there is extracellular matrix breakdown at 
the blood-brain interface.415 
 
Tracking haematopoietic stem cells post stroke 
Understanding the capacity of a stem cell to migrate to its therapeutic target is a 
key determinant of how potential cell therapies can be delivered in future care. 
Following administration via intravascular or intracerebral routes, cells have 
been tracked with a variety of techniques in animal models that clearly have 
limited application in human clinical trials. The majority of previous human cell 
tracking studies use radiolabelling (17 studies, mostly in acute or chronic 
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myocardial infarction 450) compared with 3 assessing iron labelling studies in 
spinal cord injury,424 brain trauma 422 and diabetes.423  
 
We have concentrated on iron-labelling techniques in Chapter 3, a systematic 
review of the pre-clinical literature assessing paramagnetic labelling of stem 
cells in ischaemic stroke. This draws attention to the heterogeneity between 
experiments; including differences in stroke model (transient versus permanent 
ischaemia), timing and route of cell transplantation, stem cell type and dose, 
and inconsistent use of a transfection agent as part of the labelling process. Our 
experiment (Chapter 7) demonstrated that compounds already licensed in 
humans for other indications (ferumoxide and protamine sulphate) show 
promise for use in future cell-labelling studies.385, 389, 391, 392 The presence of 
foreign material within a cell may lead to cellular dysfunction; intracellular iron 
concentration therefore needs to be kept to a minimum in order not to interfere 
with cell dynamics (e.g. the ability of a cell to migrate to another site) but should 
be high enough for the cells to be visualised on MRI scans. However, altering 
the intrinsic components of a cell by adding intracellular compounds could not 
only have detrimental effects on cell viability but also on the potential 
therapeutic target. This has been observed in animal models of stroke using 
GRID labelled cells over a 1 year follow up; animals receiving labeled cells had 
a poorer outcome in the form of increased stroke lesion volume.397 
 
It was not apparent from the existing medical literature that undifferentiated 
CD34+ HSCs would internalise SPIO without a transfection agent. We therefore 
addressed this (Chapter 7) and established that CD34+ cell uptake of 
ferumoxide is enhanced by but is not dependent upon the transfection agent 
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protamine sulphate. The techniques used did not demonstrably affect CD34+ 
cell viability or differentiation capacity when compared to unlabelled cells in the 
short term but we have not addressed the effects of labelling on long term cell 
function. Before prospective mechanistic trials using iron-labelling techniques 
are used to assess cell dynamics in stroke, further research assessing long 
term follow up in cell labelling experiments is therefore justified. 
 
In Chapter 6, we have demonstrated that labelling CD34+ haematopoietic stem 
cells (HSC) with an extracellular paramagnetic iron oxide nano-particle and re-
administering them intravenously in the subacute phase of ischaemic stroke is 
safe and feasible. We noted a new hypodensity within an infarct on gradient 
echo (T2*) imaging subsequent to administration of labelled cells in one patient 
and suggest this may be evidence of CD34+ cells migrating to the stroke lesion. 
Interpretation of cell migration is restricted by the presence of blood (iron) in 
infarcted brain tissue, present in a high proportion of ischaemic strokes on MR 
imaging.400 Future trials tracking stem cells in stroke using iron labels should 
therefore be more highly selective and exclude patients with baseline 
haemorrhagic transformation of infarction. It would also be interesting to assess 
CD34+ cells labelled with intracellular iron (such as ferumoxide, a 
superparamagnetic iron oxide particle, SPIO), to trial higher cell doses or 
alternative routes and times of administration. If it were possible to recruit a 
sufficient number of patients after HTI was excluded in order to explore these 
parameters further, interpretation of subsequent MR images will always be 
qualitative and under question: is the new hypodensity new blood or label? 
There will also be questions over cell specificity (i.e. another cell type can 
phagocytose the label) and cell viability. With these significant limitations in 
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mind, pursuing iron labeled techniques in stroke is unlikely to be successful in 
providing clear evidence of cell migration in human stroke. 
 
Limitations of the current work 
STEMS-2 was a robust randomised placebo-controlled safety trial but, in 
addition to the limitations of the labelling substudy described above, there are 
other caveats to consider. First, the total sample size of 60 does not allow any 
conclusions about treatment efficacy to be reached. Our updated Cochrane 
review (of five small trials) does not indicate that treating stroke with G-CSF 
improves death or dependency when compared to placebo. Encouragingly, 
however, the review revealed a trend towards improvement in early impairment 
(as measured by NIHSS) in subjects treated with a colony-stimulating factor 
(weighted mean difference -0.4, 95% confidence interval -1.82 to 1.01, p=0.58). 
Furthermore, in STEMS-2, the median value in some efficacy parameters 
(NIHSS, grip strength, motricicty index, NEADL, MMSE) was non-significantly 
better when compared to placebo. This did not hold true for the mRS or Barthel 
index, in which the median values were the same in each group. Progression to 
a larger phase III efficacy trial would be necessary in order to confirm the 
presence of any possible treatment effect. Further criticism can be made 
regarding the choice of the mood and cognitive assessment tools; these were 
both affected by the presence of dysphasia and more appropriate and validated 
tools could have been used, such as the SADQ-H10 (10-item Hospital version 
of the Stroke Aphasic Depression Questionnaire), which is valid and reliable in 
measuring depressive symptoms in stroke patients with aphasia.328  
 
  248 
Other restrictions, by nature of the trial design, are introduced when subsets of 
patients were excluded from STEMS-2 and its substudies (a selection bias). 
The trial required subjects to be hospital inpatients for a minimum of 8 days 
(recruited on day 3 post-stroke, followed by 5 days of treatment); hence patients 
with mild stroke and short lengths of hospital stay were not included. In addition, 
selection by presence of limb weakness excluded those with isolated dysphasia 
and posterior stroke syndromes, an important group of patients with functional 
loss who could also benefit from the proposed treatment. The wide time window 
of inclusion (3 to 30 days) should also be refined in future trials; considerable 
changes in neurological status can occur over this period and this confounds 
comparison of the 2 groups (for example, a patient with an NIHSS of 8 three 
days after a stroke has a greater chance of improvement than a patient with the 
same NIHSS score at 30 days). All measures taken will be influenced similarly 
by the wide time window of inclusion. Nonetheless, mean time to randomisation 
(one of the minimisation factors) in both groups was similar (8.0 days in the G-
CSF group, 8.3 days in the placebo group). 
 
Finally, the CD34+ cell labelling and post mortem substudies suffered from 
small sample sizes (n=8 and n=3 respectively) and consequential selection 
bias. Bias was introduced, for example, by clinical judgement that in some 
cases would have been inappropriate or insensitive to approach patients and 
families to discuss brain donation in the event of death so soon after a major 
stroke. Nonetheless, both these facets of the trial represent novel scientific work 
and progress our understanding of the relationship between G-CSF, CD34+ 
cells and stroke. In chapter 8, the cellular profile of infarcted brain tissue 
subsequent to treatment with G-CSF was explored. Although no differences in 
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expression of CD34 antigen, G-CSF protein and its receptor were found when 
compared to control, expression of the G-CSF receptor on macrophages / 
microglia, neurons and astrocytes suggest that it is important to continue to 
evaluate the effects of G-CSF as a potential therapy for stroke. 
 
The future for clinical trials of G-CSF and stroke 
3 paradigms are currently being investigated: the effects of G-CSF on 
hyperacute, subacute and chronic stroke. AXIS-1 reported a small safety study 
of hyperacute administration in 44 patients.368 The full results of AXIS-2 (n=328) 
are awaited. 302 AXIS-2 enrolled patients with ischaemic stroke in the MCA 
territory within 9 hours of onset and baseline NIHSS scores between 6 and 22. 
Patients were recruited if rtPA had been received provided the NIHSS score 
was still greater than 6. Initial data presented at the recent international stroke 
conference (February 2012, New Orleans) did not show a difference in efficacy 
between treatment and placebo groups: G-CSF mean mRS 3.31 (95% 
confidence interval 3.06-3.56) vs placebo mRS 3.12 (95% CI 2.87-3.37). There 
were no significant differences in safety or mortality between groups though the 
absolute number of deaths was higher in the treatment group (22% vs 18%, 
p=0.4). These are not very encouraging results and assessment of G-CSF in 
the hyperacute phase of stroke is unlikely to continue. 
 
Evaluation of G-CSF in stroke in its subacute and chronic phases has not yet 
been sufficiently tested in order to comment on efficacy. STEMS-1,294 STEMS-2 
304 and other smaller safety trials 295, 296, 303 administered G-CSF in the subacute 
phase (between 3 and 30 days post stroke) assessing the treatment concept of 
neurorepair with the assumption that mobilised haematopoietic progenitor cells 
  250 
influence neuronal and vascular regeneration.161 Most pre-clinical data have 
been developed in models that administer the drug in the hyperacute phase,376 
but positive benefits on outcome with drug administration in the subacute phase 
(between 1 day and 1 week post ictus) have also been seen.235, 236 One 
negative preclinical experiment has demonstrated, however, an exacerbation of 
inflammation within the stroke lesion when G-CSF was given 24, 48, and 72 
hours after induction of stroke.167 No other negative pre-clinical trials in this area 
have been reported, suggesting the presence of publication bias. Therefore, the 
optimum time window of administration is not clear but it seems sensible to 
adopt a time when the inflammatory reaction has started to settle (beyond three 
days), to target a period 1-2 weeks post stroke, or in the chronic phase when 
scar tissue has formed. One ongoing trial, Stem cell Trial of recovery 
EnhanceMent after Stroke 3 (STEMS-3), is enrolling patients 90 days after 
ischaemic or haemorrhagic stroke using a total G-CSF dose of 10mcg/kg for 5 
days. 
 
Stroke is a heterogeneous disease, and selecting the most appropriate stroke 
population for future G-CSF trials is also unclear. The vast majority of pre-
clinical evidence uses rodents with transient MCA ischaemia. This is a good 
representation of a proportion of human stroke but there are no models that will 
consistently represent other forms of stroke that behave differently, for example, 
a lacunar stroke or those with specific cortical signs such as dysphasia. Further 
experimental work may help to derive the most suitable population. Though 
rodent stroke models with other co-morbidities (diabetes,359 age 245) have 
shown benefit from G-CSF, there are fewer experiments using permanent 
models of ischaemia.376 There are also no experiments published using larger 
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animal models (e.g. primates), which would help in determining validity across 
species with gyrencephalic brains. Despite this uncertainty, it would be 
reasonable  to include all stroke subtypes in a phase II/III trial as they may all 
benefit from a strategy underpinned either by cell replacement (if migrated cells 
reach the lesion) or  by enhancing endogenous regeneration (via secretion of 
chemokines from mobilised cells).  
 
In ischaemic stroke, it is thought that the neuroprotective effect of G-CSF is 
mediated by inhibiting apoptosis. This mechanism may be of benefit also in 
patients with intracerebral haemorrhage (ICH) since compression effects of 
blood also cause ischaemia in neighboring cells. In rodent models of 
haemorrhagic stroke, G-CSF given 2 hours after ICH (50!g/kg, intra-peritoneal), 
then daily for 3 days, improved sensori-motor behavioural tests when compared 
to placebo measured up to 5 weeks after the stroke;247 there was also evidence 
of reduced inflammation, brain oedema and peri-haematomal cell death. In 
another study, G-CSF was given to male rats 24 hours after ICH (15!g/kg, 
intra-peritoneal) then daily for 5 days. Compared to control, functional 
restoration was significantly better in the G-CSF treated animals;451 circulating 
CD34+ HSCs were identified in peri-lesional tissue and not in control animals. 
There was also evidence of neurogenesis with expression of GFAP (astrocytes) 
and nestin (neurons) in the G-CSF group.451 Furthermore, high serum levels of 
growth factors, such as G-CSF are associated with a good outcome following 
intracerebral haemorrhage.452 More recently, the same authors evaluated 
CD34+ cell counts and outcome in 32 patients with ICH;453 day 7 CD34 levels 
were independently associated with a good functional outcome (modified 
Rankin score <2), suggesting that CD34+ haematopoietic progenitor cells  may 
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contribute to functional recovery in ICH. A stage II safety trial assessing G-CSF 
in patients with ICH is therefore warranted. It is supported by positive outcomes 
in preclinical experiments of ICH,247, 451 evidence of good neurological outcomes 
in patients with higher CD34 counts and serum G-CSF levels 452, 453 and initial 
safety data from the subset of patients from the STEMS-2 trial.304 
 
Although G-CSF may not be considered directly as Ôstem cell treatmentÕ, 
endogenous CD34+ cells can be mobilised into peripheral blood using G-CSF 
in a dose dependent manner following a stroke.294 G-CSF also demonstrates a 
multimodal mechanism of action, including neuroprotective and 
neuroregenerative qualities. G-CSF already possesses a good safety record 
and pharmacological profile in humans and, though it is essential that that 
thorough pre-clinical work precedes human clinical trials, the use of G-CSF in 
the hyperacute phase has rightly progressed onto phase III clinical trials. In light 
of the results of STEMS-2, it is now reasonable to consider evaluating the 
efficacy of G-CSF in the subacute phase of stroke. 
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Appendix A 
Immunoaffinity-based cell separation 
This method relies on a specific ligand (e.g. monoclonal antibody) binding to a 
cell surface protein (e.g. CD34 or CD133).454 
   
 
 
Methods in chapter 6 employ immunoaffinity-based cell separation using a 
monoclonal anti-CD34 antibody conjugated to iron oxide nanobeads. After 
incubation of the stem cell product with the antibody, the cells are passed 
through a magnetic column which attracts the antigen-antibody complex whilst 
the remainder of the cells are washed away (the negative fraction). Removing 
the magnet subsequently allows collection of the CD34+ cells (the positive 
fraction). The iron-oxide nanoparticle attached to the selected cells will act as a 
contrast agent for T2* weighted MR imaging when injected into a patient. The 
above method uses a CliniMACS system (Miltenyi Biotec). 
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The volume of blood taken from the patient for CD34+ cell selection and 
labelling is approximately 150mls and is collected in a blood bag containing 
anti-coagulant (Baxter PL146-CPDA-1-35mls ref R8107). The CliniMACS 
system will not process whole blood effectively as other cell types interfere with 
immunomagnetic selection. It is therefore vital to minimise interruption from 
these cells by removing them first. Several methods of cell separation could 
achieve this aim but each has its drawbacks. Density gradient centrifugation 
with Ficoll would enable selection of the mononuclear cells but the procedure, 
which ideally requires a closed system to reduce contamination risk, involves 
too many ÔopenÕ steps for the volume of blood required here. Furthermore, no 
clinical grade Ficoll (or equivalent) is available so should not be used if the final 
product is going to be used in humans. Overall, it was felt that red blood cell 
sedimentation using Dextran 70 followed by separation of the Ôbuffy-coatÕ 
(containing the leukocytes of interest) was the most appropriate initial step. This 
method and the steps involved in selecting the CD34+ cells are described 
below. The procedure took place in a clean room (Clinical Tissues Laboratory, 
Queens Medical Centre, Nottingham), an environment necessary to ensure 
sterility of the final product. It complied with ÔGood Manufacturing PracticeÕ 
(GMP) and held a license with the Human Tissue Authority. The air was filtered 
to remove air-borne contaminants and there was a full sample tracking system 
in place. 
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Harvest of CD34+ Progenitor Cells 
Materials 
1. Blood collection bag (Baxter PL146 Ð CPDA-1 Ð 35mls, Ref R8107) 
2. Transfer bags 
a. 600mls Teruflex Transfer bag (Ref BB*T060CM) 
b. 600mls Baxter (PL1813/1 Ref R4R2022) 
c. 150mls Teruflex Transfer bag (Ref BB* T015CM) 
3. Luer spike connector (EMC1401) 
4. Flexible Luer spike connector (RMC 3476) 
5. Plasma transfer tubing set with coupler and Luer adapter (Baxter Ref 
VMC2240) 
6. Plasma Expressor 
7. Heat Sealer (Hematron III) 
8. Vibrax shaking mixer / orbital rotator 
9. Top pan balance (S-2002) 
10. Preparation room centrifuge: 3-16k 
11. CliniMACS CD34 complete kit including: 
a. CliniMACS CD34 reagent, 7.5mls 
b. CliniMACS tubing set 
c. CliniMACS PBS/EDTA buffer, 3 x 1 litre 
d. Flexible Luer spike connector (RMC 3476) 
e. Pall filter, 40!m 
12. 50ml syringes. 
13. 10ml syringes. 
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14. 19g long form hypodermic needles.  
15. Plastic tubing clamps (ÔhemostatsÕ) 
16. Dextran 70 for infusion (Baxter, 500ml, code B5013) 
17. Normal saline 500mls  
18. CD34 antibody for FACS analysis (CD34-PE, human) 
19. CD45 antibody for FACS analysis (CD45-FITC, human) 
20. Human serum albumin (HSA), 20% solution Ð BPL. 
 
Procedure 
1. Weigh the blood collection bag in order to accurately measure the total 
volume collected (empty bag is approx 75g).  Total volume will be 
approximately 150mls. 
 
2. Using the heat sealer unit, seal the collection port on the blood bag about 
2cm from the bag.  Transfer the bag to the clean room.  
 
3. [CLEAN ROOM]. Add 20%v/v dextran 70 (approximately 30mls) using a 
50ml syringe into a Luer spike connector (EMC1401) inserted into the right 
hand port.  
 
4. Mix the dextran with the contents of the blood collection bag by hand.  
Leave the bag and contents on the manual expressor device and allow the 
cells to sediment (figure 47). This process takes approximately one hour.   
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Figure 47. Blood collection bag. 
 
 
5. Whilst waiting for RBC sedimentation, make up the centrifuge balance 
bucket: 
a. [CLEAN ROOM] Using a transfer bag (T060CM), insert a flexible Luer 
spike connector (RMC3476). Attach to this a 500ml bag of normal 
saline using the plasma transfer tubing set (VMC2240). Close the two 
existing clamps and pass to the preparation room. 
b. Open the clamps and transfer the saline into the transfer bag up to a 
total weight of 400g using the S-2002 balance. Stop the transfer at 
390g and use the tubing clamp to control the final weight. Place the 
transfer bag in the centrifuge bucket. Close the bucket using a safety 
lid and place in the centrifuge (3-17k) 
 
6. [CLEAN ROOM]. After approximately one hour, express plasma/buffy layer 
into a 600ml transfer bag (T060CM): the spike from the transfer bag is 
inserted into the central port on the blood collection bag (figure 48). Use a 
haemostat to clamp the tubing about 6cm from the bag.  
Blood mixed with 
dextran: 
 
Buffy coat layer 
 
Sedimented red 
blood cells 
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Figure 48. Transferring buffy layer from blood collection bag. 
 
 
7. Transfer the bag set to the preparation room. Heat-seal the transfer tubing 
about 4cm from the bag and remove the clamp. Dispose of the initial blood 
collection bag and pass the transfer bag to the clean room. 
 
8. [CLEAN ROOM]. Add HSA to the CliniMACS buffer to a final concentration 
of 0.5% v/v albumin (using 20% HSA, add 25ml in total). Use the right 
needle port in the CliniMACS buffer pack and a 19g (long) hypodermic 
needle fitted to a 50ml syringe.   
 
9. [CLEAN ROOM]. Connect the buffer pack to the transfer bag (containing the 
separated buffy layer) via a flexible Luer spike connector (RMC3476) 
inserted into the left port of the transfer bag and unused port on the buffer 
pack using a plasma transfer tubing set (VMC2240). Attach the CliniMACS 
buffer pack and clamp the tubing using both the (attached) tubing clamps.  
Transfer to the preparation room. 
 
Plasma 
Expressor 
Central port 
Buffy coat 
layer 
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10. Transfer the buffer/HSA manually: make up to 400g using the S-2002 
balance (this is sufficient to fit into a centrifuge bucket) Ð see figure 49.   
Stop the transfer at 390g and use the tubing clamp to control the final 
weight. Finally, ensure the clamps on both the tubing set and on the transfer 
bag are closed. Pass the connected set back to the clean room. 
 
Figure 49. Transferring CliniMACS buffer / HSA to the transfer bag 
 
 
 
11. [CLEAN ROOM]. Separate the buffer bag and the transfer bag and replace 
both caps (buffer bag and transfer bag). Place the transfer bag in the 
centrifuge bucket. Close the bucket using a safety lid. Transfer to the 
preparation room.   
 
12. Place the bucket and contents in the rotor of the 3-16k centrifuge. All four 
buckets in the centrifuge must balance (otherwise the centrifuge will cut out).  
Put the bucket inserts in the empty balance buckets to increase the weight.   
Plasma transfer 
tubing set 
CliniMACS 
Buffer / HSA 
Transfer bag 
containing buffy 
layer 
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Ensure that safety lids are placed on all buckets. Centrifuge the bag at 300g 
for 10 minutes using soft start/soft stop settings. When centrifugation is 
complete, pass the unopened centrifuge bucket (containing the transfer bag) 
to the clean room.  
 
13. [CLEAN ROOM]. Place the centrifuged bag in the expressor. Attach a waste 
bag (R4R2022) using the existing Luer spike (RMC 3476). Let the expressor 
spring exert the necessary pressure on the bag contents, in order to effect 
the transfer to the attached bag (i.e., do not force expression of the 
supernatant by hand, see figure 50).  Removal of the supernatant is 
complete when the bag is ÔflatÕ. Disconnect the waste bag and discard. 
Resuspend the pellet within the transfer bag. Attach the CliniMACS 
buffer/HSA bag using the existing tubing set and Luer spike (RMC3476). 
Return this connected set to the preparation room. 
 
Figure 50. Using the plasma expressor 
 
 
14. Using buffer/HAS (from the attached CliniMACS buffer bag) fill the transfer 
bag to a final weight of 400g, using the S-2002 balance.  Clamp the tubing 
Pellet 
Plasma 
expressor 
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using both (attached) clamps. Transfer the connected bag set to the clean 
room.  
 
15. [CLEAN ROOM]. Disconnect the buffer bag and replace both caps (buffer 
bag and transfer bag). Place the transfer bag in a centrifuge bucket, close 
the safety lid and pass the bucket plus contents to the preparation room.  
 
16. Place the bucket and contents in the rotor of the 3-16k centrifuge. All four 
buckets in the centrifuge must balance (otherwise the centrifuge will cut out).  
Put the bucket inserts in the empty balance buckets to increase the weight.   
Ensure that safety lids are placed on all buckets. Centrifuge the bag at 200g 
for 10 minutes using soft start/soft stop settings. When centrifugation is 
complete, pass the unopened centrifuge bucket (containing the transfer bag) 
to the clean room.  
 
17. [CLEAN ROOM]. Place the transfer bag in the expressor and attach a waste 
bag (R4R2022) via the existing Luer spike (RMC3476). Remove the 
supernatant, letting the expressor spring exert the necessary pressure on 
the bag contents (i.e. do not force expression of the supernatant by hand). 
Detach the waste bag and discard. Resuspend the pellet.  Reattach the 
CliniMACS buffer bag using the existing tubing set and Luer spike 
(RMC3476). Close both (attached) clamps. Transfer the bag set to the 
preparation room.  
 
18. Add CliniMACS buffer/HSA after releasing the tubing clamps to a final 
weight of 129g; i.e. 95g buffer + 34g (the weight of the transfer bag), using 
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the S-2002 balance. Close both (attached) tubing clamps. Transfer the bag 
set to the clean room.  
 
19. [CLEAN ROOM]. Detach the buffer bag and replace the caps. Add 
CliniMACS CD34 reagent to the transfer bag: withdraw 7.5 ml of the reagent 
from the vial with a 10ml syringe and add to the bag via the transfer tubing. 
Finish with 50ml of air (via a 50ml syringe) Ð to gently inflate the bag (this 
ensures easier mixing of the contents).  Clamp the transfer bag tubing using 
the clamp on the Luer spike connector. Transfer to the preparation room.  
 
20. Place the transfer bag plus contents on the Vibrax shaking mixer at 100rpm. 
Allow mixing for 30 minutes (no need to clamp the bag in place).  Ensure 
that bubbles within the bag are moving to ensure that mixing is effective 
(see figure 51). Transfer the bag plus contents to the clean room. 
 
Figure 51. Mixing CD34 reagent within the transfer bag 
 
 
21. [CLEAN ROOM]. Add HSA to a new pack of CliniMACS buffer to a final 
concentration of 0.5% v/v albumin (using 20% HSA, add 25ml in total). Use 
Shaking 
mixer 
Transfer bag 
containing 
CD34 reagent 
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the right needle port in the CliniMACS buffer pack and a 19g (long) 
hypodermic needle fitted to a 50ml syringe.   
 
22. [CLEAN ROOM]. Attach the (new) CliniMACS/HAS buffer bag to the transfer 
bag using a plasma transfer set (VMC2240) and the existing Luer spike. 
Clamp both bags using the (attached) tubing clamps. Pass the bag set to 
the preparation room.  
 
23. Release both clamps and transfer the buffer/HSA manually: make the 
transfer bag up to 400g using the S-2002 balance. Finally, ensure the 
clamps on both the tubing set and on the transfer bag are closed.  Pass the 
bag set to the clean room.   
 
24. [CLEAN ROOM]. Detach the CliniMACS buffer bag and replace the caps.  
Place the transfer bag in a centrifuge bucket and close the safety lid. Return 
the centrifuge bucket and contents to the preparation room.  
 
25. Place the bucket and contents in the rotor of the 3-16k centrifuge. All four 
buckets in the centrifuge must balance (otherwise the centrifuge will cut out).  
Put the bucket inserts in the empty balance buckets to increase the weight.   
Ensure that safety lids are placed on all buckets. Centrifuge the bag at 300g 
for 10 minutes using soft start/soft stop settings. When centrifugation is 
complete, pass the unopened centrifuge bucket (containing the transfer bag) 
to the clean room.  
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26. [CLEAN ROOM]. Remove the transfer bag from the centrifuge bucket. Place 
the transfer bag in the expressor and attach a waste bag (R4R2022) via the 
existing Luer spike (RMC3476). Remove the supernatant, letting the 
expressor spring exert the necessary pressure on the bag contents (i.e. do 
not force expression of the supernatant by hand). Detach the waste bag and 
discard. Resuspend the pellet.  Reconnect CliniMACS buffer pack number 1 
(this should have the smaller quantity of the 2 buffer packs). Close both 
tubing clamps and pass the bag set to the preparation room.  
 
27. Release the tubing clamps and add CliniMACS buffer/HSA to a final weight 
of 94g; i.e. 60g buffer + 34g (the weight of the transfer bag), using the S-
2002 balance. Close both (attached) tubing clamps.  Transfer the bag set to 
the clean room.  
 
28. [CLEAN ROOM].  Detach the CliniMACS buffer bag and replace the caps.  
Clamp the transfer bag.  Take a 1ml sample from the transfer bag, using a 
2ml syringe and 19g needle. Transfer this sample into a ÔbijouÕ vial.  This 
sample will be used to obtain a CD34+ cell count (before harvest).   
 
29. [CLEAN ROOM]. Open a CliniMACS tubing set (figure 52). 
 
  
  265 
Figure 52. CliniMACS tubing set 
 
 
Three connections within this to set up in the clean room: 
a. Spike in the central port (this is the spike with the microbead filter 
attached) into the Pall filter (spike into the top of the filter). Clamp 
below the Pall filter using a plastic tubing clamp (haemostat) and then 
spike the Pall Filter into the transfer bag containing the product. 
b. Spike into the CliniMACS/HSA buffer bag (the 2nd pack containing 
the most buffer) and clamp with a haemostat. 
c. Spike the 150ml transfer bag (T015CM)  (this will be the positive 
fraction bag) with a Luer connector (EMC1401) and attach this to the 
final available port in the CliniMACS tubing set. 
 
Do not clamp the waste priming bag tubing.   
Pass the prepared ClinMACS tubing set to the preparation room.   
 
 
Port for 150ml 
transfer bag 
Spike for 
Pall filter 
Spike for 
CliniMACS / 
HAS buffer 
bag Waste 
priming bag 
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30. Prepare the CliniMACS machine:  
a. Programme the CliniMACS harvester.  Follow the onscreen 
instructions. 
b. Input the tubing set reference number. 
c. Input the CD34 reagent reference number.  
 
31. Take both this Ôcell +veÕ buffer bag and then the waste priming bag and hang 
from the top of the CliniMACS machine. The pre-column is inserted with the 
ÔfinsÕ facing outward. Adjust the height of the bags.  Attach the selection 
columns (fins outward). Attach the tubing through the valves as per the 
onscreen instructions. When the onscreen instructions indicate Ôattach buffer 
bagÕ, remove the clamp.  The valves can be adjusted manually if necessary 
(push button, pull tubing).  The thicker of the tubing goes through the pump.  
The contents of the buffer waste bag and negative fraction bag are directed 
into the waste container. Check that all tubing is seated correctly (e.g. check 
for twists etc.). 
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Figure 53. The CliniMACS machine and tubing set 
 
   
          
 
 
32. Start the run as per the onscreen instructions.   
 
33. The screen prompts for an Ôintegrity testÕ.  This is an extra priming step (for 
FDA regulations) and takes 30 minutes.  Omit this step as the original 
priming step tests the system sufficiently.   
 
Pall filter 
CliniMACS / 
HAS buffer 
bag 
CliniMACS 
machine 
ÔCell +veÕ 
buffer bag 
Waste 
priming bag 
Thicker tubing passing through 
pump 
Tubing and valves 
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34. When prompted to Ôconnect bagÕ, remove the clamp (hemostat).  Collect the 
harvest Ð this should be 42g ± 7g (plus the weight of the empty bag = 22g).  
The negative fraction bag = 30g.  Negative fraction = 230g (total = 260g). 
 
35. Analyse the following three samples for FACS analysis: 
a. Pre-harvest CD34+ cell separation (already taken). 
b. CD34 positive fraction  - withdraw 1ml via the Luer spike connector. 
c. CD34 negative fraction Ð withdraw 1ml. 
 
36. Record the process code at the end of the harvest run.   
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